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PRESIDENT’S COMMENTS: BEHAVIORAL SCIENCE
IS FUNDAMENTAL TO DRUG ABUSE RESEARCH
AND TREATMENT
George E. Bigelow
It is an honor to have this opportunity, as president of the College, to offer some
personal comments relevant to the drug abuse field. The theme I have chosen to
emphasize is that behavioral science methods arc of great importance and value --
indeed fundamenral -- to both the scientific study of, and the practical treatment
of drug abuse.
This theme is important for two reasons -- one a congratulatory reason related to
the past, the other a cautionary reason related to the future. First, the
congratulatory and historical reason: Throughout NIDA’s 20-year history there
has been a strong and mutually beneficial relationship between the Institute and
the behavioral sciences. Behavioral science research has guided and transformed
our conceptualization of the nature of drug abuse and has contributed to major
scientific advances in both the laboratory and the clinic. NIDA has served as a
model Institute for demonstrating how behavioral sciences can be effectively
represented and integrated with more fundamental biological sciences to sustain a
broad and balanced research program addressing all aspects of the drug abuse
problem. NIDA is to be congratulated for this continuing success. The second
reason for emphasizing this behavioral sciences theme is the cautionary one
regarding the future: NIDA is undergoing a period of transition -- with a new
Director and administrative transfer into NIH -- and special vigilance and efforts
may be needed to sustain into the future NIDA’s successful broad-based, and
balanced research program. Specifically, there is reason for concern that the
behavioral science components of NIDA’s research program may suffer as a
consequence of the transfer to NIH, where there is a strong molecular biology
zeitgeist and where behavioral sciences have traditionally been poorly
represented despite repeated congressional mandates to provide greater
emphasis. Ideally, NIDA, NIAAA, and NIMH would serve as models for the
rest of NIH about how effectively to integrate behavioral sciences so as to
sustain broad-based and balanced research programs. However, as the grant
review of these institutes is transferred to NIH special effort and caution will
likely be needed if the important contributions of the behavioral sciences are to
be preserved.
The sections below briefly address the following points regarding the role of
behavioral sciences in drug abuse research and treatment: First, that drug abuse
is a behavioral disorder for which the critical endpoints of interest are behavioral;
second, that drug self-administration is biologically normal; third, that drug-
taking is learned behavior and is controlled by the normal principles of learning;
fourth, that there are excellent behavioral models of drug abuse available in both
the animal laboratory and the human laboratory; fifth, that behavioral-science-
derived treatments arc effective, and appear to have a cross-drug generality that
is lacking in more pharmacologically- or biologically-based treatments.
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BEHAVIORAL DISORDER
It should be self-evident that drug abuse is a behavioral disorder. The core
defining feature of the disorder is the behavior of drug self-administration, and
the critical endpoints of interest at both the individual level and the societal level
are behaviors. Drug self-administration itself is not the only behavioral endpoint
of interest; drug-seeking behavior is also of major interest, since it often appears
as criminal activity. One of the especially interesting relationships revealed by
behavioral science research is that these two behavioral endpoints may be
affected in opposite directions by the same manipulations. This is illustrated by
the effect of variations in the ease of drug availability (or cost) on drug use
versus drug seeking behavior. Making drugs more difficult to obtain or more
costly can decrease use at the same time that it increases drug-seeking-related
criminal activity. This adverse behavioral effect of supply-reduction strategies is
one of the strong empirical bases for advocacy of demand-reduction strategies as
preferable.
BIOLOGICAL NORMALITY
The development of laboratory animal models of drug self-administration three
to four decades ago has transformed scientific conceptualization of the nature of
drug abuse. The discovery that normal healthy laboratory animals will self-
administer the same drugs that humans abuse has made evident the biological
normality of drug reinforcement and drug abuse. No longer is it necessary to
postulate brain disease, psychiatric illness, or sociologic disadvantage as a
necessary foundation for drug abuse; these are now seen as being neither
necessary nor sufficient. Rather, it is recognized that drugs of abuse have CNS
effects in normal individuals that, in appropriate behavioral circumstances, can
lead to these drugs’ functioning as reinforcers and coming to control behavior.
I have recently been reading the popular non-fiction best-seller “Listening lo
Prozac” by psychiatrist Peter Kramer, about the behaviorally transforming
effects of psychotherapeutic medications, in this case fluoxetine, or PROZAC.
One of the messages that Kramer is surprised to learn by listening to PROZAC --
i.e., by observing the effects of fluoxetine in patients -- is that even individuals
without significant disorders, normal individuals, can be behaviorally
transformed by the medication. I am not as surprised as Kramer is; his
realization seems analogous to what we have learned in the drug abuse field.
Even normal individuals are vulnerable to the behaviorally transforming effect of
drug reinforcement.
LEARNED BEHAVIOR
Behavioral science has not only shown drug reinforcement to be biologically
normal, but has identified the mechanism of acquisition of drug self-
administration to be the normal processes of learning that are relevant to
acquisition of other learned behaviors. That is, the mechanism of the
behaviorally transforming effect of drug reinforcement is learning. Extensive
research has further documented the substantial commonalities between animals
and humans with respect to the controlling variables of this learned drug-taking
behavior (Griffiths et al., 1980).
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BEHAVIORAL MODELS
One of the great strengths of the drug abuse field is that it has excellent
experimental behavioral models of drug abuse that can be used to study the
phenomenon and to examine factors that influence it. These arc available in both
the animal laboratory and the human laboratory. Procedures such as assessing
the profile of subjective and behavioral effects of drugs. drug discrimination,
and drug self-administration have proven remarkably useful as research tools,
making it possible to bring into the laboratory the critical defining elements of
drug abuse and to examine directly the effects of variables that can be
manipulated. Integration of these methods with more basic
neuropharmacological information has permitted characterization of the specific
pharmacodynamic effects associated with different profiles of neuroreceptor
binding (Preston and Bigelow, in press).
These behavioral models have now been productively adapted and directed
toward use in medications development research. In this research the goal is to
identify medications that will reduce the drug-abuse-related characteristics of
drugs of abuse.
This use of these laboratory behavioral models is illustrated by research related
to the development of buprenorphine as a treatment for opioid abuse and
dependence. A study in our laboratory examined the ability of buprenorphine to
attenuate the subjective, behavioral and physiological effects of opioid challenge
injections (Bickel et al., 1988). The maintenance dose of buprenorphine was
varied and response to opioid challenge infections was assessed at each
buprenorphine dose level. The results showed an orderly buprenorphine-dose-
related decline in opioid challenge response. Similarly, Mello and Mendelson
(1980) used a human laboratory opioid self-administration model and directly
demonstrated that buprenorphine reduced opioid self-administration. These
laboratory studies were critical steps in the developmental sequence for
buprenorphine as a drug abuse treatment medication, and they provided the
empirical basis for selection of the dosages to be used in subsequent multi-site
outpatient clinical trials.
These human laboratory-model methods have now been adapted by several
laboratories, including our own, to screen for compounds that may useful in
treatment of cocaine abuse (Bigelow, 1993; Walsh et al., in press).
THERAPEUTIC EFFICACY
Drug abuse treatment procedures directly derived from behavioral science data
and conceptualizations of drug abuse have repeatedly been shown to have
significant therapeutic efficacy in outpatient clinical trials of drug abuse
treatment. One of the basic principles of behavioral science is that if one wishes
to reduce the frequency of some behavior it is most effective to reinforce some
alternative, incompatible behavior. One such approach has been to offer
incentives or reinforcers contingent upon providing drug-free urinalysis
samples. There have now been numerous demonstrations that such positive
reinforcement approaches to promoting drug abstinence are effective. These
methods were pioneered by Stitzer at our laboratory at Johns Hopkins (e.g.,
Stitzer et al., 1992), and suhsequently elaborated and more fully developed by
Higgins at the University of Vermont. For example, in one of Higgins’ studies
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cocaine abusers received either a standard abstinence counseling treatment based
on the traditional AA 12-step model, or a behaviorally-based contingent
reinforcement treatment in which vouchers exchangeable for goods or services
were earned contingent upon providing drug-free urinalysis results. Outcomes
were dramatically superior in the behavioral treatment condition (Higgins et al.,
1991)
One of the especially attractive features of these behavioral treatment methods is
that they appear to have broad applicability to abuse of different drug classes.
That is, methods developed and used to treat one type of drug abuse ( e.g.,
opioid abuse) may be readily transferable and efficacious in the treatment of
another type of drug abuse (e.g., cocaine abuse). This is in marked contrast to
the very narrow pharmacological specificity that typically characterizes the
efficacy of biological or pharmacological treatments.
A final point to be made regarding efficacy is that integration of behavioral and
pharmacological treatments may be more effective than either alone, and in some
cases such integration is essential for the pharmacological treatment to show any
efficacy at all. For example, naltrexone treatment for opioid abuse and
disulfiram (Antabuse) treatment for alcoholism have non-significant clinical
efficacy when the treatment is provided as a routine medication prescription.
However, when these medications arc combined with behavioral interventions --
especially interventions designed to maintain medication ingestion -- these
treatments can be remarkably effective. Even in the case of methadone
treatment, which has substantial pharmacological efficacy (Strain et al., 1993),
treatment outcomes depend critically upon the intensity of concurrent behavioral
and psychosocial intervention provided (McLellan et al., 1993).
CONCLUDING REMARKS
In extolling the value, importance and contributions of behavioral science to the
drug abuse field, I do not in any way minimize the value, importance and
contributions of other research approaches. Drug abuse is a broad
multidisciplinary field, and we should be committed to sustaining and promoting
strong science throughout all of the diverse aspects and domains of the field.
Science has two general goals that must be pursued simultaneously. One is to
gain fundamental knowledge. The other is to yield practical benefits. Especially
in the drug abuse field publicly-supported researchers are called upon to produce
practical benefits to society. Practical benefits require appropriate technology.
Appropriate technology is technology that is both effective and feasible within
the system with which one has to deal. In drug abuse, the important individual
and public health outcomes are at the level of complex behavioral systems and
we must rely upon a substantial degree of compliance and individual
acceptability in order to implement interventions. I would argue that in this
context behavioral science or behavioral technology is appropriate technology.
While we must concurrently pursue all levels of technology and analysis to
answer basic scientific questions about drug abuse, we must continue to
preserve and expand our behavioral science knowledge base in order best to
achieve our practical public health and therapeutic goals in drug abuse.
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DRUG ABUSE AND ADDICTION RESEARCH:
OPPORTUNITIES FOR PROGRESS IN 1995
Alan I. Leshner
I am extremely pleased to be here representing the National Institute on Drug
Abuse (NIDA) as its new Director and to share with you my sense of excitement
about the boundless opportunities for progress that await us in the drug abuse and
addiction research field.
This year, as most of you know, marks the Institute’s 20th anniversary -- two
decades of progress in drug abuse research supported through NIDA. To
commemorate the many remarkable achievements that have been made in the field
we have planned a number of activities. These include a satellite symposium, co-
sponsored by NIDA and the National Foundation for Brain Research, to be held
later this month at C.I.N.P. which will highlight some of the field’s most notable
advances in neuroscience and a day-long symposium to be held at NIH in the fall
covering the full breadth of NIDA’s research. Since many of you in this audience
have played such a critical role in the accomplishments we celebrate, we hope that
you can participate in these events and garner some of the recognition you so
richly deserve.
From my perspective, we in the drug abuse arena are faced with the most
complex, and probably the most alarming social and public health issue
confronting this country. And, at the same time, we are faced with the most
stigmatized public health issue that there is. We hide our drug treatment centers
so no one knows what they are. We never enlist addicts to help us advocate. It is
a terribly stigmatized disease and a terribly stigmatized set of problems and
scientific issues which clearly makes our job al1 the more difficult.
Because of the magnitude of the problems, and because of the social concern that
surrounds drug abuse and addiction, I believe that MDA must evolve itself into
what I’ve been calling a prototypical public health institute. This is more than just
the scientific establishment that carries out activities because they are interesting
and potentially useful. In my view, a prototypical public health institute is
characterized not only by superb science, but by the systematic interactive set of
activities it engages in to reach out to the public; to the practice community; to the
consumer and the advocacy communities in an effort to increase their
understanding of and appreciation for what we do; and to help us in shaping our
research agenda. Faced with a public health problem like drug abuse and
addiction, it is not responsible to shape our research agenda in a vacuum. And
therefore, over time, we will increase our interaction with the community, and
will engage in more dialogue with policy makers to try to ensure that the
questions that we as an Institute are asking are the questions that in fact are of
paramount importance in the minds of these groups.
Since the College on Problems of Drug Dependence comprises most of the key
figures in drug abuse research, I feel it is important for me, as NIDA’s new
director, to describe for you my philosophical position with regard to an Institute
like NIDA and how it administers science. While at the National Science
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Foundation and then at the National Institute of Mental Health, I was often called
upon to articulate, for a wide range of communities, my views on the federal role
in the support of science. In an idealized view of how science, technology and
product development or service delivery progresses, science informs technology
which, in turn, informs product development. However, as we all know, this
concept does not always match up with reality. Technology at the moment is
driving science far more than science is driving technology. The molecular
genetics revolution, the imaging revolution, the computer and information science
revolutions are all changing the way in which we engage in scientific investigation
far more than science is changing technology. In the case of product development
in our fields, it has often been the discovery of products that drives science and
technology far more than in the other direction. Nonetheless, the process, in
general, is truly an interactive one.
There is also an idealized view in which basic research informs clinical research,
which, in turn, informs applied or services research. In practice, however, the
process is far more complex than this, and no one does any of these things in a
vacuum. The truth is that progress in a particular area is an interactive process.
Because it’s an interactive process, we as a scientific institute have an obligation
to be listening to the world as much as we are telling the world. Although this
concept is easy to articulate, it is an extremely difficult thing to operationalize and
something NIDA will be working on over the next few years in a very systematic
way. If we want to have an impact, it is imperative that we find ways to enhance
our interactions and our dialogue with our constituency groups.
The third philosophical point I would like to address involves the way in which
we relate to the scientific community. If we characterize the various ways the
federal government supports science as being along a continuum, on one end
would be a totally reactive approach. That is, the products coming in are
reviewed and then the best are supported. This strategy, also known as the
thousand flowers, field generated, or reactive approach is what was said to be
true in the good old days.
And then we went through a period characterized by the Sputnik event that shifted
the Federal Government’s approach to the other end of the continuum which was
putting a man on the moon -- a very directive, targeted, pro-active tactic which is
viewed as the other end of the continuum. That era came to be known as the bad
new days because the scientific community felt that they were essentially being
directed by the Federal Government.
In truth, this continuum varies by agency or institute, and it varies according to
the purpose of the scientific enterprise. And it tracks with whether we as a
Federal Government are at that point in history supporting science for its own
sake, for knowledge’s sake, or whether we do it because it is meeting a specific
set of national needs.
As a public health institute NIDA probably stands somewhere in the middle of
this continuum. That is, we are not able to or interested in just propagating a
thousand flowers -- let the world send us whatever there is. Employing this
approach, science often does not progress as rapidly as it might with at least a
somewhat targeted strategy. At the other extreme, there are few problems for
which a totally strategic, targeted approach has been taken, and too much
targeting has not been helpful as an overall strategy.
So for NIDA I think we need to determine where the frontier is and where the
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cutting edge is and move in that direction on the continua, about in the middle.
To illustrate my views, I find the metaphor of a hockey game particularly
appropriate. As Wayne Gretzky has said, “I skate to where the puck is going to
be.” What we need the drug abuse research community to do is to help us
identify where the puck is going to be and determine the best way to get there.
This is what we will be soliciting your input on in the coming months.
In carrying out this metaphor, skating translates into setting our priorities, our
emphases, and our initiatives. Our task is to try to help to focus the research that
we support in particular areas. What we will be asking of you as knowledgeable
members of the drug abuse research community is to help us skate in the right
direction.
In order to lay out a plan for addressing the problems of drug abuse and
addiction, I think it is important for me to spend a little bit of time talking about a
conceptualization of this complex disease. First of all, I consider it extremely
important to recognize drug abuse and addiction as both a social and a public
health issue. And we must focus our research efforts on both aspects. I would
also like to make the point that drug addiction itself, once it occurs, is a brain
disease; it is an event that modifies the brain in some way that is expressed in
behavioral ways and in a social context. And when you conceptualize drug abuse
and addiction in these ways, you see it not only as among the most complex, but
the most difficult kinds of issues that you could try to combat. Because of its
complexity, the study of drug abuse and addiction requires that we take a multiple
discipline attack.
What we need to do is to bring the multiple levels of analysis and the tools of
multiple disciplines to bear on this problem. NIDA historically has taken this type
of broad-based approach, from the molecular level all the way to the level of
studying political systems and policy systems, and service systems, and we will
continue to do that as well.
Since my arrival at NIDA about three and a-half months ago, we have been trying
to articulate some of the major initiative areas and some of the major priorities that
NIDA is going to take on in the near term. These have included the programs that
are already ongoing as well as activities that we have in the mill. I would like to
go through these sequentially and give you some very broad descriptions of what
we’ve triggered internally and, hopefully, research areas that you will help us
shape.
TREATMENT DEVELOPMENT
Historically, drug abuse and addiction treatment has been directed in two ways at
NIDA and we will continue to do that, focusing both on the development of
medications and on more traditional behavioral and psychosocial treatment. I
subscribe to the view that, in many cases, the most effective treatment ultimately
will be a combination of these. If you view addiction as a brain disease that is
expressed in behavioral ways and in a social context, you cannot use only
biological treatment, nor can you use only behavioral treatment. Increasingly, we
are learning how behavioral treatment can modify the brain in addition to changes
in the brain having the capability of altering behavior.
In medications development, we take basically two kinds of approaches. One I
call opportunistic, the other is strategic. Although the opportunistic approach has
actually been highly productive in many fields, it has not given us too many
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medications to treat drug abuse and addiction so far. The second approach is a
more strategic one, to use the science that we generate as a base from which we
then proceed to develop new medications. That is, applying medicinal chemistry
and other similar techniques to capitalize on neuroscience advances. The area that
I think we are most hopeful about and that our Medications Development Division
has been working diligently on is, taking advantage of the discovery that cocaine
works via the dopamine re-uptake transporter, searching for a dopamine sparing
cocaine blocker. This is a far more strategic approach to developing effective
treatments than we have been able to take in the past. Over time, we will try to
become more and more strategic so that the small amount of funds we do have
available is employed in the most leveraged way that is possible.
NIDA’s treatment improvement program also includes the area of behavioral or
psychosocial treatment. My limited experience suggests to me that much of what
we currently support in this area is incremental research. There are a range of
extant behavioral treatments that we have been exploring but, to date, we have not
really devoted a great deal of our energy or resources in search of truly new or
novel approaches. We will, of course, continue to support research to provide
incremental improvements on treatments currently available and to understand
what can make those treatments work better and for whom. But at the same time,
I believe that we need to expand our horizons and start looking for truly novel
approaches to treatment as well.
To facilitate this process we have begun to talk inside the Institute about
convening a meeting of treatment researchers from within the drug abuse field and
treatment researchers from outside the drug abuse field, to brainstorm about
approaches that have proven to be effective in other areas of scientific
investigation which might be applied to drug abuse and addiction. I believe that if
we want to achieve a measurable increment in drug treatment in this country, we
are going to have to take some novel looks at ways in which to approach
treatment. As a scientific institute, we will always do that based on science. We
will do it based on theory. We will do it based on findings that have occurred in a
variety of fields. But we have to start looking at some novel approaches.
NEUROSCIENCE
Neuroscience is an area in which NIDA has made remarkable advances over the
course of the last few years. There are a variety of activities that we are currently
involved in as well as others we hope to be initiating soon.
First of all, soon after I arrived at NIDA, we established an Institute-wide group
we have called NIDA’s Neuroscience Consortium. Formerly our Neuroscience
Program Management Committee, the name of this group was modified not only
to reflect its importance but also the fact that we want the activities the group
becomes involved in to span the entire range of what NIDA supports -- basic
science, clinical science, and, where possible, applied science as well. Co-
chaired by Drs. Christine Hartel and Karen Skinner, the group is currently in the
process of developing a strategy and a set of steps we should take to advance
what we do in the neuroscience arena.
The long standing Clinical Human Neuroscience Initiative NIDA has been
supporting is another example of the Institute’s commitment to broadening our
neuroscience program. I personally view this as an exciting and necessary area to
explore. Thus far, we have received numerous excellent proposals and we are
very hopeful that as these projects are reviewed we can make some significant
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awards in the near term.
The Human Brain Project is another activity you may have heard about on
numerous occasions as something NIDA is centrally interested in. I am proud to
be among this project’s fathers, and I believe that the information that will result
is a significant contribution that the Federal Government will make to the
establishment of an infrastructure for neuroscience research. For this reason, I
think every neuroscience institute has an obligation to be a part of it. NIDA will
continue to play an active role in this important activity.
The progress made possible by the technological advances of the past decade are
particularly extraordinary. It is truly astonishing that over the past 20 years, the
drug abuse field has accomplished the task of cloning one or more receptors in the
brain for every major drug of abuse. This is an achievement that the drug abuse
field alone can purport and one whose implications for research in the field are
enormous. Building on these advances, NIDA will move beyond cloning, using
the technology currently available to pursue this basic cloning phenomenon both
from a neuroscience perspective as well as from a medications development
perspective.
AIDS
HIV infection and AIDS continue to take an enormous toll on the health of our
nation. Drug related behaviors such as sharing of contaminated injection
equipment or having sex with an injecting drug user are the second leading cause
of HIV infection and AIDS, accounting for more than one-third of cases reported.
Our efforts to bring drug using individuals into treatment are the first and most
effective line of defense. But for those who continue to use drugs, modifying the
behaviors that place them at risk can significantly reduce their chances of
contracting this devastating disease. For over a decade, NIDA’s efforts at
devising effective behavior change strategies have helped to curtail the potential
magnitude of the problem. But much still remains to be done. Clearly, our AIDS
program needs far more rationalization. In the months to come, we will be
spending more time working on our portfolio and plans for this area. AIDS
related research represents one-third of our budget and we need to be very
systematic about what we are doing and what more we need to do in this arena.
HEALTH SERVICES RESEARCH
Another area where NIDA has made a great deal of progress recently is services
research. This field represents a major opportunity and one for which it is vital
that we play an active role now. Although we may not have articulated the extent
of our involvement as best we might, NIDA has actually been at the forefront of
the activity that has recently been taking place. There has been one issue on the
table which has been of paramount importance in the public health arena in 1994,
and that issue is health care reform. If we want to be credible players in the
process, if we want to make sure that the people we serve -- people with drug
abuse and addiction problems in this country -- are fairly treated; we must be sure
that we have a knowledge base that we can contribute about the effectiveness of
treatment and about cost effective ways to organize and finance care. Although
this type of knowledge base is a critical need in all areas of public health,
throughout much of the debate over health care reform, the addictive and mental
disorders have been experiencing a relatively more difficult time in ensuring their
inclusion in the health care legislation being proposed. We are constantly being
asked for data about the effectiveness of treatment, whether or not it works, who
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does it work for, is it cost effective, and what does it cost. It is the services
research base that will provide the information to answer these and a host of other
policy related questions.
What NIDA intends to do is to move from the live year planning process that has
been under development and devise a strategic plan for services research that will
involve a large number of people in both the policy and practice communities, as
well as in the scientific community. It is my hope that many of you will help us
determine what questions need to be asked, and what issues need to be addressed
in order to best inform policy and practice. Over time, we intend to increase our
efforts to generate scientific information to bring to bear on these issues.
CLINICAL RESEARCH INFRASTRUCTURE
Tied to our need for a variety of approaches to drug abuse treatment is the
concomitant problem of having far too sparse a clinical research infrastructure for
drug abuse in this country. It is clear that our clinical research infrastructure is
inadequate. There is an urgent need to attract more clinical researchers to the drug
abuse and addiction field and to expand our overall capability to support their
efforts. We will accomplish these objectives in a variety of ways, focusing both
on more researchers and on more institutions.
RESEARCH INFRASTRUCTURE
In addition to the clinical research infrastructure inadequacies that exist in the drug
abuse field, research infrastructure in general is also relatively deficient. That is,
we have far too few researchers in our field. This is a smaller field than it ought
to be, given the magnitude of the problem, and given the public interest it
receives. In order to actually accomplish that mu1tiple discipline strategic attack
on drug abuse and addiction that is necessitated by the problem’s complexity, we
are going to have to be systematic about the way in which we increase the size
and the scope of the field. And again, we will have to do it both institutionally
and in terms of individual investigators.
Within the NIH structure we support a number of mechanisms which provide
opportunities for strengthening the field’s infrastructure including First Grants --
the awards for young investigators, small grants and research training. Over
time, you will be seeing increased attention to these kinds of activities. It is
imperative that we develop seed corn for the future in order for the field to
continue to flourish.
It is my firm belief that the best way to recruit people into a particular scientific
field is through mentoring. I would challenge anyone to tell me how you could
conceivably get interested in an area of research if you never met anyone who did
that kind of research. A study was done many years ago of how Nobel Laureates
had come into science. And every single one of them had done it by a hands-on
research experience with someone they bonded to. In order to facilitate this
process we need to find ways to provide resources to the scientific leaders in our
field to enable them to function as mentors. This, I would argue, is a
complementary strategy to developing seed corn to try to bring additional people
into the field. Thus, NIDA will also be developing opportunities in each of these
areas.
In addition to needing more researchers, we also need to make sure that we are
making the best use of the mechanisms we have available. Among the things I’ve
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been concerned about since coming to NIDA, is to ensure that the Institute’s
Research Centers program is organized in as strategic a way as possible. We
have, therefore, begun discussions to try to rationalize and develop our Research
Centers program.
This is a very important issue, because the way you conceptualize research
centers determines both what you are trying to accomplish by establishing them as
well as the way in which you structure support for them. In my view, research
centers fall into two groups -- those that I would term enabling research centers
and those that are stimulating research centers.
The stimulating research centers are relatively easy to conceptualize. In an area
where research is sorely needed but is not being conducted you might infuse
some money to initially set up a program. This was the technique used,
incredibly effectively, when the AIDS problem began. The Public Health Service
established a large number of AIDS centers initially to stimulate research on
AIDS. As more and more researchers came into the AIDS field, the centers
became a much smaller part of the total AIDS budget and there were more and
more R01s being supported, but it was a way to draw people into the field. This
method has been used effectively in services research, in prevention research, and
a whole variety of other areas. It is a very useful technique and a very important
one in stimulating research in an area where it is needed. In designing our
portfolio we may need to create centers for this purpose.
However, I believe that most of the centers we support should be of the other
category which I call enabling research. Why do you want a center? You want a
center in order to do something that you couldn’t do if you just had an R01.
There is no point in having a center if it is merely an aggregation of R01
applications. In this case, each of the projects gets reviewed individually and
instead of going through five committees, the projects go through one committee
as one large integrated project. From NIDA’s point of view, all that does is eat
R01s. This is not a very effective way of supporting centers in the majority of
cases.
What we do want is to provide support for research that could not be done
without a center vehicle. And clinical research is very often an example of that.
For example, if you don’t have the infrastructure present, if you don’t have a
subject population, if you don’t have beds, if you don’t have the kind of core
support that you need to do clinical research, it often is very difficult to do that
research. It also is true in cases of shared equipment. One of the biggest things
that has come along and is providing tremendous opportunities for progress in
our field is the neuro-imaging revolution. I believe that neuro-imaging will
revolutionize our understanding of the brain. However, we are finding it difficult
to get any time on existing machines. And if you can’t get time on machines and
you have to line people up four weeks in advance -- a little hard with people who
are addicted to drugs -- then the fact that the technology exists does you very little
good. We need to create mechanisms to enable the research we want done to be
done.
Over time, we will try to rationalize our Research Centers programs so that the
centers that we establish are designed to accomplish specific goals. Our job is to
then provide the resources that are necessary to accomplish the goal. If you view
our task, as I do, as facilitating science or enabling the science to be done, we
must not only provide the resources necessary to conduct the work, but we must
do it in such a way as to ensure that the goal of the research is accomplished.
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MINORITY/SPECIAL POPULATIONS
There are also a set of research issues relating to minority/special populations in
which we need to invest more of our efforts and resources. First of all, I think
we all know that drug abuse and addiction disproportionately afflict people in
minority groups. Therefore, we have to pay far more attention to the issues
surrounding these differences than we have in the past. In addition to this, there
are an embarrassingly small number of minority researchers in our field. So we
will need to be devoting significant amounts of energy to increasing the pool of
minority researchers.
Historically, people have talked about recruiting minority researchers as an equity
issue. I want to make it clear however, that for me, this is not an equity equity
issue. This is not an issue about giving minority people chances. This is an issue
about taking full advantage of the human resource pool available for science in
this country. We have tremendously untapped resources and tremendously
untapped expertise because we have not reached out in a very effective way to the
community of potential researchers who come from minority groups. Thus, in
the future, we will strive to be far more systematic about how we direct our
efforts. This is not just an issue of fairness, it is a critical national need.
It is also the case that there are tremendous differences among subgroups within
what are classified as minority groups. The two examples I know best are the
“Asian” population and the “Latino” population. That is, the Asian population is
of course made up of many different ethnic and cultural groups. And we have
learned the hard way that by addressing all of the various factions collectively, we
are not getting very far in finding workable solutions. The same is true for the
Latino population. Here too, there are very real and significant differences; for
example, between the Mexican American community and the Puerto Rican
community. If we do not attend to these differences and continue our current
practice of aggregating groups, we are not going to be successful in developing
drug abuse prevention and treatment strategies that are effective with these
groups. This is an area of NIDA’s research we are actively attempting to
strengthen.
A similar situation also exists in drug abuse research related to women. There is
no question that the area of maternal/fetal drug effects is a very important one and
one to which NIDA will have to devote sustained efforts. However, at the same
time, it is clear that we have paid far too little attention to women, irrespective of
their reproductive/maternal roles. We need to consider the fact that there are
physiological, behavioral, and social gender related differences and we need to
attend to the relevance of those issues per se. We will be expanding our activities
in that realm as well.
INFORMATION EXCHANGE
One of the major messages that I have been conveying to people on the Hill and
in the Administration is that NIDA wants to be useful. We want to be perceived
as a part of this country’s battle on drug abuse and addiction and we want the
world to see us that way. This we hope to accomplish by moving our strategies
involving information exchange into a more interactive mode than they have been
in the past and by significantly broadening our community and constituency
outreach and interaction efforts. And in order to ensure our research’s relevance,
we also need advice from people in the field about what questions we should be
asking.
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TOPICS IN THE MILL
In addition to the areas already addressed, there are a number of other topics that
we have begun discussing. I would like to briefly mention some of these
activities that we have “in the mill”.
PROTECTIVE/RESILIENCE FACTORS
Over the years we have spent a lot of time and a lot of effort attempting to
identify factors which place certain individuals at risk for drug abuse and
addiction. A vast number of such factors have been implicated, ranging from
biological to psychological, social or environmental in nature. Since there appear
to be so many risk factors for drug abuse which, in some cases, serve only to
stigmatize those considered to be “at high risk”, it makes sense to focus more
efforts on identifying those characteristics which make certain individuals more
resistant to drug abusing behaviors than others. Particularly where precursors of
substance abuse are not amenable to change (such as economic deprivation),
prevention programs can foster protective mechanisms that will increase the
chances that participants can overcome their high-risk circumstances without
turning to substance abuse. To gain that insight, in the future we intend to devote
far more effort to the study of protective and resilience factors.
EPIDEMIOLOGY RESEARCH
In the area of epidemiology research, NIDA needs to move to the next generation.
Here, we will focus efforts on improving existing methodologies for collecting
and analyzing epidemiologic and ethnographic data and on increasing the
reliability and validity of instruments that measure the nature and extent of drug
abuse and dependence.
PREVENTION RESEARCH
Prevention research is also an area which we need to expand. Research has shown
a reduction in drug use among young people who are exposed to comprehensive
drug abuse prevention programs that promote the formation of anti-drug attitudes
at all levels of society. We hope to do more in identifying effective comprehensive
prevention interventions that use schools, media, family, peers, and community
organizations to shape and reinforce positive self-regulated behavior changes. We
will also support efforts to determine the efficacy of drug-free policies and
legislation in a variety of settings. In addition to the more traditional approaches
we have been taking to identify effective interventions, this is another area where
we will be looking for novel approaches with demonstrated success in other fields
to apply to the prevention of drug abuse.
BEHAVIORAL SCIENCES
Until recently, many areas of behavioral science that have relevance to drug abuse
and addiction were not very prominent in our research portfolio. Because drug
abuse and addiction is a disease expressed in behavioral ways, it is important that
we concentrate more efforts on the study of the complex processes affected
including learning and memory, motivation, and cognition. Clearly, this is an area
in which I think we need to devote some strategic thinking.
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CHILDREN AND ADOLESCENTS
To a large extent, drug abuse and addiction are diseases of childhood and
adolescence. The fact that they often have their origins there is an important point
to consider in designing effective prevention and treatment strategies. Some of
NIDA’s public information activities have been fashioned with close attention paid
to age differences. Since such targeted approaches offer the best hope of reaching
their intended audience they will be employed more and more as new efforts are
launched.
Clearly, the need to expand our knowledge about drug abuse and addiction has
never been greater. The enormous health, social, and economic costs of using
illicit substances; the apparent resurgence of illicit drugs among our youth; the
devastating toll that drug abuse and addiction related HIV infection and AIDS
continues to take on our nation’s health all continue to heighten the urgency of the
work that we do.
Fortunately, the opportunities for exploration and discovery in the drug abuse field
have never been more abundant. And the technologies available allow us to
venture into increasingly exciting areas. As NIDA begins its third decade, I look
forward with great optimism to working with all of you in the drug abuse research
community to surpass the remarkable achievements made thus far in the field, and
to bring to those we seek to help, the best prevention and treatment strategies that
science can offer.
AFFILIATION:
National Institute on Drug Abuse, Rockville, MD 20857
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INTRODUCTION TO THE NATHAN B. EDDY MEMORIAL
AWARD RECIPIENT
J. V. Brady
It has been well over a quarter of a century since my path first crossed that of
Jerome Jaffe, the honored recipient of this year’s Nathan B. Eddy Memorial
Award. It was the 1960s and we shared a role in that perennial agony we have
come to know as “Study Section”. Then, only in his early thirties, Jerry brought
to the table an unparalleled reputation for scholarship as the author of the first
“Drug Addiction and Drug Abuse” chapter in the prestigious Goodman and
Gilman’s, “The Pharmacological Basis of Therapeutics,” a contribution he has
continued to revise and update every five years for the past three decades. His
accomplishments as an innovator of the model Illinois Drug Abuse Programs
were equally well-known at the time and he was already credited with some of
the earliest studies on long-acting pharmacotherapeutic agents for opioid
dependence. His LAAM studies for example, had a 30-year jump on the FDA,
about the lead time he continues to maintain over the rest of us in the drug
abuse field.
Jerome Herbert Jaffe was born and bred in Philadelphia, bursting upon the scene
as one of the early “New Deal” babies shortly after Independence Day, on July
6, 1933. His undergraduate and graduate degrees in Psychology, as well as his
medical degree, were all awarded by Temple University between 1954 and
1958, and by 1959 he was a Resident in Psychiatry at the United States Public
Health Service Hospital in Lexington, Kentucky. It was during this tour of duty
in the Public Health Service that Jerry made early contact with the founding
fathers in the field at the Addiction Research Center - Abe Wikler, Harris Isbell,
Frank Fraser, among others - who were to have an abiding influence on his
most productive career.
Within but a few years after returning to an academic appointment at the Albert
Einstein College of Medicine in New York in the mid-1960s, he moved to the
University of Chicago and the Directorship of the Illinois Drug Abuse
Programs. And, at the ripe old age of 36, Jerry was summoned to service on the
World Health Organization Expert Committee to rub elbows in Geneva with
Dale Cameron and no less a luminary than Nathan B. Eddy, for whom this
highest CPDD award has been named.
With this kind of a track record, it is little wonder that Jerry’s accomplishments
would come to the attention of the White House when the President found
himself in need of a Special Consultant for Narcotics and Dangerous Drugs, and
ultimately, a Director of the Special Action Office for Drug Abuse Prevention -
the first “Drug Czar”. It was in those first few highly visible years in
Washington during the early 1970s under Jerry’s leadership that the first Federal
Strategy was written and many of the programs that formed the basis for current
research and treatment in drug abuse were initiated. Those years also witnessed
the reversal of a 50-year policy prohibiting the use opioids in the treatment of
narcotic dependence. As a result, methadone maintenance was approved and
16
guidelines were developed for what has since proven to be the most effective
available treatment for opioid dependence.
Jerry’s return to teaching and research at Columbia and the University of
Connecticut in the mid 70s and early 80s was characterized by yet another
investigative initiative that proved to be a decade or two ahead of its time -
nicotine dependence. It was largely through his efforts that recognition of the
disorder was acknowledged by inclusion in the DSM III diagnostic manual and
he assumed a primary role as an expert witness in the first and only successful
litigation against the tobacco industry.
Over the past decade, our distinguished Eddy Awardee has been back at the
helm in the greater Washington megalopolis. He first served as Director of the
relocated Addiction Research Center in Baltimore, then briefly as Acting
Director of NIDA, and most recently at the PHS complex in Rockville,
Maryland where he lent an expert hand to the establishment of the Office of
Treatment Improvement with Beny Primm, and is presently on duty with the
newly constituted Center for Substance Abuse Treatment.
At the ARC, Jerry was responsible for assembling the nucleus of the
neuroscience group, now under the productive leadership of such luminaries as
Mike Kuhar. In addition, he continues his own scholarly involvement through
recently published reports on PET studies of drug effects in the human brain,
adding to a pre-existing bibliography of some 300 or more research papers and
authoritative reviews in the drug abuse field.
While this recognition of Jerome Jaffe’s many accomplishments may be long
overdue, it is nonetheless as richly deserved an Eddy Award as any this College
has ever been honored to present for outstanding scientific and professional
contributions to the field of drug dependence and abuse.
AFFILIATION:
The Johns Hopkins University School of Medicine
Baltimore, Maryland
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THE NATHAN B. EDDY LECTURE: SCIENCE,
POLICY, HAPPENSTANCE
J. H. Jaffe
I am profoundly honored to have been selected to receive the Nathan B. Eddy
Award. To be numbered among those previous awardees who have created and
shaped this field is an unexpected event. I consider this recognition by my
colleagues to be the high point of an academic/medical career that has been
influenced (if not defined) by unexpected events. I would like to tell you about
three of these events and the impact they had on my career and, indirectly
perhaps, on drug abuse research.
In 1957, my third year of medical school, I read Abraham Wikler’s book, “The
Relation of Psychiatry to Pharmacology.” This led me by a circuitous route to the
Public Health Service Hospital at Lexington, Kentucky--not as a researcher, as I
had hoped, but as a resident in psychiatry. Nevertheless, I attended the seminars
of the great researchers of the Addiction Research Center: Harris Isbell, Abraham
Wikler, H. Frank Fraser, William Martin, and others. I also developed lasting
relationships with clinical researchers, such as Jack O’Donnell, James (Fred)
Maddux, and Karst Besteman.
EINSTEIN AND THE BLUE BIBLE
I decided to seek more training in pharmacology before continuing my psychiatry
residency, and was accepted as a post-doctoral fellow at Albert Einstein College
of Medicine. I was attracted by the quality of the faculty in psychopharmacology.
There was, too, a sense of excitement at the prospect of working in a department
headed by Alfred Gilman, the co-author of “The Pharmacological Basis of
Therapeutics”-- G & G -- the “blue bible” I had used as a medical student just a
few years before.
At Einstein, in 1961, Seth Sharpless and I hypothesized that the counteradaptation
underlying physical dependence on centrally active drugs might be linked to the
phenomenon of denervation or disuse supersensitivity. Our work on barbiturate
physical dependence showed that, contrary to what was believed at that time,
rebound hyperexcitability phenomena associated with barbiturate use developed
very rapidly (Jaffe and Sharpless, 1965). The onset was perhaps as rapid as with
opioids, which, as Wikler, Fraser and Isbell had shown in 1953, probably begins
with the first dose. We also demonstrated rapidly developing tolerance and
withdrawal-like phenomena after cholinergic blockade (Freedman et al., 1969).
In 1963, Murray Jarvik invited me to my first CPDD meeting. There I met
Nathan Eddy and other luminaries in the field. Later that year, the first of the
significant unexpected events of my career occurred. Lou Goodman and Al
Gilman decided it was time for a 3rd edition of G & G and that the text would be
multi-authored. To my great surprise, (since I had not ever published a refereed
paper), I was asked to contribute two chapters, one on narcotic analgesics, and
another--possibly the first in a general pharmacology text--on drug addiction. I
was flattered to be asked to contribute and could not turn down such an invitation.
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A cardinal rule when writing for G & G was not to exceed the number of words
or pages allotted. Every word counted, including citations and references; the
more the citations, the less room for facts. Despite admonitions, my chapter on
addiction exceeded the allowable length when I sent it to Lou Goodman in July of
1964. Goodman’s exacting editorial style and encyclopedic knowledge were
legendary - raw material for nightmares. I fully expected the chapter to be returned
from his scrutiny with large blue marks on every page, and derisive comments of
the kind he sometimes lavished on distinguished professors of pharmacology.
Gilman had shown me one such manuscript with Goodman’s comments, perhaps
to help me focus my efforts. Instead, in Lou Goodman’s characteristic bold hand,
a brief and very complimentary comment appeared on the face sheet. He and
Gilman decided to put the entire chapter into small print rather than cut it. Gilman
expressed his view that, because the text was used throughout the world, my
chapters might ultimately do more for patient care and for the field in general than
anything that I could have accomplished at that time in the laboratory or in direct
patient contact. (In retrospect, I’m not certain whether he was expressing
confidence in the influence of G & G or some doubts about my clinical and
laboratory skills.)
In the 29 years since the third edition of G & G, the process of revising the
chapters every five years has made it necessary for me to periodically revisit the
entire literature in the field and has afforded me the wonderful opportunity to be a
chronicler of the progress of knowledge on addiction and opioids. I welcome this
occasion as an opportunity to express my appreciation to all of you who have
contributed to what is now a vast body of scientific literature.
Because of my junior status in 1964, there was limited scope for my inherent
iconoclasm. But I did put forward a conceptualization of drug dependence that
differed from the authorities of the time. Eddy, Seevers, Halbach, and Isbell had
not yet published their suggested revision of the WHO perspective that divided
drug using behaviors into habits and addictions, the latter being distinguished by
the presence of physical dependence. In an attempt to convey the complexity of
the notion of compulsive drug use as I saw it, I wrote:
Addiction will be used to mean a behavioral pattern of compulsive
drug use. ... Addiction is thus viewed as an extreme on a
continuum of involvement with drug use and refers in a quantitative
rather than a qualitative sense to the degree to which drug use
pervades the total life activity of the user. Addiction in this frame of
reference cannot be used interchangeably with physical dependence.
(Jaffe, 1965a, p. 286.)
Some years later, the idea of a behavioral syndrome varying in severity and not
equivalent to physical dependence was incorporated into the DSM-III-R generic
definition of drug dependence. I found it curious even in 1964 that tobacco use
was not generally viewed as an addiction, and I managed to squeeze this comment
into an already over-length chapter:
Next to caffeine, nicotine (tobacco) is the substance most widely
used for its effect on mood. ... The evidence that smoking is linked
to cardiovascular and neoplastic disease and the inability of many
persons to refrain from the use of tobacco in spite of efforts to do so
suggest that this form of compulsive drug use will receive increasing
attention in the future. (Jaffe, 1965a, p. 302)
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This was a cautious comment. After all, Al Gilman was a heavy smoker and there
were limits to his faith in his junior staff. (Besides, nicotine was in the chapter on
Ganglionic Stimulating and Blocking Agents.) In 1973, I included nicotine and
tobacco in the first Federal Strategy for Drug Abuse and Drug Traffic Prevention;
and, in 1974, I was permitted to include nicotine in the revision of the chapter on
addiction for the 5th Edition (1975) of G & G. I noted then that tobacco use,
although rarely viewed as a form of drug abuse or an addiction, meets all of the
accepted criteria for drug dependence. The following year, I had the satisfaction
of working with Bob Spitzer to develop criteria for including tobacco dependence
along with other forms of dependence in DSM-III; and in 1976 I persuaded
William Pollin that NIDA should not continue to neglect nicotine.
At the time I wrote the chapter on narcotic analgesics, in 1964, physicians were so
concerned about causing iatrogenic addiction that they were often unwilling to
prescribe adequate doses of opioids for patients in pain. For that reason, I wrote:
Some degree of physical dependence and tolerance develop
whenever a narcotic is given in therapeutic dosage over a prolonged
period, . . . such considerations should not in any way prevent the
physician from fulfilling his primary obligation to ease the patient’s
discomfort.  . . . no patient should ever wish for death because of his
physician’s reluctance to use adequate amounts of potent narcotics.
(Jaffe, 1965b, p. 264)
As many of you have heard me say before, those last words, in italics, were for
my father, who died of cancer--in pain. Despite my status on a pharmacology
faculty, I had been unable to convince the attending physician that his fears of
addicting my 70-year-old father were unfounded. Starting in 1975, I co-authored
this chapter with William Martin, but this phrase was not changed.
METHADONE, LAAM, AND CYCLAZOCINE
By 1964, the problem of illicit drug use and heroin addiction had become a front
page topic and arguments for heroin maintenance were being made by some
respected scholars. Although my NIMH Career Development Award was based
on laboratory work aimed at understanding physical dependence, I had become
interested in exploring the clinical implications of opioid maintenance. I initiated a
study aimed at testing the notion that opiate addicts become tolerant to the euphoric
“rush” if allowed to use opioids i.v. over a prolonged period. I worked with a
few patients maintained on hydromorphone i.v., which caused me to be visited
regularly by an agent of the Bureau of Narcotics, but I was allowed to proceed. As
I now recall, I learned of Vincent Dole and Marie Nyswander’s work on oral
methadone in early 1965, and quickly found in my own work that there was
substantial benefit to both patients and therapists when oral methadone was the
only opioid maintenance option.
At a CPDD meeting in February 1965, Martin, Gorodetzky and their coworkers
suggested that cyclazocine, an opioid antagonist, might provide a means to test
Abe Wikler’s ideas about the role of conditioning. By September of 1965, I had
designed a study, obtained supplies and, with my colleague, Leon Brill, launched
a pilot study of cyclazocine. (Obviously, initiating clinical research was easier 30
years ago.) We presented our findings on 3-month’s experience with cyclazocine
at the CPDD meeting in February 1966, and our paper was published that year
(Jaffe and Brill, 1966). The eagerness with which heroin addicts sought such
treatment contradicted the belief that they were unmotivated to stop using drugs. It
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was obvious then that it would be useful to compare treatment with antagonists to
treatment with methadone. I had gotten hooked on what works for whom.
Around this time I became interested in finding out if alpha-acetyl methadol
(LAAM), a long-acting, methadone-like agent, would be effective in treating some
of the addicts I was seeing. The slow onset and long duration of LAAM,
described by Fraser and Isbell in 1952, seemed to be properties that could be
advantageous for treating opioid dependence. Unable to locate any space on the
Einstein campus for these clinical studies, I was happy to accept Daniel X.
Freedman’s offer to join his department at the University of Chicago and to carry
out both basic and clinical studies of opioid dependence.
THE UNIVERSITY OF CHICAGO AND THE ILLINOIS DRUG
ABUSE PROGRAMS
Although I formally joined the Chicago faculty in July of 1966, I did not move to
Chicago until six months later. In the interim, I had the good fortune to work in
Vincent Dole’s laboratory at Rockefeller University. At the same time, I provided
consultation to the newly established Narcotic Advisory Council of the State of
Illinois--a role arranged by Danny Freedman.
In stark contrast to New York, Illinois had virtually no provisions for taking care
of drug addicts. New York had a major detoxification hospital, a large-scale state-
supported civil commitment program with active acquisition of residential
facilities, and an expanding methadone program. There was also a growing
therapeutic community movement sponsored by the City of New York which built
on the techniques of Daytop Village and eventually gave rise to the Phoenix House
program. The only way an addict could get help in Illinois was to plead guilty to a
misdemeanor and then be detoxified under supervision in the infirmary of the jail
-the Bridewell.
In January, 1967, I moved to Chicago and began to set up my laboratory at the
University of Chicago. I also continued to provide consultation to the Illinois
Narcotic Advisory Council. My advice can be quickly summarized. Addicts, I
told them, are a heterogeneous group and we really don’t know what treatment
works best for which drug addicts. Therefore, Illinois should build a system that
supports each type of treatment approach for which there is some evidence of
efficacy; e.g., methadone maintenance, therapeutic communities, detoxification
and post-detoxification aftercare with or without antagonists; then carefully
evaluate the outcome for various patients, expand those methods that work, and
shrink or eliminate those that don’t. I also suggested that, despite the
Congressional wisdom expressed in the Narcotic Addict Rehabilitation Act of
1966 establishing a Federal civil commitment program, civil commitment, already
in the law in Illinois, should be held in abeyance. The Council decided that my
advice made sense and said they would put through legislation to establish and
fund a quasi-experimental treatment program for Illinois along the lines I
suggested. However, they had one condition: I had to agree to run it. I knew
from my New York experience that, for many people, treatment can make the
difference between a decent life and one of stress and misery. I believed I had no
real moral choice but to agree. This was the second unexpected event that sharply
altered the course of my life.
Here ends the part of the narrative where the work involved just a few coworkers
whose roles can be individually acknowledged. The next two episodes involve the
work of many talented coworkers and facilitators who formed the teams for which
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I am only a spokesperson. In both instances, they are too numerous to list. Yet
some played such vital roles that on this occasion their names must be mentioned.
Over the course of five years, Danny Freedman and the University of Chicago
were generously supportive -- even more so than I realized at the time. So, too,
were others in positions of authority, such as Governor Richard Ogilvie and
Harold Visotsky, then Director of the Illinois Department of Mental Health, who
responded with forbearance and resources to the unusual activities of what came
to be called the Illinois Drug Abuse Programs (IDAP).
Within the first 18 months, IDAP had established a 15-bed detoxification ward at
the hospital of the University of Chicago, residential and daycare facilities for
patients who completed detoxification, several methadone maintenance programs,
and a new therapeutic community--Gateway Houses Foundation, all in the
immediate vicinity of the University. With Danny’s help we recruited able
scientists, like Bob Schuster and Patrick Hughes, to the University of Chicago and
the Illinois Drug Abuse Programs. Others already in the Department of
Psychiatry, such as Ed Senay and John Chappel, were seduced to get involved
almost full time in the research and clinical work. Somewhat later, in mid-1969,
we persuaded David Deitch and several of his top level coworkers at Daytop
Village to come to Illinois - not just to strengthen the nascent therapeutic
community that we had started at Gateway, but to help build firm links between
the varied approaches we had initiated for helping opioid addicts recover and to
develop a staff training program.
PHARMACOLOGICAL AND EPIDEMIOLOGICAL STUDIES
Although Dole and Nyswander had initially stabilized their patients on methadone
on an in-patient basis, we found that our patients did quite well with totally
ambulatory transfer from heroin to methadone. We also found that many patients
showed remarkable improvement on relatively low doses of methadone. Our
retention rates for these patients were comparable to those seen in New York.
Further, about 20% of the first patients admitted to IDAP’s methadone program
elected to discontinue methadone but remained affiliated with the program. A few
of these patients later required restabilization on methadone. The observation that
some patients wanted to stop taking methadone and were able to do so
successfully led us to the next study, which asked whether patients maintained at
these lower doses were more likely to be able to successfully withdraw from
methadone, when compared to patients maintained on doses closer to those that
had been used in the studies by Dole and coworkers. In a study of patients
randomly assigned to an average of 35 or 100 mg of methadone we found, as
others have subsequently, that the low dose group was more likely to have urine
tests positive for illicit opioids. In this short study, the first of its kind, we did not
find that lower doses were associated with successful withdrawal (Jaffe, 1970).
Early in 1969, Bob Schuster, Ed Senay, and I launched our first studies of LAAM
and found that it had promise as an alternative to methadone (Jaffe et al., 1970).
Patrick Hughes and his coworkers initiated work on the social structure of heroin
using communities and on the epidemiology of heroin addiction (Hughes et al
1971-1972). John Chappel carried out work with cyclazocine and with mutual
support groups (Chappel et al., 1971).
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MULTIMODALITY AND ACCOUNTABILITY
IDAP was founded with the intention of conducting a study of random assignment
to maintenance, detoxification, and the Gateway therapeutic community. We
actually initiated that study, but it proved impractical and it was discontinued after
about eight months. Apart from the more formal scientific studies that were
carried out and published, IDAP developed a system of treatment accountability
that impressed the State of Illinois and assured us of continued support. We had
been awarded one of six NIMH community grants in 1968, but by 1971 this
provided only 14% of the program support. In the end we built a cohesive
multimodality program in which the focus was on how to help people recover
from addiction by finding which of the available programs worked best for them at
a given time, rather than on which single treatment approach was better than
another. It was a team approach that recognized the unique contributions of
scientists, clinicians, and of former patients--many of whom developed skills and
became program managers. The rancorous battles that characterized relationships
among programs in New York seemed to have been avoided (Glasscote et al.,
1972).
During the time we operated the inpatient detoxification unit, we noted that few
major medical problems arose that required the resources of an acute medical unit.
(The problem of HIV infection was not yet on the horizon.) But many problems
did develop due to limitations on space and to hospital regulations and procedures
designed to deal with different types of patients. In mid-1969, we closed the 15-
bed hospital detoxification unit at the University (much to the distress of Danny
Freedman and the hospital administration) and used the same funding resources to
open a new facility. The new program component was housed in an unused
building, intended as staff housing, on the grounds of Tinley Park, a mental health
center outside of Chicago. The building accommodated 100 people. Staffed only
with a part-time psychiatrist, two nurses, and several counselors, the Tinley Park
facility was nevertheless able to handle routine withdrawal. In addition, it provided
a TC-like atmosphere for patients referred from other units of the program who,
for a variety of reasons, needed more services or support than the existing
ambulatory program could provide. Unlike the typical TC of the time, the duration
of residence was adjusted to each patient’s needs. Tinley Park served as a crisis
center for outpatients on methadone, as well as for those who were not. All
patients were expected to take responsibility within the community. Some patients
stayed for a few weeks; others for several months; some brought their children
with them. There was a separate program for adolescents. Tinley Park was also
the training site for new staff and the presence of trainees enriched the program.
An even more complex multimodality unit, Safari House, was developed within
IDAP in a building provided by the University of Chicago. Because it was located
in the community, it served not only as a crisis intervention and residential unit,
but also as an outpatient unit and day hospital. Like Tinley Park, Safari accepted
women with children.
THE SYSTEM AND THE PEOPLE
As the program expanded and diversified, IDAP developed a central intake to
address the gatekeeper function of conducting rapid assessments and helping to
match patients with the treatment that seemed most appropriate. The objective was
same day treatment. A centralized oversight responsibility made IDAP responsible
for setting standards for staff qualifications, for treatment quality based on
objective outcome measures, and for developing contracts between community
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organizations and IDAP for services. Payment for treatment services was based
on capitation, an average cost for a year’s treatment for a patient of average
complexity. We also assumed responsibility for providing training and for the
networking that would facilitate moving patients among treatment units as the
needs of the patient changed. We put constraints on the use of acute hospital
inpatient space and instead developed residential, day-hospital, and outpatient care.
Two medical beds at a hospital on the north side of Chicago sufficed as medical
backup for the entire program.
By late 1970, we also developed a “re-entry” clinic that allowed patients who had
done poorly in one unit to get a fresh start, this time with more attention paid to
concurrent psychiatric problems. When the waiting list got long, we started a
“holding clinic,” or pre-treatment methadone dispensary, attached to central intake
to help actively addicted opioid users until a place in a regular treatment unit
opened. In today’s terminology, this would be called “interim” methadone. We
knew it wasn’t much, but it was the best we could do, and patients and staff
believed it was better than nothing. At the same time, Patrick Hughes’
community outreach team was showing us that people who don’t seek treatment
spontaneously may do so if only they are asked, and they do well if made to feel
welcome.
Many interested people from the U.S. and abroad visited the Illinois Drug Abuse
Programs to see what we were doing. One visitor who later played a major role
in the field, and in several subsequent events, was Robert DuPont, who shortly
thereafter initiated a major treatment program in Washington, D.C.
By July of 1971, IDAP had established more than 20 geographic units that were
providing care to more than 2,000 people. The IDAP staff developed data on
outcome of our methadone programs comparable to the studies done by other
methadone programs. Gateway contracted for a follow-up of its residents. These
data showed that a substantial percentage of patients had made major
improvements in their lives, as well as reduced their drug use.
There are many kinds of evidence in addition to the follow-ups, urine tests,
employment pay slips and rap sheets that researchers generally use as measures of
improvement. At IDAP we also had the evidence of our day to day interactions
with our patients. These interactions were not limited to brief office visits. We
got to know dozens, if not hundreds, of patients quite personally. There were
program picnics, baseball games, and celebrations. We met wives and husbands,
reunited; children no longer ashamed of parents or worried that a parent might die
or go to jail; parents no longer ashamed of their children. Patients and staff
shared food and the pride of an enterprise jointly undertaken. Some of the
celebrations were held in my home. My children were regular visitors at Illinois’
first therapeutic community, in a large house two blocks from our own on
Chicago’s South Side. Former IDAP professionals only recently have told me
that the great 1970 Fourth of July picnic at Tinley Park, when the staff and the
patients of all the programs and their families joined together, remains one of the
most memorable and emotionally uplifting events of their lives.
Here, listed alphabetically, are the names of some of the people at IDAP without
whom none of this could have happened. Ed Senay and I agree that this is only a
partial list: John Acheson; Ellen Afterman; John Chappel; Carl Charnett; Gail
Crawford; Michael Darcy; David Deitch; William Duerk; Sam DiMenza; Barbara
Evans; Nevin Fidler; Kirkland Fritz; Patrick Hughes; Krishan Kaistha; Herman
Lancaster; Clarence Lawson; Mary Ann Manson; Pierre Renault; Charles R.
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Schuster; Edward Senay; Edward Washington; Matthew Wright; and Mischa
Zaks. Some key IDAP staff included in this list began as patients. Their role in
IDAP’s success cannot be overstated.
NATIONAL STRATEGIES AND THE WHITE HOUSE AD HOC
COMMITTEE
It was around the time of the Tinley Park picnic that some of the groundwork was
laid that ultimately led to the third unexpected event. That summer, I spent
several weeks in London with Griffith Edwards, of the Institute of Psychiatry,
drafting a working paper for the WHO Expert Committee on Drug Dependence.
The Vice-Chairman of the committee was Nathan Eddy. Over the few days of the
meeting in Geneva, I came to appreciate why Dr. Eddy was held in such universal
high regard. The working paper Griffith Edwards and I submitted to the
Committee focused on questions of national strategies; e.g., how does a nation
decide which varieties of drug use are of concern; who is charged with
determining the responses to these concerns and specifying the goals; who is
responsible for reviewing data to determine the degree to which the responses
have been effective.
Shortly thereafter, I was contacted by Jeffrey Donfeld, a member of the Domestic
Council staff at the White House. We had met previously when, Donfeld, at Bob
DuPont’s suggestion, visited IDAP in the course of looking at drug treatment
programs throughout the U.S. Donfeld had become convinced, probably by
DuPont’s efforts in D.C., that much could be done about drug abuse just by
expanding treatment. On behalf of the Domestic Council, he asked me to convene
an ad-hoc committee of non-government experts to review and report
confidentially to the White House on the Federal government’s activities in drug
abuse treatment, prevention, and research; and also to make recommendations on
how to spend additional resources if they were made available. Over the eight
weeks Donfeld allotted to the task, Edward Brecher, Sydney Cohen, Jonathan
Cole, Gilbert Geis, John Kramer, William McGlothlin, Jack Mendelson, Helen
Nowlis, John O’Donnell, Roger Smith and I carried out the review and drafted
the report. Those of you who have attended these meetings for a long time will
recognize that the group could have been a subcommittee of the CPDD.
The committee report recommended expanding treatment, including methadone;
involving academic centers in the evaluation of treatment; and establishing an
agency or office charged with developing and evaluating an overall national
strategy. I heard nothing more from the White House until the following Spring,
when I was invited to the White House to discuss a very different problem--
heroin use in Vietnam.
HEROIN, VIETNAM, SAODAP
Eighteen years ago, in 1976, I described to a CPDD audience how my
involvement in the Vietnam intervention was linked to President Nixon’s
announcement of the “War on Drugs” and the creation of the Special Action
Office for Drug Abuse Prevention (Jaffe, 1976). That intervention was
predicated on the belief that behavior could be altered more effectively by a
modestly aversive but highly predictable consequence, such as a urine test and
brief treatment in Vietnam, than by an improbably catastrophic consequence, such
as a court martial. I also acknowledged my debt to a number of colleagues whose
work provided the intellectual framework for that intervention. Among others,
these included Abe Wikler, Bill Martin, Don Jasinski, and Avram Goldstein.
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What I did not describe in 1976 were the unexpected events surrounding the
President’s announcement on June 17,  1971. Based part ly on the
recommendations of the Ad Hoc Committee report, the White House had been
preparing legislation to coordinate the Federal government’s efforts to address the
growing drug abuse problem. As I recall, on June 17th, I was invited to consult
with the Domestic Council staff, and I fully expected to return to Chicago that
evening. Instead, I was escorted to the Cabinet room and there, in front of a
bipartisan group of Congressional leaders, President Nixon announced his plan
for a War on Drugs and the establishment of a new office to run that war - the
Special Action Office for Drug Abuse Prevention (SAODAP). He then
introduced me as the person who would be in charge of the new office. This
statement left me too shocked to say to the President that no one had asked me. It
also left me wondering how to tell Faith, my wife, that we were moving again.
She heard it for the first time on the news that night.**
I would like to mention briefly some of the work of SAODAP during its first two
years. The challenges we faced were wide ranging. One goal was to make
treatment so available that no drug users could say they committed crimes because
they could not get treatment for their addiction. But which treatments, and on
what infrastructure? NIDA did not yet exist. As far as the White House could
determine, in all of the Federal agencies combined, only 250 people were
involved with drug abuse research, education, grants administration and
evaluation. This included those charged with implementing the NARA civil
commitment programs.
At the same time, we needed to ensure a legislative base for the agency. Initially
funded by Executive Order, without Congressional consensus on its necessity
and authority, SAODAP would have run out of funding in less than a year. Then,
a task of particular interest to me, there was the need to create a science base. And
a special challenge to me, as a neophyte in government, was the explicit charge to
coordinate the activities relating to drug abuse carried out by all the different
departments and agencies of government. Once the legislation was enacted, we
were also charged with developing a written strategy. If such a strategy was to be
more rational in the future, we also had to develop the data necessary to determine
whether the elements of the strategy were having the intended impact. These
broad task descriptions encompass most of what we did in two incredibly busy
years. But under each of these headings there were sub-tasks, some of which
were themselves major challenges.
DEMAND AND SUPPLY
The Vietnam intervention continued to be a front burner issue. The results of the
urine testing seemed to indicate that the intervention was having the intended
effect: with each passing month, fewer Army personnel tested positive for opiates
at time of departure. I used these data repeatedly to point out that sometimes less
is more: that while all the MPs and electronic fences and threats of court martial
could not bring heroin use under control, it was being reduced by properly
arranged contingencies, even though the severity of the penalty had been reduced.
The argument I presented internally within the Executive branch was that more
can be accomplished by demand reduction than by supply control. These
arguments were temporarily effective, as can be seen from budget allocations of
that time. For a brief interval, policy was driven by data and results, and
SAODAP was showing that at least one of its programs (the intervention in the
military) was effective.
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A central theme was the expansion of treatment capacity. In doing so we used
several principles developed at IDAP. We funded a variety of programs,
including residential programs, but we limited the use of acute hospital beds.
While residential and outpatient capacity grew, the percentage of Federally
supported treatment capacity that used inpatient beds, including V.A. Hospital-
based programs, shrank from 6% to 4%.
It was our intention to increase not just the number of programs, but their actual
capacity and their geographic distribution. Just specifying treatment capacity was
a problem, since up to that time grantees were not necessarily funded to treat any
particular number of people and, once funded, they sometimes felt no particular
concern if no one sought the kind of treatment they offered. We adopted the
IDAP management concepts, including words like “slots,” “static capacity,” and
“dynamic capacity,” which probably have outlived their utility and await some
equally simple concepts to replace them.
METHADONE TREATMENT EXPANSION AND OTHER SMALL
TASKS
Legitimizing methadone maintenance and developing acceptable regulations for it
was highly visible, highly controversial, and very expensive in terms of political
capital. But it was only incidental to the overall mission of making effective
treatment more than an afterthought in the national response to the drug problem.
Within the first 18 months, the number of communities with Federally supported
drug treatment programs rose from 54 to 214 and the number of programs to
almost 400. We had developed more federally supported treatment capacity
within the first two years than had been developed over the previous 50 years.
Paul Perito, the Deputy Director of SAODAP, and Grasty Crews (in the office of
the general counsel) played critical roles in the process of establishing the
legislative base for the office. The requirement for a formal written National
Strategy emerged in response to a question at one of those numerous
Congressional hearings associated with the SAODAP legislation, as various
congressmen probed to learn how we would use the power of the office to solve
problems. (Perito estimates that we testified more than 100 times before 11
committees in the House and the Senate over two years.) Other ideas that were
converted into legislative authorities or mandates included special authorities to
develop new pharmacological agents, and a national training center. Finally I
learned to say less in front of Congress. The authority to establish a National
Institute on Drug Abuse (NIDA) was written into the same legislation that created
the Special Action Office, and it was my able successor at SAODAP, Bob
DuPont, who initiated and was the first director of NIDA.
Here is a short list of some of the other projects that kept us busy: Vietnam
intervention and follow-up; methadone treatment and methadone regulations;
confidentiality regulations; Federal Strategy; NIDA research centers; naltrexone;
LAAM; TASC; Career Teachers; National Training Center; Young Men & Drugs;
DAWN; CODAP; formula grants; management concepts and language; treatment
in the V.A.; laboratory standards for urine testing facilities. I should at least
comment at this meeting on the development of pharmacological treatments. The
Veterans Administration study of LAAM that SAODAP designed and funded
formed one of the pivotal studies that allowed NIDA, 20 years later, to obtain
FDA approval. Clinical studies of naltrexone were also funded, and CPDD
played a critical role in one of these studies.
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Last year’s Eddy Award winner, Lee Robins, related how I contracted with her to
conduct the Vietnam follow-up study and how happy the Department of Defense
was to learn that relapse to heroin addiction was unexpectedly low (Robins,
1994). She did not tell you how I selected her to do the work, or how unhappy
the DOD was initially with the idea of a follow-up study. I would like to
acknowledge some other contributors to this classic study. Shortly after I was
appointed “drug czar,” I went to Vietnam (accompanied by my friend and
colleague Beny Prirnm, among others) to inspect the intervention program I had
designed and DOD had implemented. On my return, I reported to President
Nixon at San Clemente. After hearing my report, the President said, “You should
write a book about this; some of the greatest advances in medicine have come
about from the lessons learned in wars.” I took this as a directive, and so was
born both the decision to conduct a follow-up study and the authority to see that it
got done. Danny Freedman recommended Lee Robins as the best person to carry
out the follow-up, and David Nurco, as a consultant to SAODAP, worked with
Lee and reported back on any agency roadblocks to the study, all of which were
grudgingly removed after phone calls from the White House to the reluctant
agencies.
SAODAP AND RESOURCE ALLOCATION
It was obvious to me that more resources were needed for research on drug
abuse. For those in this audience who have been in this field for less than 20
years, it is useful to be reminded how little research support there was in 197 1. In
1969, in the last Johnson administration budget for drug abuse issues, the total
for all Federal demand side activities and law enforcement efforts was less than
$100 million, with about $50 million devoted to treatment and prevention.
Although the treatment and prevention budget increased in 1970, in the initial FY
197 1 budget, the total for research - clinical, basic, epidemiological, evaluation -
for all agencies was about $12 million. The 1971 Supplementary amendment
doubled the research budget. The growth in Federal funding for research,
treatment, and training took place over a relatively few years and then was again
flat. For a brief period, from 1972 through 1974, the balance between support
for supply control and demand reduction activities shifted in the direction of
demand reduction. In 1974, two-thirds of $750 million of Federal resources for
drug abuse went to treatment, research, education, and prevention. According to
an analysis by the Institute of Medicine (Gerstein and Harwood, 1990). when
adjustment is made for inflation, the absolute level of support for treatment and
prevention was lower in 1989 than it was in 1974. While the 1974 proportion of
the resources allocated to demand side activities has not survived over the years,
SAODAP’s early decisions provided a solid beginning for research and a
foundation for later expansion.
As the years have passed and my experience with government grows, I have
come to appreciate what an extraordinary period that was, and what a supremely
competent and dedicated group of people were assembled to work at SAODAP.
Here is a partial list, in alphabetical order: Robert Angarola, Virginia Bannister,
Deborah Hastings Black, Richard Boucher, Grasty Crews, Gerald DeAngelis,
Lee Dogoloff, Jeffrey Donfeld, William Duerk, Alan Green, Jim Gregg, Ralph
Howard, Thomas Keegan, Richard Klass, John Kramer, Brian LeBert-Francis,
Mary Ann Manson, Bernard McColgan, John Meagher, Raymond Milkman,
Stuart Nightingale, Vincent Nowlis, Paul Perito, Robert Pinko, Jack Richard,
Kathleen Ross, A. John Rush, and Charles Yarbrough.
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I have already mentioned the vital role Paul Perito played as Deputy Director. In
addition, to the small staff of SAODAP itself, we were able to use consultants
who could not make a full time commitment. Among the consultants who gave
generously of their time and expertise were John Ball, Roger Meyer, Jack
Mendelson, David Nurco, and Beny Primm.
With the exception of the data on the efficacy of methadone maintenance, the great
expansion of treatment in 1971 was based largely on faith and persuasive
advocacy. In the intervening 23 years, we have developed not only better
methods for assessing the efficacy of treatment, but better questions as well. We
know a lot about the characteristics of patients likely to do poorly. We also know
a lot about what makes a good program - but improving poor programs involves
management and resources issues more than science.
TREATMENT, SCIENCE AND RESOURCE ALLOCATION
It seems to me that with respect to the science of the treatment of drug dependence
several knotty problems remain - and they are probably interrelated. First there
remains the puzzling and sometimes inspiring capacity of drug dependent
individuals to improve as a result of a variety of life changes, not all of which can
be thought of as treatment. For example, Lee Robins told us last year about
opioid dependent drug users who regained control over drug use unrelated to any
identifiable intervention. A follow-up of some addicts from the early years of the
California Civil Commitment program found that those who had achieved
abstinence from opioids (albeit only 30%) generally had positive views of their
treatment experience under the program, but frequently attributed their recovery to
religion as well (Bailey et al., 1994). George Vaillant (1973) long ago told us of
the relationship between parole supervision and recovery from opioid
dependence. There are also those who achieve recovery as a result of treatment in
therapeutic communities. Even when we look at treatment with methadone we
find that, while many patients do best when maintained on methadone
indefinitely, there are those 15 to 30% who find a way to do well after withdrawal
from methadone.
Despite our efforts thus far, we are still not able to predict with great accuracy
which individuals will respond best to which treatment at a particular stage in their
drug-using careers. While we may be making some progress in matching
alcoholics to specific treatments, in the case of cocaine dependence we are
probably no further along than we are with opioid dependence. For the work-a-
day clinician there is still a need for data to help with the decisions about what to
recommend to that next patient who comes through the door.
Perhaps related to our current inability to specify the one best treatment that will
help a given individual at a given time, there persists in some influential quarters a
disbelief in the efficacy of treatment in general. Too often I have heard
individuals, who until recently were in policy making positions, say that treatment
just doesn’t work. Without the efficacy of supply control interventions being
questioned, for the past 18 years Federal resources were disproportionately
directed at crop control, border interdiction, and law enforcement activities aimed
at control of local drug distribution. A recent RAND analysis suggests that
available data indicate that treatment is far more cost effective in reducing cocaine
use than are crop control, border interdiction, or even domestic law enforcement
(Rydell and Everingham, 1994) a point I believed but could not prove 23 years
ago.
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Without waiting for Congress to act on health care reform, private insurers have
been carving out treatment of drug problems as an area where sharp cost
reductions are possible. Unfortunately, even as the data mount showing that time
spent in treatment is a powerful predictor of outcome for many patients, the
amount and duration of treatment is being reduced along with costs. To an
undetermined extent, the trend to move medicaid patients into managed care
arrangements is probably reducing the time spent in treatment. The system seems
to be responding to factors other than data. It would seem that some fiscal
decision makers have drawn the inference that since so many interventions work
for some people, then all interventions are probably equally efficacious, and we
might as well emphasize those that cost the least and offend the sensibilities of the
fewest. Take heart. Press on with clinical and basic research. Every once in a
while an unexpected event occurs and data competently developed and honestly
interpreted regain their capacity to influence policy.
On behalf of my wife, who has been responsible for almost every manuscript I
have ever turned in; my children, now grown, who six times sacrificed their
dining room table at the altar of the blue bible (and once for the first Federal
Strategy); and on behalf of my coworkers at IDAP and SAODAP and those in the
Federal bureaucracy and Congress who made SAODAP make a difference, I
gratefully accept this Nathan B. Eddy Award.
** ADDENDUM
Shortly after I gave this lecture, I found a memorandum written by Jeffrey
Donfeld describing a meeting in the Oval Office on June 10, 1971, at which,
apparently, I first met President Nixon and discussed the plan for the Vietnam
intervention. The memo also describes my suggestion that it was important to do
a follow-up study of that intervention. The discovery of the Donfeld memo led
Faith to search out the press clippings that she and other family members had
saved. During the days following the Oval Office meeting, my name and picture
appeared in the media describing me as the person likely to head a major program
dealing with drugs. It is clear that I must have known that I might be asked to
play some role in a new program. Nevertheless, the emotional impact of being
publicly named by the President to head the program at the meeting in the Cabinet
Room on the 17th --without my having been formally offered such a position --
was such that, for the 23 years since then, I have mis-remembered the precise
chronology of the events.
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THE RELATIONSHIP OF SCIENCE TO DRUG ABUSE
POLICY
H. Kleber, R. Weich, A. Solarz, and M. Kleiman
According to many, drug abuse is the number one ethical, moral, legal, social,
and public health problem that faces the United States today. Further, since
different members of our pluralistic society conceptualize this multi-faceted
problem in different ways, the social and public health policies suggested for its
solution are diverse and often contradictory. Finally, as is the case with most
contentious areas of human behavior, there is often an inverse relationship
between the passion with which people express their views about a policy and the
availability of evidence supporting its effectiveness. Consequently, it is with
some fear and trepidation that a scientist enters this arena.
Nonetheless, in this symposia the participants have attempted to bring some light
to the discussion of the potential role of science in the conceptualization,
elaboration, implementation, and evaluation of policies in the area of drug abuse.
It began with comments by the chairs on the way in which policies are often
predetermined by the way problems are conceptualized, and then moved to the
participants who discussed some specific ways in which science and drug abuse
policy interact, and the obstacles which must be overcome to facilitate this
interaction.
To start with, it is important to identify who the policy makers are and how they
can best be informed about relevant science. Dr. Herb Kleber provided his
unique perspective as the former Assistant Director of the Office of National Drug
Control Policy, and Mr. Ron Weich from his perspective as a Congressional staff
member dealing with drug abuse policy and legislation for Senator Edward
Kennedy. Dr. Andrea Solarz discussed her experiences as a science advocate in
attempting to educate congressional staff on the latest biobehavioral research
findings that are relevant to drug abuse, and Dr. Mark Kleiman served as
discussant.
In his presentation, Mr. Weich gave the conference attendees an appreciation of
the rapid pace and time sensitivity of policy making, speaking via telephone from
his office in Washington, D.C. during a break in ongoing staff meetings, on the
legislation which would later become the Omnibus Crime Bill of 1994. He
emphasized (and demonstrated) that the pace of legislative activity on drug-related
issues is sometimes quite rapid and often enmeshed within much larger legislative
initiatives. The bill he was working on at the time was an excellent example, given
that millions of dollars of drug abuse treatment provisions (although not research)
were included among the many anti-crime provisions of the bill. He
acknowledged the important work of the College and of the research community;
noting that although data may often be used inappropriately to lend support to a
certain partisan position, in the final analysis the knowledge gained from the
body of research on drug abuse and dependence is extremely valuable in guiding
the legislative process.
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Herb Kleber was the Deputy Director of Demand Reduction in the Office of
National Drug Control Policy for two years, where he had responsibility for
setting the national strategy for reducing the demand for illegal drugs. He also
has a long and distinguished career in research in the substance abuse field, and
brought this wealth of first hand experience in both the policymaking and
scientific realm to the symposium. He noted that policy should ideally be driven
by timely and accurate scientific data. Unfortunately, often either such data
does not exist or exists in a form not usable or useful for policymakers. There
are, of course, those not infrequent episodes where good data does exist and is
ignored, for example, the Swedish Methadone Study.
There are many policy issues that could benefit from accurate data, and Dr. Kleber
reviewed several of them. For example, many call for alternatives to incarceration
or for increased treatment in prison. However, Attorney General Janet Reno has
emphasized that prison cells are a scarce commodity in many communities and
should be used to their maximum advantage. This speaks to the need for more
information on predicting dangerousness and recidivism as well as exploring
possibilities for shorter but surer and swifter prison sentences.
Funding for treatment in the recent past has been a bipartisan failure -- the
Republican administration, under President Bush, asked for insufficient funds
and the Democratic controlled Congress provided about 1/3 of what increase was
requested. This stems from a lack of belief in treatment efficacy, both among
policy makers and the general public. No one ever lost an election by not voting
for more funds for treatment, but many have won or lost depending on whether
they called for more police. This, of course, also relates to the moral belief that
the public should not be paying for treatment for individuals who brought their
problems on themselves, although we ignore that for other diseases, such as heart
attacks related to life style issues.
Dr. Kleber summarized the primary research needs for drug policy in three areas:
epidemiology, treatment, and prevention. In the area of epidemiology, he
identified the critical need for better data on the numbers and characteristics of
addicts: how many individuals are addicted to various drugs?; what are their
relevant demographic and psychological characteristics?; how many need
treatment?; and what kind(s) of treatment are needed? Also, critical to
development of policy is valid, reliable and timely data on changes in drug use in
various segments of the population. In the treatment area, he identified several
important needs. First, there is a lack of data on what happens to individuals once
they enter the treatment system, the “natural history” of treatment services.
Second, there is a need for better information on what treatment services work
best for what individuals, that is, on matching patients to the optimal treatment
modality and services. Finally, we need to do a better job of measuring treatment
outcome in ways that make sense and are useful to the policymaker. Finally, in
the area of prevention, we need to collect more information on factors which are
protective against drug abuse and addiction; and how to target our prevention
efforts to different segments of the adolescent population.
Dr. Kleber identified several policy areas that he thought were ready for change.
He called for a more equitable division of anti-drug funding between supply
reduction and demand reduction activities, which would include expansion of
treatment services capacity to 2.5 million episodes per year. He also called for
increased emphasis on addicts involved with the criminal justice system; for
example, by utilizing therapeutic communities as alternatives to prison; and for
increased efforts to improve the comprehensiveness of treatment to include HIV
and TB services.
Andrea Solarz, Assistant Director for Science Policy of the American
Psychological Association, titled her presentation, “Scientists and Policymakers:
Strange Bedfellows?” In it she noted that there actually is a relationship, albeit
tenuous, between the two. Unquestionably, national policies do get developed
without being adequately informed by what we have learned from relevant
research. At the same time, however, there are many opportunities to get the
results of scientific study into the policymaking process. The major challenges
facing organizations that are trying to foster a greater appreciation for the
contributions of science to the policy process, are informing Congress about the
important contributions behavioral science can make to the policymaking process,
and convincing scientists that they have an important role to play in this activity.
Few scientists are actively involved in public policymaking, and many actually
resist involvement. There arc a number of reasons for this: they are
uncomfortable with the policy world and the policy process, which seems
unmethodical and unpredictable; they may not believe that advocacy is an
appropriate role for scientists; or they may feel that they arc not well enough
informed or skilled to participate. There are many reasons why policymaking
should be important to scientists. For example, there arc a number of direct
“pocketbook” issues. Congress decides how much money will go to the federal
research institutes, and often directs what areas should be funded. Congress may
also direct what types of studies CANNOT be done, sometimes targeting studies
that had previously been approved through peer review. Legislation may even
direct HOW research can be conducted, for example, by regulating the use of
animals in research or restricting the types of questions that can he asked of
human subjects.
Scientists have significant information to contribute. There are many areas where
behavioral scientists offer special insight and expertise because of their knowledge
of behavior, for example, in the areas of anti-crime legislation, welfare reform, or
drug prevention legislation. Finally, the involvement of scientists is critical
because if they don’t participate, there are many other voices competing for
attention, and those are the ones that will be heard. There is not presently a loud
advocacy voice on Capitol Hill with a primary focus on substance abuse research.
Most of the organizations in Washington that focus on substance abuse are
interested primarily in services issues. And although most would agree that
research is important, their support is incidental to the main work that they do.
Scientists should become more involved and can, through professional
associations, such as the American Psychological Association. For example, the
APA often invites members to present testimony before Congress, brief
Congressional staff on research relevant to critical policy issues, and help identify
gaps in the field. While few scientists pursue interests in policymaking by
actually working on Capitol Hill, there are many other ways in which they can be
involved. Visits to legislators, or calls or letters on legislation can have real
impact. And, scientists can help to educate policymakers about the importance of
science and its contributions to the development of sound public policy, for
example by actually hosting a visit to their institution.
The relationship between policymakers and scientists is one that works both
ways: what policymakers do affects science; hut what scientists do can influence
policymakers as well. Clearly, a choice does not need to be made between doing
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science and doing public policymaking. Scientists have much to contribute to the
process, and can do so even without a big commitment of time or an in-depth
understanding of the process.
The discussant, Mark A. Kleiman, noted that the influence of science on policy
may be less powerful than the influence of policy on science. In the desired
arrangement, key uncertainties whose resolution would inform important policy
choices are identified, and research resources are directed toward activities that
might resolve those uncertainties. More common, however, are situations in
which research resources are made differentially available for projects which fit
pre-conceived notions or current drug policy. In today’s political environment,
that means research which reinforces the public fear of drugs (to reduce
prevalence) and of drug users (to create political support for prevention,
treatment, and enforcement). The situation is further complicated by the
legislative distinction between licit and illicit drugs. Obviously, from a scientific
standpoint, the current legal status of drugs should not but too often does affect
research. Several examples of how data can be used to support one policy
position over another were given to illustrate the complex and evolving
relationships between science and drug policy.
Conclusion
Policies are determined by many different factors in addition to scientific data.
Political and economic considerations, as well as ethical and moral judgments
enter into the decision-making process of policymakers. Which of these
influences predominates depends not only upon the issue but as well, the
“zeitgeist” of the society. The principle role of the scientist is to provide, where
possible, scientific data to assist in the policy-making process, recognizing that
only rarely will such contributions be determinative of the outcome. It is hoped
that symposia, such as this, will provide a context in which scientists and policy-
makers and policy analysts can begin a discourse that will lead to greater
communication and understanding. In this manner the CPDD membership may
become of greater assistance to policy makers in the establishment and evaluation
of drug abuse policy. In fact, several mechanisms already exist, through the
auspices of the American Psychological Association and the American Association
for the Advancement of Science, for researchers to contribute directly to the
legislative policy process through fellowship programs. Attendees were
encouraged to become more actively involved in science policy-making through
these and other programs.
SUMMARY
Steven W. Gust
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Characterization of Opioid Receptors at the Molecular Level
Chris Evans, Ph.D., Department of Psychiatry & Biobehavioral Sciences,
University of California, Los Angeles, CA
The molecular characterization of the opioid receptors at the nucleic acid level has
begun to reveal the features that constitute the heterogeneity that has been
observed for two decades in both opioid binding sites and the physiological
action of different opioids. The original isolation of a opioid receptor cDNA
from the neuroblastoma/glioma cell line NG108-15 provided the template from
which the µ and opioid receptors have subsequently been identified. These
three cloned receptors, which thus far constitute the opioid receptor family, have
high interhomology (70-80% identity) with the exception of the N- and C-
terminal domains and the third and fourth extracellular domains. The homology
profile is highly consistent with the observation that all three receptors act
through similar intracellular signalling systems although with somewhat different
ligand selectivities. The repeated isolation of identical µ, and receptor
sequences has raised questions as to the etiology of the subtypes of these receptor
classes i.e., whether subtypes such as indeed have different primary
structures. The lack of appropriate clones for these subtypes has reinstated the
hypothesis that the environment of the receptor or post-translational changes may
contribute to the observed pharmacological heterogeneity.
Genomic analysis has identified multiple introns in the protein coding region of
all three opioid receptor genes and conserved features in the intron/exon
boundaries. Unlike some G-protein coupled receptor families, the human opioid
receptor genes are not clustered and have been mapped to distinct chromosomes
with the delta on chromosome 1, the kappa on chromosome 8, and the mu on
chromosome 6.
In situ hybridization with cRNA probes in both human and rodent tissues has
begun to reveal the individual cells expressing the , µ, and opioid receptors.
The distribution of mRNA encoding the receptors is, in the main, consistent with
prior mapping studies based on radioligand binding and autoradiography. For
example, the distinct patch distribution of mu receptor binding in rodent striatum
is consistent with a patch-like distribution of the µ receptor mRNA, whereas in
human striatum both the µ receptor mRNA and binding does not appear to
conform to an obvious patch/matrix distribution. In situ has revealed a number
of additional areas in rodent brain that may express opioid receptors including the
motor neurons of the ventral horn which express receptor mRNA and the deep
cerebella nuclei which express both µ and receptor mRNA. Clearly the nucleic
acid and antibody probes derived from the cDNA and genomic clones will
considerably enhance our understanding of the neuroanatomy of the endogenous
opioid receptors.
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Human Opiate Receptors and Their Genes
George Uhl# * ! + ,  J ia-Bei Wang# , Peter Johnson#!, Yasuo Imai#, Donna
Walther, Jun Min Wu#, Wen-Fei Wang#, Akiyoshi Moriwaki#, #Molecular
Neurobiology Branch, *Office of the Director, Intramural Research
Program/NIDA, !Pharmacology Research Associate Program, NIGMS; +Depts.
of Neurology and Neuroscience, Johns Hopkins University School of Medicine
Baltimore, MD
µ Opiate receptor distributions and pharmacologic properties place them among
the receptors most identified with the analgesic and addicting properties of opiate
drugs. Recent studies have identified cDNAs encoding rodent and human µ, and
and rodent opiate receptors. The availability of these cDNAs has allowed us
to define the structure of the human µ opiate receptor gene, to identify human
opiate receptor cDNAs, to stud developmental and other patterns of the µ opiate
receptor’s regulated expression, and to identify structure-function relationships in
these interesting members of the seven transmembrane domain, G-protein linked
receptor family. Analysis of 50kb of genomic sequence reveals that the human
µ receptor gene contains three introns interrupting four protein-coding exons,
ranging in size from 359 to >750 base pairs. Studies with chromosomal in situ
hybridization and rodent/human hybrid cells both indicate localization of a single-
copy gene to chromosome 6, bands q24-25. Ribonuclease protection assays
revealed the most abundant µOR mRNA was in thalamus, hypothalamus,
midbrain, and spinal cord. In situ hybridization studies reveal that
subpopulations of neurons in several thalamic nuclei express µOR mRNA, with
most abundant expression in neurons of the medial aspect of the lateral habenula.
µOR immunoreactivity was detected in the dorsal horn of the spinal cord, nucleus
caudalis of the trigeminal nuclear complex, the vagal nuclei, nucleus ambiguous,
the locus coeruleus, the periaqueductal grey, and other brainstem regions. These
distributions of mRNA and protein appear in developmental patterns that display
regional specificity. A subcloned PCR amplification product from human brain
cDNA which encoded amino acids corresponding to the putative second
extracellular loop of the human opiate receptor sequence was introduced into
the human µ opiate receptor by recombinant PCR. The N/ chimera retained high
binding affinities for morphine, DAMGO, and naloxone; while, its affinities for
a-neoendorphin, dynorphin A (1-13), and dynorphin A (1-17) were increased by
more than 250-fold, 100-fold, and 10-fold, respectively, when compared to
affinities for these peptides displayed by the wildtype µ receptor. The chimeric
receptor was fully active in cyclase inhibition mediated by morphine and
dynorphin A. These experiments appear to identify substantial contributors to the
“address” aspect of dynorphin recognition.
Opioid Receptors: Molecular Cloning and Cellular Function
Lei Yu, Ph.D., Department of Medical and Molecular Genetics, Indiana
University School of Medicine, Purdue, IN
The µ opioid receptor represents the high affinity binding site for the opioid
narcotics with high abuse liability such as morphine, codeine, methadone, and
fentanyl. In addition, heroin (diacetylmorphine), a semi-synthetic derivative of
morphine, crosses the blood-brain barrier much more readily than morphine due
to its increased hydrophobicity. Once in the brain, heroin is rapidly hydrolyzed to
morphine, which acts at the µ opioid receptor and results in an euphoric effect,
thus conferring the reinforcing properties of the drug and contributing to the
development of drug dependence. Because of its high affinity for these aped
narcotics, the µ receptor is considered the main cellular mediator in the
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narcotics, the µ receptor is considered the main cellular mediator in the
development of tolerance and opioid addiction (Di Chiara and North, 1192).
Using a strategy of low stringency hybridization for isolating opioid receptors
(Chen et al., 1993) related to the mouse opioid receptor, we have cloned the
cDNAs for the µ opioid receptor from the rat and human brain. Upon transfection
into cultured mammalian cells, the cDNA clones express the µ opioid receptor
with nM affinity for opioid narcotics, as well as for endogenous opioid peptides
ß-endorphin, Met- and Leu-enkephalins, and dynorphin A (1-17).
The µ opioid receptor is known to exert two types of inhibitory effects on a cell:
reduction of the intracellular level of cAMP; and inhibition of neuronal firing.
Using the cloned µ opioid receptor, we have started to study the molecular
mechanisms for both of these processes. A mammalian cell line has been
established in which the µ opioid receptor is expressed at a high level. Acute
activation of the µ receptor results in a decrease in the intracellular cAMP. After
the cells are chronically exposed to morphine, withdrawal of morphine causes a
rebound in cAMP, suggesting that the cells may be used as a model for study of
the biochemical changes that may occur in aped dependence. When expressed in
amphibian oocytes, the µ opioid receptor inhibits a low voltage-activated Ca2+
channel and stimulates a G protein-activated K+ channel. Upon repeated
stimulation, the µ receptor-coupled K+ current is desensitized. Interestingly, the
desensitization is modulated by protein kinases: the cAMP-dependent protein
kinase (PKA) blocks desensitization, whereas both the protein kinase C (PKC)
and the type II Ca2+ /calmodulin-dependent protein kinase (CaM kinase II)
potentiate desensitization. Our results suggest that these cellular models are useful
in studying the cellular function and tolerance development involving the µ opioid
receptor (Chen and Yu, 1994).
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Genomic Structure and Analysis of Promoter Sequence of a Mouse
µ Opioid Receptor Gene
Bon H. Mink, Lance B. Augustin*, Roderick F. Felsheim*, James A. Fuchs”,
and Horace H. Lob*, * Department of Pharmacology, University of Minnesota,
Minneapolis, MN; ˆDepartment of Biochemistry, University of Minnesota, St.
Paul, MN; and &Department of Biochemistry, Kon-Kuk University Choongju-
city, Korea
We have isolated mouse µ opioid receptor (MOR) genomic clones containing the
entire amino acid coding sequence corresponding to rat MOR-1 cDNA, including
additional 5’ flanking sequence. The mouse MOR gene is .53 kb long, and the
coding sequence is divided by three introns, with exon junctions in codons 95
and 213 and between codons 386-387. The first intron is .26kb, the second
.8kb, and the third .12kb. Multiple transcription initiation sites were observed,
with four major sites confirmed by 5'RACE and RNase protection located
between 291 and 268 bp upstream of the translocation start codon. Comparison
of the 5’ flanking sequence with a transcription Factor database revealed putative
cis-acting regulatory elements for transcription factors affected by cAMP, as well
as those involved in the action of gluco- and mineralo-corticoids, cytokines and
immune cell specific factors.
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Mapping and Modulation of Opioid Receptor Gene Expression
Mary Jeanne Kreek, M.D., Laboratory on the Biology of Addictive Diseases,
The Rockefeller University, New York, NY
For several years our laboratory has had a major research interest in the possible
role of the endogenous opioid system in three major addictive diseases: heroin
addiction, cocaine dependency, and alcoholism. We have shown in basic clinical
research studies that the endogenous opioid system components involved in
hypothalamic-pituitary-adrenal axis as well as hypothalamic-pituitary-gonadal
axis, important stress responsive and reproductive biological systems, are
profoundly disrupted during cycles of heroin addiction. More recently, we have
also shown disruption of the hypothalamic-pituitary-adrenal axis in recently
abstinent cocaine addicts. Prolactin release is also disregulated in each of these
addictive diseases, possibly reflecting derangement of normal opioid-dopamine
modulation. We have developed an experimental protocol in which cocaine is
administered to rats in a “binge” pattern, similar to that used by cocaine addicts;
using this paradigm, we (Unterwald et al.) have shown that both mu and kappa
opioid receptor density is significantly increased in the nucleus accumbens,
caudate putamen. as well as some other brain regions which are part of the
mesolimbic, mesocortical, or nigrostriatal dopaminergic systems. Using
techniques of solution hybridization protection assay modified within our
research Center (Inturrisi, Branch, Robertson et al.), we have re-examined the
localization of opioid peptide gene expression in the brain, and have found that
both enkephalin gene expression (Branch et al.) and prodynorphin gene
expression (Spangler et al.) are abundant in the nucleus accumbens, and caudate
putamen, and also in the hypothalamus, important for regulation of endocrine
neuropeptide release.
Following the cloning of the specific opioid receptors and the availability of
probes generously supplied by several collaborators (L. Yu, G. Uhl, C. Evans,
B. Kieffer, and M. Abood), we have initiated studies in mapping of opioid
receptor gene expression. We have found that there is abundant expression of
the mu opioid receptors in the nucleus accumbens, caudate putamen, ventral
tegmental area, substantia nigra, and hypothalamus, as well as in other areas
where mu receptors have been previously identified by selective ligand binding to
be very abundant; kappa opioid receptor mRNA has been found to be abundant in
these areas (Spangler et al.). Our studies of the effects of cocaine on opioid
peptide gene expression have shown that there are no persistent changes in
enkephalin mRNA levels (Branch et al.) but increased expression of
prodynorphin mRNA levels after chronic cocaine administration (Spangler et al.).
In on-going studies, simultaneous measurement of dynorphin and kappa receptor
mRNA in the same animal following binge pattern cocaine or saline
administration is being determined; preliminary findings suggest there is a
positive correlation between the increases in mRNA of both of these opioid
system genes (Spangler et al.). In other on-going studies (Unterwald et al.), the
effects of naltrexone on mu receptor mRNA levels has been studied, and to date,
no alterations found despite significant “up-regulation” (i.e., increased density of
mu opioid receptors. Also, preliminary studies of the effects of methadone on
mu opioid gene expression (Unterwald et al.) have found no significant
changes. Studies conducted in rodent models are being paralleled with studies
using specific opioid receptor-directed ligands and the PET imaging techniques
by our group in collaboration with the NIH to determine the effects of drugs of
abuse and treatment agents in humans on the endogenous opioid system.
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Quantitation and Localization of Opioid Receptor Gene Expression
Charles E. Inturrisi, Department of Pharmacology, Cornell University Medical
College, Ithaca, NY
We have developed a specific and sensitive solution hybridization assay for the
delta opioid receptor (DOR) mRNAs using the cDNA of Evans et al., 1992.
With Dr. V. Pickel we have prepared site directed antibodies to DOR so that we
can determine both DOR receptor mRNA and protein levels. Exposure of
neuroblastoma hybrid (NG108-15) cells to either naloxone or ethanol results in
an increase in DOR transcripts. Image analysis of northern blots of the RNA
extracts of control and treated NG 108-15 cells indicates that each of the six DOR
mRNA transcripts is increased proportionately by ethanol or naloxone. The time-
course of this up-regulation differs for naloxone and ethanol and the inductive
effects of these two drugs are at least addictive. Our results suggest that they up-
regulate DOR mRNA by independent mechanisms.
After six days of exposure to retinoic acid, DOR mRNA levels in NG108-15
cells were increased 3-fold. Retinoic acid treatment induced differentiation and
when the cells are labeled with DOR antiserum we observed the presence of
neurite-like processes with numerous branching patterns not seen in vehicle
treated cells. These results suggest that the DOR gene may possess retinoic acid
regulatory elements.
Steady-state DOR mRNA levels are not altered in mice made tolerant to the
analgesic effects of the selective delta2  opioid receptor agonist, [D-
Ala2]Deltorphin II (DELT II), In contrast to NG108-15 cells which contain six
different DOR mRNA transcripts, mouse brain RNA extracts contains only a
single 10 kb DOR transcript which appears to be approximately the same size as
the largest of the six DOR transcripts found in NG108-15 cells. In samples
obtained by microdissection of CNS regions, DOR mRNA levels were highest in
the caudate-putamen at 3.3 ± .03 pg/ug RNA and lowest in cerebellum (0.5
pg/ug RNA). Intermediate levels were observed in frontal cortex, nucleus
accumbens, olfactory tubercule and medial thalamus. The DOR mRNA levels in
these CNS regions of or DELT II tolerant mice did not differ significantly from
control values. These data suggest that altered steady-state DOR mRNA levels
are not one of the adaptive changes observed in mice tolerant to this delta opioid
agonist.
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HISTORICAL SUMMARY OF NIDA SUPPORTED OPIOID
RESEARCH: A TRIBUTE TO NIDA ON ITS 20TH
ANNIVERSARY
E. J. Simon
It is a real privilege to chair the symposium entitled, “Uptake on Opioid
Receptor Cloning: Implications for Research on Addiction”, together with
my good friend, Mary Jeanne Kreek. The symposium was designated as a
celebration of the 20th anniversary of NIDA and Mary Jeanne asked me to
say a few words of a historical nature in honor of NIDA’s birthday. I am
honored and well qualified to perform this pleasant task, because I am
NIDA’s longest continuous grantee and have served on many of NIDA’s
committees as well as on its Advisory Council.
I want this brief talk to be a tribute to NIDA leadership and especially to the
wisdom and courage they have shown in supporting basic research from the
very beginning. It is not difficult to convince Congress of the need for basic
research on oncogenes, cell division or metabolic pathways in the case of
research on cancer or genetic diseases, but it takes enormous courage and
foresight to advocate basic research for a condition like Drug Abuse, which,
as you know, is not even considered a disease by most people, let alone a
condition that may involve deficiencies at the cellular or molecular level.
NIDA’s progress in treatment and prevention research was ably discussed by
Dr. Alan Leshner, the new Director of NIDA, and by this year’s winner of the
Nathan B. Eddy Award, Dr. Jerome Jaffe. I plan to concentrate on the
history of basic biochemical research on opiates. This clearly comes under
the rubric of what Dr. Leshner called “sharing the secret”. There are two
good reasons why I shall limit myself to the opiates. First, it is the area I
know something about, having been involved in it since the beginning of the
modern era of this research and second, because it is the topic of this
symposium. How well known is it that a brand new system of chemical
signaling in the brain was discovered almost entirely by NIDA grantees? It
is a much too well kept secret! This work also opened up the important and
active field of neuropeptide research, which had lain dormant until the
discovery of the endogenous opioid peptides.
We shall begin the story some decades before the birth of NIDA to pay
tribute to the organic chemists and pharmacologists whose brilliant research
laid the ground work. In their quest to find an effective, non-addictive
analgesic, a typical applied research effort, these investigators made some
very important fundamental discoveries: 1) the requirement of certain
structural features for effective analgesia; 2) the stereoselectivity of analgesic
action; and 3) the important finding that small changes, such as the
replacement of the methyl group on the tertiary nitrogen of morphine and its
congeners, leads to the production of effective opiate antagonists. Some of
the names that should be mentioned in this connection are Pohl, Unna,
Nathan B. Eddy, Harry Collier and some who are still with us, such as
Everette May, Syd Archer, Eddie Way, Hans Kosterlitz, Albert Herz and
others too numerous to mention, to whom I apologize.
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These discoveries gave rise to the receptor concept, the idea that these drugs
must bind to specific sites in the brain in order to exert their pharmacological
effects. As early as 1954, Beckett published his picture of what such a
receptor might look like, based on the structures common to all effective
opiate analgesics. This was followed by many attempts to demonstrate the
existence of such receptors. Unsuccessful but nonetheless important
contributions were made by Phil Portoghese and A. Takemori, N. Ingoglia,
and V. Dole, and by A. Goldstein. Such an unsuccessful attempt was also
contributed by Mrs. Van Praag and myself in 1971.
In this context, the contributions of Dr. Hans Kosterlitz must be mentioned.
Their importance cannot be overstated. He took the guinea pig myenteric
plexus, first developed by Paton and Schaumann, and improved it for use as a
reliable bioassay and a model for the actions of opiates. He took
considerable, usually good natured, ribbing about his preoccupation with “a
piece of gut”. However, nobody laughed when he and John Hughes used this
piece of gut to discover the enkephalins. He then went on to develop several
other bioassay systems (mouse, rat and rabbit vas deferens), which proved
useful for determination and characterization of ligands of the multiple
families of opioid receptors.
In 1973 three laboratories, Lars Tcrenius at Uppsala, Sweden, Candace Pert
and Solomon Snyder at Johns Hopkins and my own laboratory at New York
University, independently and simultaneously demonstrated the existence of
stereospecific opiate binding sites in animal and human brain. This was
quickly followed by the discovery of the endogenous opioid peptides. First,
the enkephalins by Hughes and Kosterli tz,  then the endorphins,
independently by R. Guillemin and by Smyth and Bradbury, and, finally, the
dynorphins by A. Goldstein and his collaborators.
To show you that no ideas are completely now under the sun, let me cite an
astonishing statement made in the curly 19th century by Baudelaire, a
brilliant writer and non-scientist: “Everyone carries within him his own
morphine, which is constantly being secreted and renewed.”
The speed with which the molecular genetics and biosynthesis of the opioid
peptides was worked out is truly remarkable. This work was done by
Nakanishi and the late S. Numa in Japan and by Sidney Udenfried, the late
Ed Herbert and his students, Mains and Eipper, in the USA. We know a
great deal about the structure and metabolism (biosynthesis, processing) of
the three protein precursors, which account for all of the known peptides. We
also know the structures of the genes that encode these proteins. They arc
sufficiently similar to suggest the hypothesis that during evolution they were
derived from a single gene-by-gene duplication.
The idea that there may be several types of opioid receptors had been in the
air for a while, but it was the late Bill Martin who provided the first evidence.
His work together with the discovery of receptors in the mouse vas deferens
by Kosterlitz and co-workers, provided the evidence for the existence of three
major opioid receptor families, µ, and There is evidence for subtypes of
these as well as for other types of opioid receptors. However, these three
types remain the best studied and best established ones.
The race to clone one or more of the opioid receptors started about six to
eight years ago. All of the major opioid biochemistry laboratories, including
my own, and many of the outstanding cloning laboratories all over the world
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(I counted 17 laboratories without really trying) spent much time and effort to
achieve this goal, but without success. It was thus left to two young
investigators, C. Evans, UCLA and B. Kieffer, University of Strasburg,
France, one of whom (Evans) is speaking at today’s Symposium, to solve this
problem. They did it by using expression cloning techniques to clone and
sequence the receptor from NG108-15 cells in culture. Once its sequence
was known, low stringency screening with oligodeoxynucleotide probes,
derived from the receptor cDNA structure, quickly led others to the
sequences of the µ and types of opioid receptors. At the time this is being
written, only one gene has been cloned for each of the three major receptor
types, but subtypes will surely be found in the near future. Some of the
people involved in this work (Lei Yu, George Uhl) are also represented here
and we shall hear from all of the speakers that indeed “there is life after
cloning”.
This brings the story up-to-date with, of necessity, many omissions. I hope
that it proves to the younger scientists the considerable foresight and great
courage of the NIDA leadership in supporting first class fundamental
neuroscience research related to the opiate drugs and that this policy has paid
off in very important results. I want to end by welcoming Alan Leshner to
his new and exciting position and compliment the search committee on its
excellent choice. I wish NIDA well for the next 20 years and more. I am
willing to make the prediction that the results I have reviewed, together with
the important findings impact on our understanding of the underlying causes
of drug abuse and of other mental disorders. They will undoubtedly lead to a
more rational approach to treatment and prevention. I am certain that under
the able leadership of Alan Leshner and Richard Millstein the wise policy of
supporting basic research will be continued, the secret will be told, and NIDA
will be one of the most respected members of the NIH community of
Institutes.
AFFILIATION:
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DRUG ABUSE AND THE HEALTH OF WOMEN
L. P. Finnegan, Z. Sloboda, H. W. Haverkos, N. K. Mello,
M. J. Kreek, L. B. Cottler and D. A. Frank
Drug abuse among women has risen again as an important issue after an almost
20-year hiatus. In the mid- 1970s, as a result of the women’s movement, a great
deal of interest in women drug abusers and their special needs, particularly
relative to bearing children, spurred several meetings, articles and monographs
summarizing the state of knowledge and specifying directions for new research.
The dual epidemics of cocaine and crack abuse and of the human
immunodeficiency virus and their differential and devastating effect on women,
has lead to a resurgence of interest in women and drug abusing behaviors. In
general, studies of deviant and antisocial behaviors have shown that prevalence
rates are significantly lower for girls and women than for boys and men.
However, these observations are changing, and certainly for substance abuse,
women are beginning to show increasing rates of involvement. Women’s
substance abusing behaviors also have been of a more traditional nature-using
alcohol or prescription medications thus avoiding the criminal distribution
networks. And even when women do use more stigmatized drugs such as
marijuana, cocaine, and heroin, they generally have received these drugs through
their male significant other. Recent trends in our national and locally-based
epidemiologic studies indicate that these trends appear to be changing; i.e., more
women are using tobacco and marijuana and, in some cities (i.e., Atlanta), more
women are involved at high levels, in the trafficking of drugs. It is not clear as to
why these changes are taking place but there arc several hypotheses related to the
changing role of women in this society and to the multiple generations of drug use
in families. Current epidemiologic data on drug using behaviors among women
have been reported. Drug use by women, as reported in the 1992 National
Household Survey on Drug Abuse, for the 30 days prior to the interview was: 4.4
million women used an illicit substance; 3.1 million used marijuana; 0.4 million
used cocaine. Lifetime prevalence of heroin use among women is estimated to be
1.0 million (1991). The percent use of cocaine in the past year was 1.8% white
female, 2.7% black, 2.3% hispanic. Heroin use is difficult to ascertain.
Marijuana past year use in women was 7.4% white, 8.2% black, 5.0% hispanic.
The 1992 National Client Data System women admissions was 411,839; 53% are
non-hispanic white; 29% are non-hispanic black; and 8% are hispanic.
Infectious diseases are commonly diagnosed and reported among female drug
abusers. Severe communicable infectious diseases, such as HIV infection
/AIDS, tuberculosis (TB), hepatitis B virus infection, and syphilis are common
among women and amenable to intervention in drug abuse treatment settings. In
fact, drug abuse treatment programs may be ideal sites to identify those infections
and initiate and maintain appropriate medical management. AIDS is the newest,
fastest growing, and most life-threatening of the four listed above. In the 1990’s,
AIDS is increasing twice as rapidly among women than among men; female
injecting drug users and female sexual partners of injecting drug users are at
especially high risk. Tuberculosis has re-emerged as an important pathogen in
several parts of the USA, due, in part, to the HIV epidemic. Making an early
diagnosis of active TB and ensuring compliance with TB treatment regimens will
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be instrumental in blunting the impact of TB in the drug using community.
Hepatitis B virus infection is a common disease among drug users and can be
prevented by Hepatitis B vaccination, which became available in the 1980’s.
Syphilis is making a resurgence in the U.S., due in part to the “crack” cocaine
epidemic. Increases in congenital syphilis rates in some parts of the country are
disturbing. Drug abuse treatment providers can be instrumental in battling these
diseases among drug users by integrating services and follow-up with primary
medical care and public health providers.
Studies have shown that several aspects of human physiology are significantly
disrupted in the setting of drug abuse. These abnormalities include profound
disruption of neuroendocrine function and possibly related disruption of specific
indices of immune function. Both restoration of drug induced abnormalities of
neurocndocrine function, and possibly related indices of immune function, as well
as prevention of HIV infection is essential for women and men, and may be
achieved. The endogenous opioid system, with the now defined three classes of
endogenous opioid peptides, the endorphins, enkephalins, and dynorphins, and
three types of opioid receptors, mu, delta, and kappa, is deranged in the setting of
heroin addiction. Of a special importance is the opioid peptide precursor,
proopiome-lanocortin (POMC), which yields both ACTH and beta-endorphin; the
release of POMC neuropeptides, as reflected by circadian rhythm and plasma
levels, is abnormal in the setting of heroin addiction. Studies on the HPA axis in
our laboratory and others have determined that, in addition to the well established
control of POMC peptide release by CRF and the negative feedback control by
cortisol, that the endogenous opioids, acting at mu and possibly also kappa opioid
receptors, are involved in the normal tonic regulation of the synthesis-release of
the POMC peptides. In humans, acute use of any opiate, and chronic use of any
short-acting opiate such as heroin or morphine, causes suppression of the HPA
axis; conversely, in the setting of opiate withdrawal, (or following administration
of an opioid antagonist to an opiate naive subject) activation of the HPA axis is
observed. During long-term methadone maintenance treatment, normalization of
this important axis occurs. The responsivity of the HP axis to chemically induce
stress has also been shown by our laboratory to be abnormal in the setting of
opiate dependency with suppression of responsivity. This response is restored to
normal in the setting of chronic methadone maintenance treatment. However, it
has recently been found to be hyper-responsive in both drug-free former opiate
addicts and recent abstinent cocaine addicts.
Immune function also is profoundly disrupted in heroin addicts. This may be due
in large part to injection of foreign substances, infection with multiple diseases,
and lifestyle. However, laboratory models have shown that the endogenous
opioid system may be involved in normal regulation of the endogenous opioid
system, and thus exogenous opioids may contribute to the derangements
observed. Studies have found that whereas there were significant abnormalities of
absolute numbers of CD4 and CD8 cell numbers, levels of immunoglobulin G
and M, and of special importance, a natural reduction of natural killer cell activity
in heroin addicts, each of these indices normalize during long-term methadone
maintenance treatment. Further studies are ongoing using techniques of molecular
biology and imaging to study the derangements of the endogenous opioid system
in the setting of addiction, and the changes which occur during specific
pharmacotherapies. Many of these findings are of special importance to women
with respect to the effects of the endogenous opioids in the normal modulation of
prolactin release, exogenous opioids in abnormal disruption of prolactin release,
as well as of the peptides of the hypothalamic-pituitary-gonadal axis.
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Alcohol and cocaine abuse each are associated with a series of reproductive
disorders including amenorrhea, luteal phase dysfunction, anovulation and
hyperprolactinemia. The way in which abused drugs affect the regulation of the
hypothalamic pituitary ovarian axis is poorly understood. The increasing
prevalence of polydrug abuse further complicates efforts to analyze the effects of
individual drugs in clinical studies. Fortunately, neuroendocrine control of the
menstrual cycle in rhesus monkey is very similar to that of women, and the effects
of drugs on the endocrine system can be studied in the primate model of drug self-
administration. One of the major recent findings to emerge from both clinical and
primate studies is that acute alcohol and cocaine intoxication can increase rather
than suppress hormones important for a normal reproductive function. For
example, alcohol stimulates estradiol under basal (non-stimulated) conditions as
well as after luteinizing hormone releasing hormone and opioid antagonist
stimulation. High estradiol during the follicular phase may disrupt
folliculogenesis by decreasing FSH which in turn may lead to luteal phase
defects. An increase in estradiol during the luteal phase could result in luteal
phase defects by a direct suppressive effect on progesterone. Both cocaine and
alcohol stimulate ACTH and by inference, corticotrophin releasing hormone
(CRH). Synthetic CRH administration suppresses gonadotropin release which
may result in anovulation and amenorrhea. Cocaine also stimulates luteinizing
hormone which could lead to premature ovulation. In summary, either the acute
stimulatory effects of alcohol or cocaine intoxication on gonadotropins, estradiol
or ACTH or the suppressive effects of chronic intoxication may disrupt the
intricate functional integration of the endocrine system and lead to infertility
disorders and menstrual cycle disruption.
In reviewing the psychosocial risk factors associated with female drug use, the
characteristics of St. Louis female drug abusers from two NIDA-funded projects
conducted from 1990 to 1994 are described. The Substance Abuse and Risk for
AIDS study aimed to determine risk factors for HIV infection and comorbidity of
psychiatric and substance use disorders among recent admissions to drug
treatment. Baseline and 12-month follow-up interviews were conducted. The
Efforts to Reduce the Spread of AIDS studied out-of-treatment drug abusers and
focused on risk factors for HIV. Abusers were offered free drug treatment and
those who accepted the treatment and those who didn’t were interviewed (at
baseline 3, 6, 9, 12, and 18 months). Women represented over a third of the sample
with 75% minority representation. Women recruited for these two projects were
stratified into two groups, those who had injected drugs (N=160) and non-
injectors (N=221). Injectors were more likely than non-injectors to have: a family
background of social disorganization; report alcoholism among siblings; higher
rate of substance dependence; higher rates of most medical problems, including
pneumonia, difficulty getting pregnant, and hepatitis B; psychiatric disorders,
especially comorbid ASPD and depression; higher rates of risky sexual behavior;
history of drug treatment and recent life events. In another comparison made
between women and men, women were more likely to have reported barriers to
drug abuse treatment. The implications of these data with regard to assess to
mental health services, life events issues and barriers to care are most relevant for
women desiring treatment.
The impact upon children born to drug using women has been a source of concern
to many. It has been nine years since a report in the New England Journal of
Medicine suggested that a mother’s cocaine use during pregnancy was associated
with important adverse effects on the newborn. Subsequently, the lay press led a
public rush to judgement, labelling children with a history of prenatal cocaine
exposure as “crack kids,” inevitably and permanently damaged, with
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developmental and behavioral deficits so profound as to jeopardize the public
school system. The peer reviewed scientific literature regarding the potential
association of in utero cocaine exposure with perinatal deficit and less optimal
developmental outcome in infancy and childhood is much less conclusive than the
dire quasi-scientific predictions in the popular press would lead one to believe.
Many complex methodological issues contribute to scientific uncertainty regarding
the possible effects of prenatal cocaine exposure. These include difficulties in
accurate identification of users, uncertain measurement of dose and gestational
timing of exposure, sample selection bias, failure to control for confounding
variables, lack of appropriate comparison populations, and selection of sensitive
outcome measures. In spite of these difficulties, there is a growing body of
relatively credible data to suggest that prenatal cocaine exposure is independently
associated with increased risk of delivering smaller infants, whether from
decreased gestation, intrauterine growth retardation, or both. However, it is not
clear whether cocaine imposes long term developmental risks in excess of that
associated with prematurity and IUGR. Cocaine may have subtle behavioral
effects, not obvious on global test scores. Moreover, poor care-giving
environment may explain in part poor developmental outcome. Compensatory
responsive environments significantly improve the outcome of infants with
biological vulnerabilities at birth.
Scientists and clinicians should never confound issues of legality or morality with
those of toxicity; using infant meconium and maternal self-report, it is necessary
to assess issues of dose and thresholds of toxicity for all psychoactive substances,
legal or not. Furthermore, it will be important to delineate which biologic and
social factors together identify infants with the greatest burden of risk following
cocaine exposure. Future research will focus on linking central nervous system
findings to developmental outcome in cocaine exposed infants. These findings
include not only obvious hypoxic/vascular lesions such as IVH, but less visible
CNS neurotransmitter alterations. Outcome measures at later ages need to include
tasks that assess the potential effects of such perturbations, particularly in areas
such as the frontal lobe, which are rich in dopaminergic projections. These
include social competence, and regulation of arousal and attention to global
developmental scores. Much more well controlled longitudinal research remains
to be done if the myth of the demonic “crack baby” is to be replaced by high
quality scientific data that will facilitate rational and effective care of vulnerable
women and children.
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AFFECTIVE DISORDERS AND SUBSTANCE ABUSE:
FROM BENCH TO BEDSIDE AND BACK
T. R. Kosten, E. Gardner, A. Markou, R. Pickens and F. Goodwin
The first presentation was entitled, “COMMON GENETIC MECHANISMS IN
DEPRESSION AND SUBSTANCE ABUSE,” by R. W. Pickens from the
NIDA Addiction Research Center. This presentation began by reviewing the
general epidemiology of substance abuse and depression. Major depression
occurs more often in alcoholic individuals and their first degree relatives than is
expected by chance. To determine if the comorbidity between alcoholism and
depression is due in part to common genetic influences, within and cross-
correlation for the disorders were examined in monzygotic (MZ) and dizygotic
(DZ) twins. In 130 twin pairs, at last one twin met criteria for DSM-III alcohol
dependence. Results suggest that co-occurrence of certain mental disorders in
alcoholics and their families observed in epidemiological surveys may have a
common genetic basis. Specifically, higher MZ than DZ cross-correlation was
observed between alcohol dependence in male probands and antisocial
personality disorder and phobia in the co-twins. For males, correlation between
alcoholism and depression was .51 within probands; correlation between
alcoholism in the proband and depression in the co-twin was .54 for MZ twins
and .32 for DZ twins. For females, within-proband correlation between
alcoholism and depression for proband and co-twin was .18 for MZ and .20 for
DZ twins.
These results were not a consequence of correlation for antisocial personality or
phobia that may have also existed in the twins nor were they due to comorbid
alcohol dependence in the co-twin. Cross-correlation between alcohol
dependence in the proband and certain drug disorders in the co-twin was
attributable to environmental factors. Additional analysts indicated that alcohol
dependence may be more heritable when the proband has a comorbid drug or
mental disorder, at least for males. Probands with a comorbid drug disorder
were significantly younger and reported significantly earlier ages of first
intoxication and alcohol problems than probands without a comorbid drug
disorder. While individuals with comorbid drug disorder exhibited more
alcoholism symptoms, they did not differ in quantity or frequency of alcohol
consumption. These results suggest common genetic influences may underlie
comorbidity between depression and alcoholism, at least for males. The results
suggest common genetic influences may underlie comorbidity between
depression and alcoholism, at least for males. The results also suggest that the
observed association between alcoholism and depression in females may be due
to environmental influences.
The second presentation by T. R. Kosten from Yale University was entitled,
“CLINICAL STUDIES ON THE RELATIONSHIP OF AFFECTIVE
DISORDERS TO SUBSTANCE ABUSE.” Since 1935, substantial increases in
both depression and substance abuse have been observed, particularly in
younger individuals. The reasons for increases in substance abuse have
included changes in public attitudes, increased availability and new more
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addictive forms of abusable drugs. The reasons for more depression in younger
patients are less clear, but in recent studies of adolescents, the rates of
depression have been three times higher in substance abusers vs non-abusers
(25% vs 8%). The additional 17% of depression has begun after the
development of substance dependence.
Many drugs may have direct toxic effects on mood. For example, chronic use of
depressants such as alcohol and barbiturates leads to dysphoria, and withdrawal
from stimulants such as cocaine is characterized by anhedonia. Opioids such as
heroin or methadone do not appear to produce mood disruptions, yet the rates of
depression are about seven-fold higher in opioid dependent patients than in the
general population. Thus, opioid dependence provides a most interesting
disorder for examining this association. Furthermore, neurobiological
comparisons of depressives to substance abusers using the dexamethasone
suppression test, the Thyrotropin releasing hormone stimulation test or CSF
levels of dopamine metabolites show striking similarities between these patient
groups.
The clinical association between these disorders includes not only high rates of
disorder, but differences in treatment response. Depressed substance abusers
usually have poor treatment responses to standard substance abuse treatments
such as detoxification from nicotine, alcohol or opiates, but these patients
respond well to antidepressants not only in symptom reduction, but also in
reduced substance abuse. This reduction in substance abuse is less robust than
the depressive symptom response, but it has been most clearly shown in
methadone maintained samples. This stronger demonstration in methadone
patients is probably because depression in these patients is less likely to result
from toxic effects of opioids on mood.
The third presentation by Gardner from Einstein University was entitled, “CO-
V U L N E R A B I I T Y  B E T W E E N  A F F E C T I V E  D I S O R D E R S  A N D
SUBSTANCE ABUSE: PRECLINICAL PERSPECTIVES.” Animal models of
drug/alcohol abuse include: a) voluntary intravenous drug self-administration;
b) voluntary intracerebral drug self-administration; c) voluntary electrical brain-
stimulation reward, and its modulation by drugs/alcohol; and d) conditioned cue
preference to alcohol/drugs. Using these models, it has been established that
drugs of abuse acutely facilitate the functioning of brain pleasure/reward
circuits, producing the euphoric “high” or “rush” that the drug user seeks. It has
also been established that the critical drug-sensitive locus of the brain’s
pleasure/reward circuits involves a) mesocorticolimbic dopaminergic (DA)
neurons arising from the ventral tegmental area, projecting through the medial
forebrain bundle, and synapsing in the nucleus accumbens, ventral striatum, and
medial prefrontal cortex; and b) endogenous opioid neurons interconnecting
synaptically with, and exerting modulatory control over, the mesocorticolimbic
DA pleasure/reward neurons. These endogenous opioid neurons appear
crucially involved in drug/alcohol abuse, since they appear to set the “gain” or
range-of-function of the DA pleasure/reward substrates, and since the effects of
drugs of abuse on these brain substrates are naloxone blockable. Also, naloxone
and naltrexone are effective treatments for craving of some drugs abused by
humans and attenuate free-choice drug consumption in addicted laboratory
monkeys. Thus, aberrations in brain opioid systems may constitute a
neurobiological vulnerability.
Animal models of depression include, most compellingly, “learned
helplessness” - an animal behavioral syndrome produced by inescapable shock
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which includes symptoms of human depression, including weight loss, lethargy,
anergy, sleep disturbance, poor grooming, diminished libido, seasonal variation,
and favorable response to antidepressant drugs. Opiate antagonists (naloxone,
naltrexone) attenuate learned helplessness. Attenuation is also seen with
intracerebroventricular injections of quaternary naltrexone, implicating central
opioid mechanisms. Learned helpless animals also show reduced naloxone-
precipitated morphine withdrawal, reduced plasma -endorphin levels, and
increased mu opiate receptors in limbic brain regions as compared to non-
learned helpless or naive control rats. Thus, aberrations in brain opioid systems
may constitute a neurobiological vulnerability to learned helplessness.
Another common neurobiological vulnerability between drug/alcohol
dependence and learned helplessness may derive from scrotonergic (5HT)
innervation and regulation of the mesotelencephalic DA pleasure/reward
circuitry activated by drugs/alcohol. That this 5HT-mediated regulation of
forebrain DA pleasure/reward neurons may have functional relevance for
drug/alcohol dependence is suggested by observations that 5HT-specific
reuptake inhibitors reduce self-administration of cocaine, amphetamines, and
alcohol in laboratory animals, reduce alcohol preference in animals, and reduce
the progressive-ratio break-point for intravenous cocaine reinforcement in
animals. In humans, 5HT-specific reuptake inhibitors reduce some alcohol-
cocaine consumption and craving. Aberrations in 5HT function have been
hypothesized for decades to constitute a neurobiological substrate of depression
in humans, and 5HT-specific reuptake inhibitors are therapeutic for human
depression. Provocatively, significant alterations in 5HT functions in limbic
brain areas have been demonstrated in learned helplessness. Thus, aberrations
in endogenous brain 5HT systems regulating and modulating mesotelencephalic
DA pleasure/reward circuitry may constitute a neurobiological vulnerability to
drug and/or alcohol dependence and to learned helplessness.
The final presentation by Markou from the Department of Neuropharmacology
at The Scripps Research Institute was entitled, “ELEVATIONS IN REWARD
THRESHOLDS AS AN ANIMAL MODEL OF AFFECTIVE DISORDERS.”
This presentation focused on one of the major symptoms of affective disorders -
“anhedonia”, which is defined as “the markedly diminished interest or pleasure
in all, or almost all, activities most of the day, nearly every day” (DSM-III-R).
Because the “anhedonia” experienced by depressed patients suggests that these
individuals exhibit alterations in reward processes, the reward thresholds
provided by the intracranial self-stimulation (ICSS) paradigm provide an
operational measure of this core symptom of depression.. Investigations of
brain stimulation reward without any prior manipulations have not provided a
satisfactory model of depression because, a) the study of reward processes in
“normal” organisms, although informative, does not mimic any aspect of
depression; and b) acute or chronic treatments with tricyclic antidepressants do
not affect dramatically baseline ICSS behavior. In contrast, the study of the
neuro-substrates of ICSS behavior following pharmacological manipulations
promises to promote our understanding of reward mechanisms that seem to be
altered in several psychiatric disorders including depression and schizophrenia
(DSM-III-R).
A pharmacological manipulation that has been used to product elevations in
ICSS reward thresholds in rats is withdrawal from long-term exposure to several
drugs of abuse, such as psychomotor stimulants, opiates and ethanol. Rats
allowed to self-administer cocaine for prolonged periods of time (3, 6, 12, 24 or
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48 hours) showed a marked elevation in ICSS thresholds. The magnitude and
duration of this effect was proportional to the amount of cocaine consumed
during the preceding self-administration episode (“binge”) which was a function
of the duration of the self-administration session. During the time-points when
maximal elevations in thresholds were observed, dialysate dopamine levels in
the nucleus accumbens, as measured by in vivo microdialysis, were decreased
compared to pre-“binge” dopamine levels. Similarly to the threshold elevation,
the reduction in dopamine levels was proportional to the duration of the
preceding self-administration session.
Pretreatment with bromocriptine, a dopamine agonist, reversed the post-cocaine
elevation in thresholds in control subjects. Furthermore, chronic treatment with
desmethylimipramine (a tricyclic antidepressant), at a dose that produced a
significant down-regulation of beta-adrenergic receptors, had no effect on the
severity of this withdrawal symptom during the first three hours post-cocaine,
but significantly shortened the duration of withdrawal. These results implicate a
role of dopaminergic and noradrenergic neurotransmission in the affective
aspects of cocaine withdrawal. In addition, the effectiveness of an
antidepressant in reversing the post-cocaine elevation in thresholds suggests a
potentially common neurochemical abnormality underlying both drug and non-
drug induced depressions.
Similar elevations in reward thresholds were also observed during naloxone-
precipitated opiate withdrawal in rats made dependent through the subcutaneous
implantation of morphine pellets. Finally, rats made dependent on ethanol
through exposure of ethanol vapor for two weeks also exhibited time-dependent
elevations in reward thresholds upon cessation of the ethanol vapors.
In conclusion, these results suggest that post-drug elevations in reward
thresholds are a reliable operational measure of the “affective” aspects of
withdrawal from several drugs of abuse, such as stimulants, opiates and ethanol.
Even though it is not known at this point what the exact relationship is between
drug-induced and non-drug-induced depression in humans, post-drug depression
in both animals and humans may provide a valuable tool in the investigation of
the neurobiology of affective disorders.
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YOUNG INVESTIGATORS’ SYMPOSIUM:
ENVIRONMENTAL MODULATION OF DRUG EFFECTS
J. B. Kamien, L. Amass, S. L. Vrana, M. A. Nader, C. R. Bush and
R. W. Foltin
Impressive advances in neuroscience and molecular pharmacology sometimes
overshadow the role of the environment in the modulation, and even
determination, of a drug’s behavioral effects. However, “it is a cardinal
principle of behavioral pharmacology that the effects of drugs cannot be
understood independently of the conditions under which the drugs are given and
the previous drug history of the organism” (Schuster and Balster, 1977). This
symposium highlights evidence of substantial environmental modulation of drug
effects in five major areas of drug abuse research.
ENVIRONMENTAL DETERMINANTS OF THE NEUROCHEMICAL
EFFECTS OF DRUGS
Sheila L. Vrana
The context of drug administration can alter the neurochemical effects of that
drug. The yoked-box (triad) procedure focuses on the effects of response-
dependent vs. response-independent administration of drugs of abuse (Smith, et
al., 1982, 1984). In this paradigm, one animal self-administered (SA) morphine,
while litter mates received either a response-independent infusion of morphine
(yoked-morphine; YM) or saline (yoked-saline; YS). Using this procedure, the
direct pharmacological effects of a drug can be evaluated (YM vs. YS) and
compared with the reinforcing actions of the drug (SA vs. YM). SA morphine
increased dopamine (DA) and acetylcholine (ACh) turnover in the frontal
cortex, and decreased DA, 5-HT and ACh turnover in the nucleus accumbens
(NAcc) as compared to YM. The same procedure has been used to examine the
effects of response-dependent vs. response-independent administration of
cocaine (0.33 mg/infusion; 80 infusions/day limit). This study found that 38%
of the animals receiving response-independent cocaine died, while none of the
rats receiving response-dependent cocaine or YS rats died. We have also used
the triad paradigm, to examine the effects of response-dependent vs. response-
independent cocaine administration on tyrosine hydroxylase (TH) and mRNA
levels. Response-independent cocaine increased TH activity and mRNA levels
in the VTA and activity levels in the NAcc compared to when the animals self-
administered the drug.
Cocaine and heroin also increase extracellular dopamine (DAec) in the NAcc
(Pettit and Justice, 1989). The triad paradigm has been used to assess contextual
effects on dopamine concentrations in the NAcc using in vivo microdialysis
during cocaine self-administration (Hemby et al., 1992). DAec increased
significantly (300%) in the SA compared to YC conditions, while there was no
difference in NAcc cocaine concentrations. When the same pattern of cocaine
infusions was delivered the next day to the SA animal in a response-independent
manner, DAec was no different than the YC pattern from the previous day.
Hemby et al., (1993) also examined the effects of acute administration of
53
heroin vs. chronic self-administration of heroin on DAec in the NAcc. An acute
i.v. dose of heroin (30 µg/infusion) in a naive rat significantly increased DAec
by 180%. However, in rats trained to self-administer 18 or 30 µg/infusion,
NAcc DAec was decreased by 20% and 50%, respectively. These results
indicate that there are neurochemical and molecular differences associated with
the environmental context of drug administration.
ENVIRONMENTAL MODULATION OF THE DISCRIMINATIVE
STIMULUS EFFECTS OF DRUGS
Jonathan B. Kamien
Drug discrimination (DD) results are commonly used to make pharmacological
comparisons between drugs. However, the impact of the environment on the
discriminative stimulus (DS) effects of drugs, although large, is often not
considered. Examples of environmental modulation of the DS effects of drugs
can be grouped into four categories: Schedules of Reinforcement, Response
Options, Exteroceptive Stimuli and Historical Influences.
Relationships among the DS of drugs can be modulated by arranging unequal
schedules of reinforcement for drug or saline responding. For example, pigeons
were trained to discriminate PCP vs. saline and tested with PCP, pentobarbital
(PB) and d-amphetamine. When the reinforcement schedules were equal (i . e . ,
no bias), only PCP and PB substituted for PCP. When more responses were
required on the PCP lever (i.e., bias towards saline), PB no longer substituted
for PCP and the PCP dose-effect curve was shifted to the right. But when more
responses were required on the saline lever (i.e., bias towards PCP), PCP, PB
and amphetamine all occasioned PCP responding and the PCP dose-effect curve
was shifted to the left (McMillan and Wenger, 1984). Another experiment
compared morphine DD under a FI 180-s and a FR 100 schedule of
reinforcement. Under the FI 180-s schedule there was much more individual
variation. Also, responding under the FR 100 schedule described a quanta1
relationship between dose and morphine responding while responding under the
FI 180-s schedule described a more graded curve (Massey et al., 1992).
The number of stimulus-response relations trained can determine the outcome of
DD generalization tests. In one example, butorphanol occasioned a maximum
of about 40% hydromorphone responding when humans were trained to
discriminate among saline, hydromorphone and pentazocine (Preston et al.,
1989). However, butorphanol occasioned nearly 100% hydromorphone
responding when humans were trained to discriminate only hydromorphone
from saline, (Preston et al., 1992). In another example, humans were trained to
discriminate triazolam from placebo. When the only response options were
triazolam or placebo, amphetamine occasioned about 25% triazolam responding.
When the response options included a response for a ‘novel’ stimulus, d-
amphetamine occasioned nearly 100% novel responding (Bickel et al., 1993).
Exteroceptive stimuli present during training and testing can influence or even
mimic the DS effects of drugs. Rats were trained to discriminate PB in darkness
and saline in light. The PB dose effect curve determined in light was shifted to
the right relative to when it was determined in darkness (Jarbe et al., 1983).
Another experiment demonstrated that an exteroceptive stimulus (exposure to a
cat) can substitute for pentylenetetrazol (PTZ) in rats trained to discriminate
PTZ from saline (Gauvin and Holloway, 1991). Behavioral and drug history can
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also alter the DS effects of drugs. Baboons were trained to discriminate
midazolam (MDZ). After the baboons self-administered MDZ, they were more
sensitive to the MDZ DS. However, when they received the same amount and
pattern of MDZ injections non-contingently, they were less sensitive to the
MDZ DS (Ator and Griffiths, 1993).
ENVIRONMENTAL MODULATION OF THE REINFORCING
EFFECTS OF DRUGS.
Michael A. Nader
Behavioral or environmental factors can influence the rate and pattern of drug
self-administration. For example, the schedule of reinforcement has profound
effects on drug self-administration rates. Identification in animals of conditions
under which drug-seeking behavior could be reduced for extended periods might
have direct practical applications. In the present review, two environmental
variables will be discussed: behavioral history and punishment contingencies.
Behavioral History Exposure to certain reinforcement schedules can produce
significant and long-lasting changes in the behavioral effects of drugs (see
Nader et al., 1992). Recently, we have begun to systematically study the
influence of behavioral history on drug self-administration. In one study, rhesus
monkeys were initially trained to self-administer cocaine 0.03 mg/kg/inj under a
fixed-interval 5-min schedule (FI), before training under a schedule that
generated high rates (fixed-ratio 50; FR) or low rates (inter-response-times > 30-
sec; IRT) of cocaine-maintained responding. When responding was again
maintained under the FI schedule, response rates were significantly higher after
an FR history than after an IRT history. In another study, a history of food-
maintained responding under either an FR or IRT schedule resulted in
significantly different rates of cocaine self-administration. Thus, past
environmental conditions influenced the rates at which animals acquired and
maintained cocaine self-administration.
Punishment Contingencies. Punishment has also been used to reduce drug
self-administration by animals. Punishment is the reduction in the probability of
a response following either the presentation (“positive” punishment) or the
removal (“negative” punishment) of a stimulus. Although negative punishment
is more analogous to treatment programs that remove individuals from
environments in which drugs are available, most punishment studies on drug
self-administration have used positive punishment. Johanson (1977) used a
discrete-trials procedure in which rhesus monkeys were given a choice between
a dose of i.v. cocaine paired with an electric shock and one not paired with
shock. If the doses were the same, monkeys preferred the cocaine dose not
associated with punishment. However, increasing the cocaine dose associated
with shock reversed this preference. Bergman and Johanson (1981) reported
that intermediate shock intensities only transiently decreased cocaine self-
administration, suggesting that positive punishment is not an effective method
for maintaining decreases in cocaine self-administration. We have begun
studies on the effects of negative punishment on cocaine self-administration.
Four rhesus monkeys were trained under a multiple FI 5-min schedule of
cocaine presentation (0.01-0.3 mg/kg/inj). The same dose was always available
in both components. When responding was stable, the schedule in the second
component was changed to a conjoint FI 5-min cocaine, VI 30-sec time-out
schedule. Responding in the second component was suppressed by response-
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contingent time-outs of 10-90 sec durations. In addition, increases in cocaine
dose did not attenuate the effects of negative punishment.
ENVIRONMENTAL MODULATION OF SELF-REPORTED EFFECTS
OF DRUGS
Craig R. Rush
Self-report instruments (e.g., Addiction Research Center Inventory, Profile of
Mood States [POMS]) are used extensively to assess drug effects in humans.
The present paper briefly discusses environmental variables that modulate the
self-reported effects of commonly used/abused drugs including: (1) the social
context in which the drug is administered and (2) the type of task the subject
completes after drug administration.
The self-reported effects of alcohol and marijuana can differ qualitatively and
quantitatively depending on the social context (i.e., group vs. isolated setting) in
which the drug is administered. Alcohol, for example, increased self-reported
“elation” in a group setting, while it decreased these ratings in an isolated setting
(Del Porto and Masur, 1984). Similarly, the “euphoric” effects of smoked
marijuana were greater in a group vs. isolated setting, while the “dysphoric”
effects of marijuana were less in a group vs. isolated setting (Jones, 1971). In a
group setting most subjects reported the overall effect of alcohol and marijuana
as “pleasant,” while in an isolated setting most subjects reported the overall drug
effect as “indifferent.”
The type of task the subject is required to complete after drug administration
also influences the self-reported effects of drugs (e.g., alcohol; O’Malley and
Maisto, 1984). Following the administration of placebo, subjects who read a
magazine reported less intoxication than subjects who played a video game.
After a high dose of alcohol, however, subjects who read a magazine reported
greater intoxication than subjects who played a video game. Similarly, the
number of response options in a drug discrimination procedure influences the
self-reported effects of drugs. When three (i.e., triazolam, placebo and novel)
vs. two (i.e., triazolam and placebo) responses were available, subjects reported
greater drug effects following low and intermediate doses of d-amphetamine and
triazolam (Bickel et al., 1993).
In conclusion, environmental factors influence the self-reported effects of
commonly used/abused drugs, a finding consistent with drug effects on other
types of discriminated-operant behavior. Recognition of the influence of
environmental factors on self-reported drug effects will help refine the use of
these instruments in understanding the human behavioral pharmacology of
abused drugs.
ENVIRONMENTAL MODULATION OF DRUG EFFECTS IN DRUG
ABUSE TREATMENT
Leslie Amass
The effectiveness of pharmacotherapy for drug abuse is not only mediated by
pharmacological effects. Treatment agents also serve behavioral functions and
these functions can be modified by the environment. Better recognition of
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environmental factors can lead to more effective use of pharmacotherapy for
drug abuse and help address three problems: compliance, retention and clinical
effectiveness. Three environmental manipulations used to address these
problems are contingency management, psychosocial interventions and
instructions. How these manipulations interact with pharmacotherapy depend
largely on whether the treatment agent functions as a reinforcer.
Disulfiram and naltrexone, which generally do not function as reinforcers, are
associated with poor compliance and treatment retention, and equivocal clinical
effectiveness. Contingency management procedures and psychosocial
interventions have been useful in addressing these problems. For example,
compliance with disulfiram in alcoholic methadone patients was increased by
making methadone contingent on disulfiram consumption (Bickel et al., 1989).
This procedure decreased drinking and increased treatment retention. Similarly,
contingent monetary payments and the schedule used for those payments
increased naltrexone compliance in recently detoxified opiate addicts
(Grabowski et al., 1979).
Behavioral therapies also improved the effectiveness of disulfiram with
alcoholics (Azrin et al., 1982) and naltrexone with opioid addicts (Callahan et
al. (1980). Use of these behavioral treatments increased compliance and
improved lifestyle relative to traditional psychotherapy.
Methadone, buprenorphine and nicotine gum, which generally function as
reinforcers, present less of a problem with compliance and retention, but their
overall clinical effectiveness can be enhanced by non-pharmacological factors.
For example, greater reduction in illicit drug use during methadone or
buprenorphine detoxification occurred when cash payments (Hall et al., 1979)
or vouchers (Bickel et al., 1993) were contingent on opioid-free urines. Further,
the level of counseling services provided was directly related to the efficacy of
methadone therapy with opiate dependent patients (McLellan et al., 1993) and
nicotine therapy with smokers trying to quit (Fiore et al., 1994).
Finally, instructions also modulate therapeutic effects. Providing patients with
specific withdrawal information during methadone detoxification decreased
withdrawal symptoms (Green and Gossop, 1988). In addition, placebo-
controlled studies demonstrated that compliance, abstinence rates and self-
reported effects in smokers trying to quit varied according to whether nicotine
gum administration was instructed or blind (Hughes et al., 1989). Thus,
instructions can modify therapeutic effects, and play an important role in
pharmacotherapy.
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BRAIN IMAGING IN SUBSTANCE ABUSE
C. P. O’Brien and A. R. Childress
Advances in imaging technology over the last decade now enable direct, in
vivo measure of the brain correlates of drug use and dependence in humans.
In this symposium, investigators from five imaging centers presented their
addiction-related work featuring PET (positron emission tomography),
S P E C T  ( s i n g l e  p h o t o n  e m i s s i o n  c o m p u t e d  t o m o g r a p h y ) ,
EEG (electroencephalography) and MRI (magnetic resonance imaging)
technologies.
BRAIN METABOLISM IN SUBSTANCE ABUSERS
Edythe London
Dr. London described research using PET to study the regional metabolism of
brain glucose during actual administration of several drugs of abuse, including
opiates, cocaine, benzodiazepines, alcohol computed tomography) EEG
(electroencephalography) and MRI (maand delta-9 THC (the active ingredient
in marijuana). These studies have generally focused upon cerebral substrates
for “euphoria”, the positive affective state produced by drugs of abuse. PET
studies using 18FDG to measure brain metabolism show that opioids,
stimulants, benzodiazepines, and ethanol reduce cerebral glucose utilization.
In contrast, delta-9-tetrahydrocannabinol stimulates glucose metabolism in the
cerebellum. In studies with morphine and cocaine, reduced glucose utilization
accompanies self-reports of euphoria. The effect on positive mood is related
negatively to glucose metabolism in the temporal cortex. Therefore, function
in this brain region appears to be a determinant of subjective responses to
abused drugs that differ in their spectrum of action, but share the property of
producing euphoria. Effects of abused drugs on cerebral metabolism may
reflect a common neurochemical action. Studies in animals have suggested
that drugs of abuse enhance dopaminergic neurotransmission in the
mesolimbic reward system. Thus, drugs of abuse may reduce cerebral
metabolism through dopaminergic activation.
FLUORO-DOPA STUDIES OF HUMAN AND ANIMAL COCAINE
ABUSE
William Melega
Dr. Melega discussed PET imaging of uptake of a radioactively labeled form
of the dopamine precursor, L-DOPA, in those exposed to chronic stimulants.
Work with his colleague, Dr. Lewis Baxter, has previously demonstrated
reduced uptake of 18F-fluoro-L-dopa (FDOPA) in human cocaine users,
suggestive of reduced dopamine (DA) synthesis. Reduced synthesis may
occur compensatory to the increased synaptic DA associated with cocaine’s
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actions (reuptake inhibition of DA). In recent work with monkeys, time-
dependent decrements in activity of the striatal dopamine system were
detected following ten days of amphetamine administration. At one month
post -amphetamine, FDOPA uptake was reduced by 75% relative to pre-drug
values, indicative of long-term dopamine depletion. At five months post-
amphetamine, FDOPA uptake was reduced by only 45%, indicative of partial
recovery of the dopamine system. Acute administration of low dose
amphetamine effected a persistent loss of FDOPA uptake only when the
monkeys were pretreated with chronic cocaine. Both the findings in humans,
and the parametric studies in monkeys with known dosing regimens, are
consistent with the notion that reduced activity in the DA system may underlie
some of the clinical symptoms of psychostimulant cessation.
EEG BRAIN MAPPING OF DRUG-INDUCED INTOXICATION
Scott Lukas
Dr. Lukas described his research using EEG imaging to study the correlates of
drug-induced intoxication, and modeling of the EEG dipole source with aid of
topographic MRI. EEG mapping of drug intoxication involves consolidating
information from many electrode sites and displaying the information in a
color-coded format. This format permits the investigator to evaluate
topographic alterations in the voltage and frequency components of the
ongoing EEG activity. Because of the fine temporal resolution, EEG brain
mapping can be performed during specific behavioral tasks performed under
the influence of drug. This technique is also useful for analyzing rapidly
changing subjective mood states. Measure of drug-induced changes in mood
states are measured using an instrumental joystick divided to minimize the
artifacts produced on the EEG recording. The results of the EEG mapping
show that EEG alpha activity was increased during discrete episodes of
euphoria produced by acute administration of cocaine, ethanol, and marijuana.
The episodes of euphoria were more frequent during the ascending limb and
peak of the plasma ethanol, cocaine and marijuana curves. Interestingly,
plasma cocaine levels were dramatically increased if the subject smoked
marijuana first. This increase in plasma cocaine levels corresponds to an
increase in subjective effects.
Dr. Lukas described advances in localization of the EEG dipole sources which
have vastly improved the spatial resolution of EEG. Estimates of dipole origin
for event-related potentials (ERPs) during an “oddball” task were calculated
via the “inverse” solution, using a 3-shell, 6 parameter model. The origin,
magnitude, and orientation of the potential were described using a Cartesian
coordinate system, and the location of key electrode sites marked with vitamin
E capsules prior to a brain MRI. Coordinates of the dipole were then
transposed onto the MR data set. This approach showed sources of spindles
and alpha activity appeared most frequently in the thalamus. Increases in
signal amplitude increase dipole amplitude, but did not distort the origin of the
signal. The combination of EEG and MR imaging procedures capitalize on
the strengths of these techniques in temporal and spatial resolution,
respectively, and permit direct study of the neurophysiolgical basis of drug-
induced euphoria in humans.
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DOPAMINERGIC INVOLVEMENT INCOCAINE DEPENDENCE
John Gatley
Dr. Gatley and the research group at Brookhaven Laboratories have evaluated
the brain dopamine system in cocaine abusers and normal controls using a
multiple-tracers approach to image pre- and post-synaptic dopamine neuronal
elements, and to measure regional brain glucose metabolism. Because regional
brain glucose metabolism is tightly coupled with brain function, this strategy
provides a way of linking dopaminergic changes with regional brain function.
Fluorine-18-N-methylspiroperidol (NMS) and 11C raclopride were used to
assess post-synaptic dopamine D2 receptors, 
11C cocaine to measure pre-
synaptic DA terminals and 18FDG to measure regional brain glucose
metabolism. In addition, 11C raclopride has been used to measure relative
changes in DA synaptic concentration secondary to pharmacological
stimulation with methylphenidate (MP), a drug that increases synaptic DA by
inhibiting the DA transporter. These studies have shown that: 1) uptake of
11C cocaine into basal ganglia is rapid, paralleling the time course of the
euphorigenic effects of cocaine; 2) cocaine abusers have long lasting changes
in DA post-synaptic receptor availability and in pre-synaptic DA terminals; 3)
reductions in DA post-synaptic receptor availability are associated with
hypometabolism in prefrontal, cingulate and orbitofrontal regions; 4) cocaine
abusers have a blunted response to MP-induced DA changes; and 5) regional
brain metabolic changes induced by MP were significantly different in
normals than in cocaine abusers. These findings suggest a possible
dysregulation of DA receptor function in chronic cocaine users.
SPECT IMAGING OF DA TRANSPORTERS IN COCAINE
DEPENDENCE WITH [123I] -CIT
Robert Malison
Dr. Malison presented studies using SPECT neurotransmitter tracers to study
pre-and post- synaptic dopamine physiology in primates and in humans. In a
paradigm for studying stimulated DA release, systemic injection of
methamphetamine into anesthetized baboons produced faster evacuation of
the DA post-synaptic radiotracer I-123 IBZM than injections of saline. The
increased rate of tracer evacuation in this paradigm may evidence competitive
displacement by endogenous DA released by amphetamine. Similar paradigms
are now ongoing in humans.
Dr. Malison described the models used to derive estimates of binding potential
for radioreceptor ligands, and elegantly demonstrated application of this
approach in his recent work measuring the DA reuptake/transporter site in
cocaine patients. Early results from within-subjects SPECT imaging of
radoactively-labeled -CIT, a DA transporter ligand, suggest that transporter
sites are higher immediately following cocaine cessation than at a point
approximately four weeks later. Transporter sites may be up-regulated during
cocaine use in response to the increased levels of synaptic DA. Changes in the
DA transporter site during the weeks following the last dose of cocaine may
correlate with clinical phenomena of cocaine cessation.
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BRAIN IMAGING DURING DRUG-CRAVING STATES
Anna Rose Childress
Dr. Childress reported on the use of cue-induced craving to image the
neurochemical and neuroanatomical correlates of drug craving states in
cocaine users. Human drug users often experience strong drug desire and
arousal when encountering reminders of the drug (drug-buying locations, drug
talk, paraphernalia, etc.). Based on this observation, audiotapes and videotapes
featuring cocaine-related content were used to evoke craving in the imaging
setting. Preclinical studies have shown that cues which signal cocaine activate
brain dopamine systems, triggering DA release. These findings suggest the
hypothesis that cocaine-related cues may also produce activation of DA
systems in humans, and that DA release may be one component of cocaine
cue-induced craving.
With regard to neurochemical correlates, Dr. Childress’ group has used
SPECT brain imaging and the reversibly binding D2 dopamine receptor
radioligand, [123I]-IBZM, to measure rate of tracer evacuation in abstinent
cocaine patients exposed to either non-drug (“neutral”) cues, or to cocaine-
related cues (audiotapes, videotapes) which trigger craving. Increased
evacuation of this tracer during the cocaine cues, due to competitive binding
by endogenous DA, would be consistent with increased DA release to the drug
cues. Initial results with IBZM have found similar rates of washout during
cocaine-related and neutral cues. The low signal-to-noise ratio of IBZM. and
the relative size of the DA signal to cues (smaller and more variable than that
occurring to a pharmacologic probe such as amphetamine) make it difficult to
optimally test the DA-release hypothesis with IBZM. With regard to
neuroanatomical correlates, recent PET studies using O 15-labeled water as a
tracer of regional cerebral blood flow (rCBF) suggest that cocaine users have
differential increases in brain blood flow to cocaine cues vs. neutral cues, and
that these changes arc often most prominent in limbic regions. Both SPECT
and PET studies demonstrated the feasibility of using cue-induced craving in
an imaging setting to study the brain correlates of drug craving state(s).
DISCUSSION
Charles P. O’Brien
Dr. O’Brien guided the symposium question-and-answer period, and closed
the discussion by noting the promise of imaging techniques for understanding
of the brain changes which occur during drug use, drug cessation, and drug
craving.
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DR. FRANKLIN M. ROBINSON
MEMORIAL SYMPOSIUM:
MEDICINAL CHEMISTRY IN
DRUG ABUSE RESEARCH
FRANKLIN M. ROBINSON, Ph.D.
(1921-1992)
Born in Arlington, Massachusetts in 1921, Franklin Robinson received a
Baccalaureate Degree in chemistry from Worcester Polytechnic Institute in 1943.
For the next three years he was a Research Associate at the Sterling-Winthrop
Research Institute. During this period, Frank realized that further education
would be important for the optimal pursuit of his newly found interest in drug
discovery. In 1946 he moved to the University of Minnesota as a chemistry
graduate student in the laboratory of Professor C. F. Koelsch. In 1950 he
received a Ph.D. degree in organic chemistry from the University of Minnesota
and joined the Merck Research Laboratories in Rahway, New Jersey. Frank was
a member of the Merck team that discovered mevalonic acid. He also participated
in the early work on vitamin B12 and Coenzyme Q.
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After serving a term as Chief of Staff for the executive Director of Basic
Research, Frank moved to the Merck Research Laboratories in West Point,
Pennsylvania. Here he began his studies on analgesic agents. These studies,
which were focused on morphinans and benzomorphans, produced MK-901 as
a development candidate. His laboratory was the first to report the synthesis of
hexahydroindeno[2.1b]pyrroles as a novel benzomorphan-related template for
construction of potent analgesic agents. During this period Dr. Robinson began
to play a major role in the Merck Recruiting Program. His skill in identifying and
attracting top talent to Merck is legendary. Among his successes, Frank could
count two recruits who eventually became Vice-Presidents and more than half a
dozen who rose to the rank of Senior Director. Perhaps more importantly he was
an able and remarkably effective mentor for several generations of Merck
scientists. His enthusiasm for science was infectious. He encouraged young
scientists in the rigorous pursuit of new ideas and set, by example, a high
standard for performance. Although Frank completed his career at Merck more
than five years ago, the positive impact of his leadership is still very much in
evidence today. The scientists that he recruited and those that he mentored
continue to emulate the spirit of cooperation, enthusiasm for science and
commitment to excellence that he taught and encouraged. This special chemistry
symposium of the 56th Annual Scientific Meeting of CPDD is respectfully
dedicated to Dr. Franklin M. Robinson.
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FRANKLIN ROBINSON MEMORIAL SYMPOSIUM ON
M E D I C I N A L  C H E M I S T R Y  I N  D R U G  A B U S E
RESEARCH
A. H. Newman; P. S. Portoghese; S. Calderon; J. Lewis; R. H.
Kline; P. Anderson; and K. C. Rice
INTERACTION OF SELECTIVE NONPEPTIDE LICANDS WITH
OPIOID RECEPTORS
Philip S. Portoghese
The opioid receptor antagonists, naltrindole (NTI) and norbinaltorphimine
(norBNI), contain key moieties that enhance binding to and receptors,
respectively. Structure-activity studies have suggested that the indolic benzene
moiety of NTI and the N2 basic nitrogen of norBNI are responsible for the
selectivity of these ligands. A simple model based on the “message-address”
concept of Schwyzer (Ann. N.Y. Acad. Sci. 1977, 297, 3) has been employed to
rationalize the selectivity. In this connection, the indolic benzene moiety of NTI
was considered to mimic the Phe4 phenyl group of enkephalin, and the N2 basic
group of norBNI was proposed to mimic Arg7 of dynorphin. That is, the
nonpeptide moieties were thought to serve an address function in a manner similar
to the corresponding groups in the opioid peptides.
Structure-activity studies of NTI congeners have revealed that ligands whose
aromatic groups share the same conformational space with the indolic benzene
moiety of NTI, possess higher antagonist potency than other analogs in the
series, suggesting that access to an aromatic binding subsite is important for
antagonist activity. However, the fact that NTI cannot be converted to a full
agonist by replacement of its cyclopropylmethy1
(oxymorphindole, OMI) suggests that agonists and
with a methyl group
antagonists have different
conformational requirements. In this connection, molecular dynamics studies of
[D-Ala2, D-Leu] enkephalin have revealed that the Phe4 phenyl group in most of
the low energy conformers is roughly perpendicular to the indolic benzene moiety
of OMI. These studies have led to the synthesis of 7-spiroindanyloxymorphone
(SIOM), a ligand whose benzene moiety is perpendicular to ring C of the opiate.
The finding that SIOM is a full agonist at receptors, both in vitro and in vivo, is
consistent with the idea of different recognition sites for agonists and
antagonists. The fact that mutation of Asp 128 to Asn in the receptor causes the
loss of agonist but not antagonist binding (Kong, et al., J. Biol. Chem. 1993,
268, 23055) also supports this conclusion.
A similar situation appears likely with norBNI in that its N2 basic group does not
interact with the same subsite on the receptor as the basic group in the address
segment of dynorphin. The fact that the µ opioid receptor has been proposed to
possess separate recognition sites for agonists and antagonists (Portoghese and
Takemori, J. Med Chem. 1983, 26, 1341) also suggests that this is a general
feature in the opioid class of G-protein coupled receptors.
In conclusion, the idea of discrete message and address subsites on opioid
receptors has been useful in the design of selective opioid antagonists. However,
the concept should not be taken to mean that the message and address subsites of
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agonists and antagonists are identical because of the possible different modes of
interaction of agonist and antagonist ligands with opioid receptors.
DEVELOPMENT OF SELECTIVE NONPEPTIDE LIGANDS FOR
F U R T H E R  C H A R A C T E R I Z A T I O N  O F  D E L T A - O P I O I D
RECEPTORS.
Silvia Calderon
The synthesis of nonpeptide agonists and antagonists with high selectivity for
delta ( ) opioid receptor subtypes is an important and challenging problem in
medicinal chemistry. Nonpeptide ligands have the advantage that they are less
subject to metabolism than peptides and also can penetrate the blood-brain barrier.
Recently, a novel nonpeptide -opioid receptor ligand, (±)-BW373U86, [(±)-1 ] ,
was reported and appears to be a prime template for the discovery of new probes
for the receptor. All the pharmacological studies of this compound to date were
performed using the racemate. To best utilize this important lead, studies with the
optically pure enantiomers of (±)-1 are required, since often drug enantiomers
have different and in some cases opposite pharmacological effects.
We synthesized the optically pure enantiomers of (±)-BW373U86, their benzylic
epimers and the corresponding methyl ethers from the enantiomers of 1-allyl-
trans-2,5-dimethylpiperazine. Receptor binding studies in rat and in mouse brain
showed that the phenolic enantiomers of BW373U86 and their benzylic epimers
have high affinity for and µ receptors. Two of the methyl ether isomers of
BW3737U86, (+)-2 and (-)-3, immediate precursors in our synthetic route,
have shown the most striking results. These compounds exhibit a dramatic
increase in selectivity for receptors over µ receptors by approximately 2000-fold
in opioid binding assays. Thus, methylation of the phenolic group virtually
eliminates the affinity of these compounds for µ receptors.
Studies with these compounds in the isolated mouse vas deferens (MVD) and
guinea pig ileum (GPI) bioassays revealed that the /µ selectivity of (+)-2 was
about 2000-fold as in the binding assays but the selectivity of (-)-3 was only 49-
fold. At 1 µM, the receptor antagonist ICI174,864, but not the µ receptor
antagonist CTAP, showed potent antagonism of the effects of (+)-2 in the MVD
bioassay. These data collectively show that (+)-2 is a potent, receptor agonist
and suggest that this compound will be a valuable tool for further study of the
opioid receptor structure and function including its role in addictive diseases.
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OPIOIDS - FROM ANALGESICS TO TREATMENT DRUGS
John Lewis
Drug discovery programs in the opioid field have in the past been directed to
“non-addictive” analgesics. The recognition of’ multiple opioid receptors turned
attention away from µ towards and particularly -agonist analgesics do not
have significant abuse potential but despite substantial research investment by the
pharmaceutical industry in the search for specific -agonists, it is unlikely that
such analgesics will contribute significantly to pain management in the future.
The prospects for specific agonists do not appear much brighter.
For the medicinal chemist involved in drug discovery, opportunities to design
opioids as pharmacotherapies for opiate abuse have become of increasing
importance and have renewed interest in activity at µ receptors. Agonist
(methadone, LAAM) and antagonist (Naltrexone) maintenance treatments are
available and a partial agonist (buprenorphine) is in late development. The latter
may be of particular value in the treatment of dual opiate/cocaine abuse.
Alternatives and improvements are required to provide appropriate treatment for
addicts in different stages of the addiction cycle.
We have been attracted to the concept of µ partial agonists of varying intrinsic
activities to provide a range of treatments to cover the spectrum between the full
agonists and the pure antagonist. An important lead was provided by
methoclocinnamox (MC-CAM), a long lasting µ partial agonist which is
converted to the irreversible antagonist clocinnamox (C-CAM) by metabolism.
We have synthesized and had evaluated by Jim Woods a number of alternative
ethers of C-CAM. In comparison with the methyl ether (MC-CAM) the alkyl,
propargyl and cyanomethyl ethers have more pronounced agonist actions; the
CPM ether by contrast appears to be more antagonist that MC-CAM and the n-
propyl ether quite similar to MC-CAM. In binding assays the ethers are
remarkable in displaying affinities for µ receptors equal to or in the case of the
propargyl ether, significantly higher than that of the parent phenol C-CAM. They
also show selectivity differences between ethers and in comparison to the phenol
which has significantly higher and affinities than the ethers.
As potential pharmacotherapies for opiate abuse, MC-CAM and the other analogs
offer an agonist, reinforcing response followed by prolonged receptor blockade
as the antagonist C-CAM is produced by metabolism. Since it may not be
desirable to block opioid receptors for such a long period, we have evaluated
some close analogs of MC-CAM and C-CAM in which the Michael acceptor
cinnamoylamido group which could form a covalent bond to the receptors has
been removed by hydrogenation and then by reduction of the amide function. It
was expected that these changes would remove irreversible antagonist actions
from the pharmacological profiles. However, both morphinones showed the
character of non-competitive µ antagonists of exceptional in vitro potency. This
suggests that the irreversible antagonism of C-CAM may be due in part to a non-
covalent binding interaction probably involving the lipophilic chlorophenyl group.
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S U B S T I T U T E D  3 - C A R B A M O Y L O X Y E C G O N I N E  M E T H Y L
ESTER ANALOGS: N O V E L  P R O B E S  F O R  T H E  C O C A I N E
R E C O G N I T I O N  S I T E  O N  T H E  C E N T R A L  D O P A M I N E
TRANSPORTER
Richard H. Kline
In the search for compounds to further characterize the cocaine recognition site on
the central dopamine transporter several 3-(N'-phenylcarbamoyloxy)ecgonine
methyl ester analogs were prepared. The synthesis of these compounds started
with the conversion of (1R)cocaine to (1R)ecgonine methyl ester via hydrolysis in
dilute HCl and subsequent re-esterification with CH3OH/H2SO4. (1R)Ecgonine
methyl ester was then reacted with appropriately substituted phenyl isocyanates
yielding the (1R) stereoisomers of the desired analogs in good yields. These
compounds were tested for their ability to inhibit [3H]cocaine binding to rat
striatal tissue and [3H]dopamine uptake into synaptosomes prepared from the
same tissue. The most potent of these analogs was (1R-2-exo-3-exo)-3-(N' -3’-
nitrophenylcarbamoyloxy)-8-methyl-8-azabicyclo[3.2.l]octane-2-carboxylic acid
methyl ester. IC50 values for inhibition of binding and uptake were 37 and 178
nM, respectively. Generally, compounds which contained meta substituents on
the phenyl ring of the C3 phenylcarbamoyloxy moiety were more potent than
those with para substituents. Also, analogs which contained electron withdrawing
substituents on the mentioned phenyl ring had considerably higher potencies than
those with electron donating substituents. A further objective of this research was
to design and synthesize ligands which could be used for the eventual purification
of the central dopamine transporter. Thus, analogs which could potentially
interact irreversibly with the cocaine binding site containing isothiocyanato or
azido moieties were synthesized from appropriately substituted amino
compounds. Preincubation of synaptosomal membranes with the meta- and para-
isothiocyanato analogs, followed by two washes, resulted in inhibition of 70%
and 85% of [3H]cocaine binding. After pre-incubation in reduced lighting, meta-
and para-azido compounds inhibited 0% and 13% of [3H]cocaine binding, while
following pre-incubation under ultraviolet light the inhibition increased to 61%
and 68%, respectively. Thus, the isothiocyanato derivatives appear to bind
covalently to the cocaine binding site, whereas the azido derivatives are apparently
photoaffinity labels at the same site. Either type of analog may be useful in the
purification of the cocaine recognition site on the central dopamine transporter.
STRUCTURE-ACTIVITY-STUDIES WITH ANALOGS OF MK 801
P. S. Anderson
The discovery of dizocilpine, MK-801 (I, 5S,10R), began with an attempt to
optimize the modest antiseizure and apparent anxiolytic activities exhibited by a
compound that had been selected for this type of screening because of its novel
structure. Pursuit of this objective by use of established pharmacological assay
methods which employed intact animals led to the discovery of 9,10,11-trimethyl-
9,10-dihydroanthracen-9,10 -imine (II). Compound II proved to be a potent
antiseizure agent with central sympathomimetic activity, thus suggesting potential
for development as a nonsedating drug to treat epilepsy. This course of action
was precluded by the observation that compound II was susceptible to oxidative
deamination to afford 9,10-dimethylanthracene, a potent mutagen.
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The structure of compound II suggested a strategy for circumventing this
problem. Its carbon skeleton was reorganized by moving one of the identical
bridgehead methyl groups into the central ring of the hydrocarbon framework as a
rnethylene unit. Through this maneuver, structures such as that of compound I
were obtained. The topography of compound I is very similar to that of
compound II; however, the additional methylene unit blocks the cheleotropic
elimination pathway, and thus it is stable toward deamination under oxidative
conditions. Unlike compound II, compound I is a chiral molecule. The
enantiomer with the 5S, 10R configuration as its hydrogen maleate salt is
dizocilpine (MK-801). As was the case with compound II, dizocilpine proved to
be a potent antiseizure agent with significant central sympathomimetic activity.
Because a mechanism to account for dizocilpine’s pharmacological actions had
not been established, studies were initiated to address this important issue. [3H]
Dizocilpine was synthesized and used to develop a radioligand displacement assay
and to map binding sites in brain. The binding site distribution in rat brain was
comparable to that previously observed for glutamate. This observation and
results subsequently obtained from electrophysiological studies on brain slices
were in accord with selective, noncompetitive blockage of the N-methyl-D-
aspartate (NMDA) subset of glutamate receptors as the mechanism for the
pharmacological activity of MK-801. Agents of this type have potential in
management of seizure disorders, as well as in management of cerebral ischemia
associated with stroke and/or cardiac arrest.
NOVEL 3 -DIPHENYLMETHOXYTROPANE ANALOGS ARE
P O T E N T  D O P A M I N E  U P T A K E  I N H I B I T O R S  W I T H O U T
COCAINE-LIKE BEHAVIORAL PROFILES.
Amy Hauck Newman
Novel dopamine uptake inhibitors have proven to be useful for elucidation of the
role of the dopamine transporter in the pharmacology of cocaine. Benztropine
(BZT, 3 -diphenylmethoxy)-l H,5 H-tropane) is a dopamine uptake inhibitor
that is equipotent to cocaine and exhibits CNS stimulant activity in animal models.
BZT shares the common tropane ring moiety of cocaine and the diphenylmetboxy
substituent of another series of selective dopamine uptake inhibitors i.e. GBR
12909. Hence, BZT appeared to be an interesting template for structural
modification towards the development of novel probes of the dopamine
transporter. An initial series of puru-substituted BZT analogs was prepared
generally by reacting tropine or pseudotropine with the appropriate para-
substituted benzhydrylchloride at 160 °C and isolating the products as the HCl
salts. All of these compounds monophasically displaced [3H]WIN 35, 428
binding in rat caudate-putamen with Ki values ranging from 11.8 to 2000 nM.
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The rank order of potency for both binding and inhibition of [3H]dopamine
uptake was 4',4"diF>4',4"diC1>4'C1>4'OMe>BZT>3 -4'Cl>4',4"diOMe.
Interestingly, when the diphenylmethoxy substituent was in the 3-position, as is
the 3 -benzoyl group of cocaine, potencies for binding and inhibition of
[3H]dopamine uptake were decreased by approximately 30-fold. The lack of a 2-
position substituent further distinguished this series from the potent cocaine-
related analogs. Additionally, phenyl ring substitution resulted in large differences
in binding potency. Behaviorally, these compounds demonstrated low efficacy
locomotor stimulation in mice as compared to cocaine, despite their (generally)
higher binding potency. Likewise, rats trained to discriminate cocaine from saline
did not recognize these analogs as being cocaine-like at behaviorally active doses.
These compounds are the first tropane analogs to be reported that have high
affinity for the dopamine transporter, block dopamine uptake but do not exhibit a
cocaine-like behavioral profile. Drug interaction studies are underway to
determine whether these compounds may act as functional cocaine antagonists.
AFFILIATIONS:
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E F F E C T S  O F  A M O U N T  O F  S E R V I C E S  O N
OUTCOMES DURING TREATMENT: PRELIMINARY
ANALYSIS FROM TWO NATIONAL STUDIES OF
COMMUNITY-BASED TREATMENT PROGRAMS
R. L. Hubbard, R. M. Etheridge, S. G. Craddock, and
G. Dunteman
It has been generally demonstrated that longer time spent in drug abuse
treatment is related to more positive outcomes. In an environment of cost-
cointainment, a critical question is whether a sufficient and equally effective
dose of treatment can be delivered in a shorter time frame. Data from two
national studies of treatment effectives, TOPS (1979-81) and DATOS (1991-
93) address the issue of measuring, analyzing and interpreting effects of
treatment dose. Preliminary investigation focused on (1) the nature and extent
of counseling and services provided during the initial three months of
treatment; (2) the cognitive and behavioral changes occurring during three
months of treatment; and (3) the potential effect of this treatment dose in
interaction with moderator and mediating variables. The initial analysis was
restricted to a sample of methadone (TOPS[n]-2,185; DATOS[n]-908), and
outpatient (TOPS[n]-763, DATOS[s]-855) clients.
The amount and diversity of counseling and services reported between 1980
and 1992 has declined substantially. Despite increases in self-reported needs
for services in many areas (medical, family, etc.), clients in 1991-93,
compared to 1979-81, reported receiving fewer services, more unmet needs for
medical services (39.6% versus 17.8% in methadone, and 32.0% versus 9.2%
in outpatient), family services (52.8% versus 17.0% in methadone and 63.0%
versus 8.1% in outpatient) and other services including psychological and
vocational.
The amount of counseling or services do not appear to have a direct main
effect on drug use outcomes during methadone and outpatient treatment. None
of the preliminary measures of treatment dose, including days attended, total
hours of counseling, number of services, or number of met needs, had a
significant positive effect. The clients using cocaine during treatment were
more likely to report receiving more services. The effect of treatment dose may
be moderated by the behavior and cognitions of clients prior to admission. The
numbers of problems and higher levels of problem indicators prior to treatment
was predictive of higher rates of use during treatment.
Involvement with the criminal justice system had significant, but opposite
effects on cocaine use in methadone and outpatient clients probably due to the
formal criminal justice referral of outpatient clients. The effect of treatment
dose may be mediated by cognitive changes occurring during drug treatment.
Cognitive measures such as relationships with a counselor, perceived
hepfulness of treatment, and self-efficacy were positively and significantly
related to reduced use during treatment. These results suggest the need for a
more comprehensive, complex, multivariate framework to investigate the effect
of treatment dose. This framework needs to consider contextual effects of
program and system, moderating influence of client characteristics, mediating
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effects of cognitive change, as well as the appropriate method of assessing and
describing treated dose.
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P S Y C H O S O C I A L  T R E A T M E N T S  F O R  C O C A I N E  A B U S E :
TREATMENT INTENSITY AS A PREDICTOR OF LONG-TERM
CLINICAL OUTCOMES
J. A. Hoffman, B. D. Caudill, J. J. Koman, III, J. W. Luckey,
P. M. Flynn, and D. W. Mayo
This report summarizes outpatient treatment outcome results at 12-months
post-treatment for 184 cocaine-abusing clients, 96% primarily crack smokers,
from a study of six psychosocial treatment interventions which varied in level
of intensity. The treatments included group counseling two or five times a
week either alone or adding individual therapy alone or with family therapy.
Subjects were 60% male, 95% African American, average age 31, 20%
married or living with a partner, 39% involved in criminal justice system, 39%
employed full-time in year prior to treatment, and on average, had a 12th grade
education. The response rate was 66% of clients eligible for follow-up, 38%
of whom completed the 4-month treatment program. Across all groups, the
sample went from 78% self-reported regular crack use (weekly or greater) in
the year prior to treatment to 19% weekly users during the year following
treatment. Although there were no significant differences in the reduction of
crack use between groups, the number of days in treatment and the number of
treatment sessions attended were significantly related to reductions in crack
use. As a group, post-treatment regular users spent an average of 33.8 days in
treatment vs. 59.5 days for clients who were not regular users (p<.005); and
post-treatment regular users attended an average of 12.4 sessions vs. 24.5
sessions for clients who were not regular users (p<.008). Reductions were
also found in the percentage of clients reporting involvement in illegal activities
for monetary gain during the 12 month period following treatment (from 36%
in the year prior to treatment to 9% in the year after) which, when grouped by
the presence or absence of illegal behavior, was also significantly related to
days in treatment (p<.03).
Post-treatment full-time employment status decreased slightly from the intake
report of employment. The results indicate that longer participation in
outpatient treatment and treatment exposure were both significantly related to
reductions in regular crack use. Once an optimal level of outpatient treatment is
offered, emphasis may be placed on interventions and incentives to enhance
motivation and participation and to provide specific additional services.
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DOSE-RESPONSE STUDIES OF PSYCHOSOCIAL SERVICES
DURING SUBSTANCE ABUSE TREATMENT
A. T. McLellan
Is it possible and practical to increase treatment effectiveness by “matching”
different “types” of patients to particular kinds of programs or treatments?
What are the system barriers to “matching”‘? Data is presented from a
prospective study of patient-treatment matching involving two treatment
settings and four accredited, private programs treating 460 employed alcohol
and cocaine dependent patients referred from a large EAP.
Stage I - patients were evaluated by the EAP using a standard clinical interview
and referred in the normal manner to one of the tour programs. All patients
were followed weekly by independent researchers monitoring the nature and
number of the services received. Patients were re-contacted (94 percent) six
months after treatment discharge and re-evaluated. These data were used to
develop a model of patient-program and treatment service matching for the
second stage of the study.
Stage II - using the stage one decision tree to randomly assign 387 new
patients to: “matched” programs and service profiles. “Matched” patients were
compared against controls treated at the same programs in the standard manner
but not given the matched services. Outcome measures were drug and alcohol
use, empoyment, crime, use of medical and social services.
Results and Conclusions - It was impossible to actually match patients to
the programs due to insurance constraints, managed care, geography and
patient resistance. However, matching treatment services to patient problems
at the program level was quite successful, “Matched” patients received the
same total services as control patients, but were less likely to drop out early.
Six-month outcome comparisons showed that matched patients had 15-25
percent better outcomes than control patients treated in the same programs by
the same staff under standard conditions. Problem-service matching at the
program level was easy to implement, well accepted by clinical and
administrative staff and cost an additional three percent (of program budgets) to
institute.
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ETIOLOGY, EPIDEMIOLOGY AND NATURAL HISTORY
OF HEROIN ADDICTION: A SOCIAL SCIENCE
APPROACH
J. C. Ball, D. N. Nurco, R. R. Clayton, M. Lerner, T. A. Hagan,
and G. A. Groves
Drug addiction can be explained as a biomedical, psychological, or sociological
phenomenon. In this symposium, the overall explanatory power of a social
science approach was delineated and some current research findings were
presented. It was held that this approach provides a more comprehensive
explanation of the problem of drug abuse in the United States than other
approaches. Although sociological findings were emphasized, it was recognized
that other social science disciplines (e.g., anthropology, social psychology and
economics) also make significant contributions.
A social science approach to the study of drug dependence involves
consideration of fundamental issues related to the nature, scope and dynamics of
this social problem. Thus, this approach addresses such basic issues as: (1) the
history of drug abuse patterns and the changing populations of users; (2)
recognition that specific drug abuse patterns are culturally determined--that
cultures (and subcultures) differ in the availability of drugs and the extent of
abuse; (3) that the demographic (and epidemiological) characteristics of abusers
depend upon the time period, nation and locale selected for study; (4) the
necessity to delineate the specific drug (or drugs) of abuse, route of
administration and length of dependence; (5) the etiology or social context in
which drug abuse begins; (6) the influence of major institutions (e.g., family,
community, peer group, schools, media) upon the onset and continuation of drug
dependency; (7) why drug abuse is more prevalent in certain populations than
others; (8) determination of institutional supports which promote successful
treatment and rehabilitation, including consideration of how persistent behavior
in subcultures can be changed.
With respect to historical and cultural contexts, it was noted that demographic
populations at high risk for opiate addiction have differed by era and location
within the United States. Similarly, for those who do become addicts, age at
onset of daily opiate use and other characteristics of their addiction careers also
differ by period and place of residence. Furthermore, it is significant that
comparable or even greater variations in addiction characteristics and
consequences have been found in other nations Thus, the problem of opiate
addiction differs by nation and historical period, although most physiological
and pharmacological aspects of addiction, such as physical dependence, remain
constant.
Consequently, social science studies of drug addiction have usually focused on
particular populations of abusers, classified specific drugs of abuse, and
formulated definite scientific questions to investigate. Therefore, it is necessary
to indicate which population (adult males, metropolitan slum dwellers, teenage
females, college students, army personnel, factory workers, prostitutes,
criminals, doctors, pregnant housewives, etc.) and which drugs of abuse (heroin,
morphine, PCP, cocaine, marijuana, barbiturates, etc.) are to be studied. In
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addition, it is important to measure frequency of use as well as to note route of
administration.
With respect to the etiology of drug dependence in the United States, the role of
peer group and community are of paramount importance, especially with respect
to persistent intravenous drug use. Thus, most heroin dependency starts as part
of a peer group recreational activity. This onset behavior is similar to juvenile
delinquency in that the boys are seeking status in the peer group by taking part
in a search for kicks and mutual excitement. Initiation into drug use is voluntary
rather than accidental or coercive. The incipient addict tasks to join the drug-
taking group whose members arc seen as friends. (The onset pattern for females
is different; most are initiated by their boyfriends or other males).
The family also has a crucial role to play in the prevention of drug abuse among
children. However, many children do not have responsible parents and,
consequently, they are deprived of suitable early socialization. In this regard,
there are not only orphans and unwanted children, but parents who are
themselves opiate addicts, criminals, or prostitutes.
In a very real sense, addiction is a community problem, rather than merely an
individual problem. This is because addiction is maintained and spread by drug-
using cohorts from generation to generation in metropolitan slum areas.
Furthermore, the fact that minority group members constitute a major portion of
inner-city dwellers only exacerbates the problem of awakening public interest
and support. So the scope and complexity of the slum problem remain intact,
and the poorer areas of our cities continue to be ignored.
When attention is turned to the rehabilitation of persistent drug abusers, it seems
apparent that treatment alone cannot be expected to contain the problem. This is
because no one approach or single institution will be sufficient to meet the
heroin addiction problem in the United States. Rather, a coordinated societal
approach is necessary, in which increased resources will be organized to meet
prevention, education, and treatment needs of communities, occupations, and
other populations. In order to explicate further the social science approach,
attention was focused on several of those basic issues.
EPIDEMIOLOGY IN THE UNITED STATES
Epidemics can occur if there is an increase in the percentage of the population
using drugs, in the number of heavy users, and/or there is an increase in the
amount of drugs consumed by both those in the general population and the
heavy users. In order to adequately understand the genesis, course of
development and regression, and the correlates and causes of a drug epidemic,
there is one requisite: valid and reliable data. In the U. S., three major sources
of national data about the extent of drug abuse are: (1) Monitoring the Future
Data about high school seniors; (2) DAWN data from hospital emergency
admissions; and (3) National Household Surveys of the general population.
The population of the United States, 12 years old and older, is clearly drug
experienced. Data from the 1992 National Household Survey show that 33%
(67.5 million) people have used marijuana, 4.4% (8.9 million) in the prior
month. Some 22.6 million (11%) have used cocaine, 1.3 million (0.6%) in the
past month. Some 98.4 million (48%) report past month use of alcoholic
beverages while 53.9 million (26.2%) report past month of smokeless tobacco.
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The DAWN system has been in existence for a considerable period of time. The
emergency room episodes for cocaine, heroin, and marijuana were examined in
six-month increments from January-June 1988 through January-June 1992.
These data show a drop until the period July-December 1990, followed by a
steady increase for all three drugs with the latest period being 1.56 times as high
as the trough for cocaine, 1.94 times as high as the trough for heroin, and 2.11
times as high as the trough for marijuana.
The Monitoring the Future data on high school seniors show a rather dramatic
decline in drug use, since 1979 for marijuana and since 1982 for cocaine.
However, comparing 1992 to 1993 data, there were statistically significant
increases in use of marijuana (8th, 10th, 12th grade). and daily use of cigarettes
in the past month (8th, 10th, 12th grade).
The following conclusions were drawn from the Monitoring the Future study.
These changes are real and may constitute a “wake-up” call for the American
public. There should be genuine concern that the reversal of the downward
trend in drug use could signal the emergence of a new epidemic of drug use. On
a number of occasions during the past 20 years there have been assertions by
highly placed officials that we have “turned the proverbial corner” on drug
abuse. Each time, the assertion has not only proven to be wrong, but has
seemed to delay timely response to the changes. It would be tragic if nothing
were learned from this history of bad guesses about where the trend line is
going.
WOMEN’S ISSUES
There is little empirical information on differing treatment needs of women in
general, or subgroups of women (e.g., opiate dependent, cocaine dependent,
Latin or African-American women). Despite this paucity of data, a number of
small studies coupled with clinically relevant information have begun to provide
a basis for further investigation into appropriate services for women. In
addition, the information and data raise important questions for treatment
provision, research, and policy planning.
Women bring a number of critical issues to treatment settings that require
comprehensive services. These issues include but are not limited to early incest
and drug use; physical abuse; family or origin chemical abuse; educational
deficits; sporadic employment in low paying jobs; lack of transportation and
child care; safe housing problems; violent current relationships; and inconsistent
parenting skills. Such diverse and multiple difficulties can precipitate problems
and symptoms ranging from: (1) psychosis; (2) flashbacks; (3) depression and
anxiety; (4) present behaviors that appear to be associated with possible
developmental delays at age of first use; (5) an inability to participate in
vocational/educational programs due to poor coping and developmental skills;
(6) difficulty in accessing treatment because of a lack of transportation and child
care; and (7) repeated negative behaviors and coping mechanisms in current
relationships.
Research should address: (1) the development of practices that encourage
sensitivity to individual treatment progression, rather than universal measures;
(2) broader definitions of treatment success; and (3) methdologies that control
for factors that can impede reliable outcome measures; (e.g., lack of housing,
transportation, and child care; bias against treatment modalities such as
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methadone; and behaviors associated with arrested developmental levels).
FAMILIES OF NARCOTIC ADDICTS
The importance of family factors of males respondents aged 12-14 as predictors
of narcotic addiction, highlight especially the role of the father in this
regard, especially the natural father family, The degree of attachment
at ages 12-14 to onee’s parents, especially to one’ father, is a major determinant
of how strong a young person’s resistance will be to the temptations offered by
addiction in neighborhoods where high levels of drug abuse are prevalent.
A positive home atmosphere and a strong parental commitment is similarly a
strong predictor of the addiction history of young people aged 12-14. Further
analyses of data, to be carried out shortly, will permit estimation of the percent
of variance in addiction or non-addiction explained by these factors, especially
after controlling for the effects of neighborhoods, the character of respondents’
peer groups, deviance within the family prior to the respondents’ age 11, and
others.
Studies reported here have thus far focused on epidemiology, but they need to
be taken one step farther with the creation of classes of patients that have utility
for a clinician. For example, approximately 40% of the population studied came
from families without two natural parents in the household and the addict
subject perceived of his father in a negative fashion. By proceeding to identify
other variables and in the process create identifiable types, clinicians can see and
develop specifically tailored techniques in order to change behavior.
CHARACTERISTICS OF METHADONE MAINTENANCE PATIENTS
With regard to drug abuse patients in treatment in the U. S., the characteristics
of 120,000 opiate addict patients in 650 methadone maintenance programs in the
U. S. were delineated. The marked metropolitan concentration of this patient
population was noted (e.g., one-third reside in New York City), was its over-
representation of males and minority group members. It was found that onset of
heroin addiction for males commonly commenced as a peer-group recreational
activity at an early age (14-18 years); for females onset commonly was begun
with their addicted boyfriends. Most patients of both sexes had five or more
years of intravenous drug abuse prior to their present treatment and most also
had lengthy criminal careers. The general effectiveness of methadone
maintenance treatment in reducing IV drug use and criminal behavior was
discussed.
CONCLUSION
From the social science perspective, then, solution to the drug abuse problem
does not lie in simply deriving chemical agents to be used in the control of
addicts’ emotions and behavior or in the mechanistic application of technical
innovations. Solutions that do not take into account the basic motivations and
propensities underlying addictive behavior are destined to failure. Addicts, for
example, can be remarkably creative in achieving their own ends; those working
with them must understand this and use laboratory advances as supplements in
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dealing with more global aspects of the individual. Unfortunately, there is no
“magic bullet” for the containment of drug deviancy.
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CLINICAL PHARMACOLOGY OF BUPRENORPHINE
M. L. Stitzer, S. L. Walsh, E. C. Strain, K. J. Schuh and G. E.
Bigelow
The clinical pharmacology profile of buprenorphine derived from laboratory
research is generally consistent with the known properties of a mu partial
agonist and supports the potential utility of buprenorphine for the treatment of
opioid dependence.
Mu agonist profile: Buprenorphine constricts pupils, produces opioid-like
subjective effects and analgesia.
Dose-effect ceiling: Human subjects have been tested with acute doses up
to 32 mg s.1. Pupil constriction, respiratory depression and subjective reports
have all shown maximal effects at doses well below 32 mg (2-16 mg
buprenorphine depending on the specific measure). The ceiling on respiratory
depression means that this is a very safe medication. Examination of plasma
drug levels showed a linear increase with dose, suggesting that the dose-effect
ceiling was not due to absorption limitations of the sublingual administration
route.
Duration of action: Buprenorphine has a long duration of action. Pupil
constriction was apparent for 48 hours after acute s.1. doses of 2 mg and
higher. Plasma levels were elevated for 48 hrs after 16 mg and 96 hrs after 32
mg buprenorphine. The long plasma half life of high doses supports the
possibility of dosing on a less than daily basis in treatment.
Blockade of opioid agonists: Buprenorphine attenuates effects of short-
acting opioids given as a challenge during chronic treatment. Extent of
attenuation was directly related to the maintenance dose from 2 - 16 mg/day,
with only partial attenuation of opioid effects during maintenance on 8 mg/day
or lower. Partial attenuation of 6 mg hydromorphone challenge was observed
for up to five days after discontinuation of 8 mg/day buprenorphine treatment.
These results support clinical utility in treatment of opioid abuse and have
implications for selection of effective doses and dosing frequency.
Antagonist properties in dependent subjects: Buprenorphine at doses
up to 8 mg has failed to precipitate withdrawal responses either in subjects
maintained on morphine at doses up to 120 mg/day i.m. or in subjects
maintained on 30 mg/day of oral methadone. Only in subjects maintained on 60
mg/day oral methadone has precipitated withdrawal been observed following
acute buprenorphine administration. These findings suggest antagonist effects
are limited and support the safety and acceptability of clinical transitions from
street heroin or low dose methadone to buprenorphine treatment.
Physical dependence: Buprenorphine is thought to have low physical
dependence potential; in animal studies it has been difficult to precipitate
withdrawal responses using naloxone challenge. Only limited data are available
thus far for humans, but it appears there are conditions under which both
spontaneous and precipitated withdrawal can be observed. More research is
needed on this topic.
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Overall, a great deal has been learned in a relatively short time about the clinical
pharmacology of buprenorphine and its potential clinical utility. Like
methadone, buprenorphine produces long-acting mu agonist effects when given
acutely. and attenuates effects of short-acting opioids when given chronically.
The dose-effect ceiling makes buprenorphine a safer medication than
methadone, but purported differences in physical dependence profiles need
further evaluation.
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BUPRENORPHINE AS A DETOXIFICATION AGENT
R. E. Johnson
The effectiveness of buprenorphine as a detoxification agent depends on two
pharmacologic characteristics: 1) the ability to suppress emergent opioid
withdrawal signs and symptoms in dependent individuals, and 2) the withdrawal
signs and symptoms produced by the discontinuation of buprenorphine. These
two issues are intertwined when buprenorphine is tested as a medication for
detoxification treatment.
Suppres s ion  Of  Opia te  Wi thdrawal  S igns  And  Symptoms  By
Buprenorphine: Suppression of the opiate withdrawal syndrome by
buprenorphine has not been demonstrated in a placebo-controlled study.
However, studies comparing the emergence of an opioid withdrawal syndrome
following the substitution of buprenorphine indicate that: 1) buprenorphine will
substitute for heroin and methadone during dose induction; 2) substitution for
heroin may be more easily accomplished than for methadone; 3) buprenorphine
administered for a short period of time appears more effective than clonidine; and
4) buprenorphine may be effective across a wide dose range.
Withdrawal Signs And Symptoms Following Dicontinuation Of
Buprenorphine: In two studies where non-dependent subjects were
maintained on buprenorphine and then withdrawn, autonomic signs and
subjective symptoms of withdrawal have been reported as absent or minimal. In
subjects dependent on heroin or methadone and treated with buprenorphine,
abrupt termination of buprenorphine has been followed by the administration of
placebo or an opiate antagonist. In both cases, “mild to moderate” opiate
withdrawal symptoms were observed. In the one study, intensity of withdrawal
symptoms appeared to be related to the dose of antagonist and of buprenorphine.
Withdrawal symptoms following the cessation of buprenorphine have been
judged severe enough to be treated with methadone. The dose of buprenorphine
and the speed of dose reduction contribute to the magnitude of withdrawal signs
and symptoms and illicit opioid use.
In summary, buprenorphine is useful for opioid detoxification treatment because it
substitutes for opioids and suppresses withdrawal symptoms in dependent
individuals. Abrupt termination of buprenorphine is associated with fewer
autonomic signs and symptoms of withdrawal than would be predicted with equal
analgesic doses of morphine or methadone. However, chronic treatment with
buprenorphine does produce a clinically significant withdrawal syndrome which
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may be related to dose. There are several critical variables that may impact on the
overall clinical outcome and utility of buprenorphine in detoxification treatment,
including: 1) severity of opiate dependence; 2) duration of maintenance on
buprenorphine; 3) buprenorphine dose; and 4) duration of the detoxification
schedule. Additional studies systematically assessing these variables are needed.
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ROUTES OF PRIOR OPIATE ADMINISTRATION: EFFECTS ON
O U T C O M E  V A R I A B L E S  I N  T H E  N I D A / M D D  # 9 9 9 a
BUPRENORPHINE MULTICENTER STUDY
D. L. Segal and J. L. Hill
NIDA’s Medications Development Division, in cooperation with the Los Angeles
Addiction Treatment Research Center, sponsored a randomized, double blind, one
year multicenter clinical trial in which 733 subjects were dosed to study the safety
and efficacy of buprenorphine in the treatment of opiate dependence. This paper
focuses on several outcome measures from the 16 week maintenance phase of the
study according to subjects’ preferred route of opiate administration at baseline.
We compared the results from intravenous injections (IV) with 216 snorters
(N=204)/smokers (N-12) (S/S). Not included in this analysis were 38 oral
abusers, at least 26 of which were addicted to prescription analgesics--Percocet
being the most common, and 15 subjects claiming preference for “other” routes.
Results: The most dramatic results were seen in the very sharp decrease in heroin
craving on a visual analog scale near 80 (with 0 being no craving and 100 the
worst craving ever experienced). After being on buprenorphine maintenance
therapy for four weeks, craving dropped to about 36 in the IV group and to 26 in
the S/S group. Craving for cocaine, however, decreased only slightly.
Regarding retention in treatment, 44% of the IV users completed the 16 week
study while 63% of the S/S completed. When comparing the percent of subjects
with 13 consecutive opiate-free urines, 14.4% of the IV users and 18.5% of the
S/S were “clean” for that time period. At baseline, however, all subjects wee
using opiates on a daily basis--one of the entrance criteria.
Based on these results, we suggest that: 1) Heroin craving can be reduced
significantly within four weeks of initiating buprenorphine maintenance therapy;
2) Heroin addicts who prefer the IV route of administration are probably more
heavily addicted and have a longer history of substance abuse than are S/S. The
IV users in this study had a prior history of having been enrolled in about 4.6
times as many methadone maintenance programs as the S/S; 3) The ritual of
injecting may have its own separate reward and is thought to be a potent reinforcer
even in the tolerant addict. Therefore, we believe it is necessary to identify
primary routes of administration in future treatment settings as well as research
studies.
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I M P R O V I N G  B U P R E N O R P H I N E  O U T C O M E S  W I T H
BEHAVIORAL TREATMENT
W. K. Bickel, L. Amass, and S. T. Higgins
Two clinical trials assessed whether behavioral treatment would improve
buprenorphine (BUP) detoxification outcomes. In the first trial, subjects received
either combined behavioral and BUP detoxification or standard counseling and
BUP. Patients (19 behavioral, 20 standard) were randomly assigned. During a
26 week detoxification, subjects received their BUP seven days a week at the
clinic and provided urine samples three times per week which were analyzed for
the presence of opioids. The behavioral treatment used the community
reinforcement and contingency management approaches originally developed for
the treatment of cocaine dependence (Higgins et al., 1993). The methadone style
counseling was typical of methadone treatment counseling (Ball and Ross, 1991).
Eighty-four percent of the behavioral treatment group and 80 percent of the
standard treatment group remained in treatment for at least eight weeks. Fifty-
three percent of the behavioral treatment group and 20 percent of the standard
treatment group remained in treatment for the entire 26 weeks. Fifty-three percent
of the behavioral treatment group and 30 percent of the standard treatment group
provided eight weeks of continuous opioid abstinence. These results suggest that
combined behavioral and BUP treatment produced outcomes superior to standard
treatment and BUP.
In our second trial, we modified the medication schedule and enhanced the
behavioral treatment in an effort to further improve outcomes. Our original
behavioral treatment was compared to an enhanced behavioral treatment during a
16 week BUP detoxification in 21 randomly assigned patients per group. The
enhanced program added procedures to address illicit opioid use and daily
attendance to the original behavioral treatment. To address illicit opioid use,
receipt of 1/2 of the daily medication was contingent on opioid abstinence with
bonus reinforcers available for providing three consecutive opioid-negative urine
samples. Bonus reinforcers were a week of alternate-day dosing or items from a
list of prosocial recreational activities. Sixty-seven percent of the enhanced
behavioral treatment group and 43 percent of the original behavioral treatment
group completed the 16-week program. Thirty-nine percent of the enhanced
behavioral treatment group and 11 percent of the original behavioral treatment
group provided eight weeks of continuous opioid abstinence. Thus, the enhanced
behavioral program appeared to improve outcomes relative to our original
behavioral treatment program.
Importantly, two-three times as many patients receiving the original behavioral
treatment, and four times as many patients receiving the enhanced behavioral
treatment, were abstinent on the last day of detoxification compared to patients
receiving standard treatment. Thus, these two controlled trials demonstrate that
behavioral treatments improve outcomes during BUP detoxification.
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J O I N T  P R O B A B I L I T Y  A S  O U T C O M E  I N D E X  F O R
PHARMACOLOGY
W. Ling, C. J. Klett, and M. A. Compton
Retention and drug use in pharmacotherapeutic trials most closely reflect
medication treatment effects. Other commonly used outcome measures, like
craving, side effects and adverse medical events, are intervening variables that are
ultimately reflected in retention and/or drug use. Self report of use, number of
consecutive days or weeks of abstinence and time to first use or relapse are but
different dimensions of use shown by urine toxicology.
Retention is usually reported as the proportion of subjects remaining in treatment
at a given point although sometimes subjects dropping out in early weeks are
ignored. Drug use is usually reported as percent negative or positive for drugs
and/or metabolites. Retention does not indicate whether patients are using drugs
whereas percent clean urine fails to take into account that at each time point the
results represent a different and decreasing number of patients. What is needed is
a way to combine the effects of these measures. For individual patient
performance we have advocated the use of the Treatment Effectiveness Score
(TES). Its application in a cocaine pharmacology trial is presented elsewhere.
For pharmacotherapeutic effects we propose the use of joint probability of
retention and abstinence (JP). Both are attempts to obtain the combined effects of
the two primary outcome variables but from two somewhat different perspectives.
The TES focuses on the relative performance of a patient in a particular
pharmacotherapeutic trial whereas the joint probability stresses the performance of
a particular medication under study. For the joint probability of retention and
abstinence we assign P1 as the probability of retention at a given time point
(number of patients with clean urines [Nr]/total number enrolled [Nt] ) and P2 as
the probability of abstinence for patients in treatment at the same time p;point
(number of patients with clean urines [Nc]/number of patients remaining in
treatment [Nr]), the joint probability P1 x P2 = Nr/Nt x Nc/Nr = Nc/Nt represents
the joint probability of being in treatment and also not using.
We computed and compared the joint probability outcome for patients in four
methadone/buprenorphine comparison studies - Johnson-ARC, Schottenfeld-
Yale, Strain-Hopkins, Long-LAATRC - using retention and drug use data from
each study. This report illustrates the usefulness of the composite index in
comparing treatment across trials. The results suggest, with one exception, an
apparent dose response effect for buprenorphine and methadone.
ACKNOWLEDGEMENT
Supported by NIDA Grant No. DA08260-01 and NIDA Interagency Agreement
with West Los Angeles VAMC. Los Angeles, CA
AFFILIATION
Addiction Treatment Research Center, Los Angeles, California
83
BIOLOGICAL EVALUATION OF COMPOUNDS FOR
THEIR PHYSICAL DEPENDENCE POTENTIAL AND
ABUSE LIABILITY.  XVIII .  DRUG EVALUATION
COMMITTEE OF THE COLLEGE ON PROBLEMS OF
DRUG DEPENDENCE, INC. (1994)
A. E. Jacobson
PURPOSES OF THE DRUG EVALUATION COMMITTEE (DEC)
The DEC was founded to ensure the continuation of the drug evaluation
program, a major program of the CPDD which has been maintained as a public
service from the CPDD’s inception in 1928 as a committee of the National
Research Council of the National Academy of Sciences. The DEC manages the
evaluation carried out by a consortium of university-based groups. The
researchers determine the physical dependence potential and abuse liability of
drugs, and establish new, or improve older, methodology. The initial program
was highly dependent on the interdisciplinary work of chemists, pharmacologists
and clinicians, focusing on the synthesis and appraisal of potent analgesics
which might lack the undesirable side-effects of morphine. The contemporary
design of the DEC is somewhat different. The pharmacologica techniques have
expanded well beyond what was originally envisioned, and the new drugs which
are examined are obtained from domestic and foreign universit ies,
pharmaceutical industry, governmental units, the World Health Organization,
and other sources. Our program now also includes testing and research on
stimulants and deprcssants.
Data obtained from the various groups associated with the DEC have provided
essential information for the regulation of these drugs by governmental agencies
and the World Health Organization, and are invaluable for scientists involved
with the chemistry, pharmacology and clinical utility of drugs with potential
abuse problems, as well as those who seek to explain the function and interaction
of these drugs with CNS receptors on the molecular level. The theoretical
exploration of the interaction of opioids with their receptors, as well as
experimentally in binding assays, has recently become possible due to the
cloning of the cDNA’s of all three opioid receptors and their sequencing.1-8 The
data obtained by DEC will play an important role in that research.
MEMBERS OF THE DEC
The DEC, under the chairmanship of Dr. T. Cicero (Washington University, St.
Louis), has three representatives from the CPDD Board of Directors who are
appointed by the President of the Board of the CPDD. These are Drs. L. Cook
(DuPont Merck Pharmaceutical Co.), S. Holtzman (Emory University School of
Medicine), and J. Smith (Bowman Gray School of Medicine). Each of the
testing groups involved with the work of the DEC have one member on the
DEC: Drs. L. Harris and G. Patrick (Medical College of Virginia), G. Winger
and J. Woods (University of Michigan), and W. Woolverton (University of
Mississippi Medical Center). I serve as Biological Coordinator for the DEC,
continuing the work of Drs. Everette May and Nathan Eddy, the latter having
initiated the coordination of the program more than 40 years ago. From its
inception, this program has been coordinated in the Laboratory of Medicinal
Chemistry of the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), NIH, although there have been several organizational name
changes over the decades.
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STATISTICS
Of the 42 drugs which were evaluated this year as analgesics by either or both
Aceto et al.,9 and Woods et al.,10 three came from the U.S. and foreign
pharmaceutical industry (7%), 23 from U.S. and foreign universities (55%), 10
from a non-profit institute (24%), and six from NIH Intramural researchers
(14%). Comparison of the sources and numbers of compounds over a five year
period is shown graphically in Figure 1. The fluctuations in the source of
compounds over the past five years can be seen in that figure. The total number
of compounds annually evaluated show modest changes (from 42 to 65 - a mean
of 51 (±9)). For the last several years the major source of compounds has been
from universities or from a combination of universities and non-profit
institutions. It is likely that this trend will continue for the next several years.
FIGURE 1. DEC ANALGESIC PROGRAM. SOURCES AND NUMBER OF
COMPOUNDS FROM 1990-1994
PROCEDURES FOR EVALUATION OF DRUGS
The various procedures which are used to determine the physical dependence
potential and abuse liability of analgesics, depressants and stimulants have been
noted heretofore,11 and are summarized in the papers by Drs. Aceto et a1.,1 2
Woods et al.,13 and Patrick et a1.1 4
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SURVEY OF EVALUATED COMPOUNDS
1) Analgesics
The chemical names for all of the drugs which were evaluated this year can be
found in table 1, and the group which evaluated the drug is also indicated therein.
In order to more easily discern the biological effect of structural changes in a
basic molecular structure, the examined drugs were grouped in structural classes
in tables 2-12 with a summarization of the DEC-derived biological data. More
comprehensive data on the individual drugs can be obtained from the reports of
the members of the DEC.9,10 The tables note the biological data obtained on
these drugs in previous years and indicate where those data can be found.
Seven 4,5-epoxymorphinans are shown in tables 2 and 3. The four compounds in
table 2 represent two pairs of epimers with different substituents at C-6 (NIH
10683 and 10684, and 10701 and 10702). The biological properties of the latter
two are similar, but 10683 and 10684 are distinctly different. Depending on the
assay, NIH 10683 might be considered a µ- or -agonist. It does not show
antagonist properties in antinociceptive studies or in the monkey analgesia study.
NIH 10683 does not substitute for morphine in the SDS assay; it does not act as a
u-agonist, but rather acts as a non-selective antagonist in the vas deferens
preparation. In drug discrimination it acts as a -agonist and not as a µ-agonist or
antagonist, and in self administration NIH 10683 substitutes for alfentanil, a µ-
agonist. It suppresses respiration in the respiratory function assay in monkeys,
like other µ-agonists. Its C-6 -OH epimer, NIH 10684, appears to have µ-
antagonist or perhaps µ-agonist properties, depending on the assay. It has agonist
activity in the PPQ assay but not in other assays in mice or monkey. It is seen as
a µ-selective antagonist in the vas deferens, precipitates withdrawal with a slow
onset and long duration of action in SDS in monkeys, and shows antagonist
properties in drug discrimination. NIH 10684 maintains self-injection in the
monkey, but it was less efficacious than alfentanil, a µ-agonist. All four of the
compounds have good affinity for the opioid receptors. The bulky iodine atom at
C-6- and - for 10701 and 10702, respectively, appears to have little effect on its
binding to µ, and receptors.
NIH 10773 (table 3) bears a sulfate ester at C-6 and is morphine-like in
antinociceptive potency in the mouse. However, it does not substitute for
morphine in SDS, appears as a weak agonist in the vas deferens, and does not
bind well to opioid receptors. The compound exists as a zwitterion, possessing
structural characteristics reminiscent of an amino acid, yet appears to easily pass
through the blood-brain barrier in vivo.
The substituents at C-1 and C-2 in NIH 10787 and 10814 (table 3) might have
been expected (from the work of others) to interfere with biological activity.
However, NIH 10787 was found to be a very potent antagonist and 10814, which
had less affinity for the opioid receptors than 10787, was noted to have
insurmountable antagonist actions at the receptor.
Table 4 lists the actions of six endoetheno- and endoethanooripavines. NIH
10805 has a chlorine atom at C-l, like NIH 10787 (table 3) and acts as a potent
antagonist. NIH 10812, however, a 2-nitro-substituted buprenorphine, does not
have opioid actions in vivo. NIH 10813 appears to be very similar to 10814
(table 3) in binding and in the vas deferens preparation. The in vivo work on
most of the compounds in table 4 is scheduled for 1994.
Four rather inactive (+)-morphinans are listed in table 5, as is a (-)-morphinan
(NIH 10802). Structurally similar molecules have affinity for sigma ( ) receptors
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or PCP binding sites. SDS data on the phenylmorphan in table 5, NIH 10779,
completes the data gathered previously on that essentially morphine-like
compound.
Table 6 displays the actions of four (+)- and (-)-6,7-benzomorphans. These, and
other N-n -alky-substituted 6,7-benzomorphans are among the compounds which
were the subject of a paper which was recently submitted to J. Med. Chem.15
Several of the authors arc DEC members. Some of the compounds in the series
were found to be among the most potent known receptor ligands. It is perhaps
somewhat surprising to note that NIH 10675 and 10697, although they are in the
(+)-benzomorphan series, have good (NIH 10675) or reasonable (NIH 10697)
antinociceptive activity.
Three arylpiperidines which seem to exert antagonist activity in the vas deferens
preparation are shown in table 7, and 10 compounds related to fentanyl are listed
in tables 8 and 9. Most of the fentanyl-like compounds had activity in the SDS
assay ranging between morphine-like to that of NIH 10792 (table 9) or 10741
(table 8) which were estimated to be 30,000 or 20,000-50,000 times more potent
than morphine, respectively. These compounds arc among the most potent known
narcotic agonists.
The remaining tables 10 and 11 consider the miscellaneous compounds. NIH
10700 (table 11) is structurally similar to PCP, but has antinociceptive activity
and some affinity for the opioid receptors. NIH 10815 (table 11) was seen to be
relatively selective, and potent, for -receptors in the vas deferens preparation, but
did not have much affinity for opioid receptors. Other workers have indicated
that it is a potent and selective -ligand in vitro as well as in the vas deferens and
guinea pig ileum preparations.
2) Stimulants and Depressants
Two compounds (stimulants) were released for publication this year (CPDD
0038 from pharmaceutical industry, and 0041, Etryptamine acetate, from
NIDA).16 The molecular structures of these compounds and the summarization
of the data collected on them by the Stimulant/Depressant testing groups of DEC
are shown in table 12. Our data on Etryptamine and several other drugs will be
used by the World Health Organization for scheduling purposes. Two or three
compounds are being processed for testing in 1994-1995.
ABBREVIATIONS USED IN TABLES 2 - 13
Rounded numbers are used in the tables; M = morphine. Precise values and
details of the procedures are given in the MCV9 and UM10 reports; NT = not
tested.
For “E” notation: 1E-3 = 1 x 10-3 or 0.001 M (1 mM), 1E-6 = 1 mM, 1E-9 = 1
nM, 1E-12 = 1 pM (picomole), and 1E-15 = 1 fM (femtomole).
1) MOUSE ED50/AD50: Antinociceptive Assays (sc injection)9
Confidence limits are listed in the MCV report.9
HP = hot plate (morphine ED50 = 0.8 (0.3-1.8))
PPQ = phenylquinone (morphine ED50 =0.23 (0.20-0.25))
TF = tail-flick (morphine ED50 = 5.8 (5.7-5.9))
TFA = tail-flick antagonism vs. morphine (naltrexone AD50 = 0.007 (0.002-
0.02); naloxone AD50 = 0.035 (0.01-0.093)).
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I = inactive, without a reasonable dose-response relationship,
or insufficiently active for statistical analysis.
2) IN VITRO (Data from UM)10
RBH = binding affinity in rat cerebrum membranes (displacement of 0.5 nM
[3H] etorphine) in the presence of 150mM NaCl (morphine EC50 = 23.6).
NE = no effect.
NOTE: Contemporary EC50 data cannot be directly compared with
those from reports before 198517 which were obtained under “-NaCl”
(without NaCl) conditions.
VD = electrically stimulated mouse vas deferens EC50 values, rounded to one
significant figure. Partial agonist indicated by % inhibition of twitch
in parenthesis; [A] = antagonism by naltrexone.
SE = slight effect on twitch.
NE = No significant agonist or antagonist effect.
ANT = Antagonist activity. Selective antagonist activity at µ,
, and/or receptors is noted in parentheses. The
antagonist effect may or may not be competitive.
Compounds which suppress the twitch and are not antagonized by
naltrexone or other narcotic antagonists are said to be non-opioid agonists
(e.g., clonidine, a non-opioid agonist, can suppress the twitch but is not
antagonized by naltrexone). Compounds which bind with reasonable affinity
in the RBH assay and do not suppress the twitch in the VD may have
narcotic antagonist properties. The opioid receptor at which the drug exerts
its antagonist effect is determined by testing various concentrations of the
drug to induce a blockade (antagonism) of the suppression of the twitch in
the VD preparation caused by sufentanil (µ), DSLET ( ) or U50,488 ( ).10
3) IN VIVO: in the rhesus monkey (from MCV9; from MCV or UM prior to
1988).
SDS = single-dose-suppression
NS = no suppression
CS = complete suppression
PS = partial suppression
(Parenthesized numbers = dose range studied, in mg/kg)
Other Studies (noted in the footnotes to the tables)
A) In Rat:
RI = rat continuous infusion (data from MCV)9
1) SM = substitution for morphine
NS = no substitution for morphine
CS = complete substitution
PS = partial substitution
2) PPD = primary physical dependence
B) In Rhesus Monkey:
1) PPt-W = studies in non-withdrawn monkeys (data from MCV)9
PW = precipitated-withdrawal at dose levels, in mg/kg, indicated
in parentheses &/or comparison with naloxone [N].
SP = slight precipitation
NP = no precipitation
2) ND = studies using non-dependent monkeys (data from MCV)9
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M-like = morphine-like effect.
3) PPD = primary physical dependence (data from MCV)9
4) SA or SI = self-administration or self-injection (data from UM)10
NE = no effect
High = codeine-like
IN = intermediate between saline and codeine
SE = slight effect
5) DD = drug discrimination (data from UM)10
NE = no effect
CS = complete substitution
6) MA = monkey analgesia (data from UM)10
7) RF = respiratory function (data from UM)10
C) In Vitro (data from UM)10
BIND - binding affinity using monkey brain cortex membranes
(selectivity for µ, , and opioid receptors determined with [3H]-
sufentanil, [3H]-DPDPE and [3H]-U69,593, respectively).
Previous Reports
Previous work on a compound is noted using the year listed in the monograph
title (e.g., work cited as “1992” indicates that the work was included in “Problems
of Drug Dependence 1992”, which was published in 1993). Note that the
monograph’s publication date may be one year after the titled year of the
monograph. Complete details of the original work on a compound can be found
in the Annual Report from either UM or MCV.
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TABLE 1. NIH NUMBERS, CHEMICAL NAMES, TABLE NUMBER,
AND EVALUATING GROUP
NIH# NAME TABLE#-
Evaluatora
04591 (+)-3-Hydroxy-N-Methylmorphinan.HBr 5-MCVa
(Dextrophan, Dromoran)
10560 (-)-5,9 -Dimethyl-2-ethyl-2'-hydroxy-6,7- 6-MCV
benzomorphan.HCl
10675 (-)-5,9 -Dimethyl-2- n-heptyl-2'-hydroxy-6,7- 6-MCV
benzomorphan.HCl
10683 14-Hydroxy-N-(2-methoxyethyl)-7,8- 2-MCV/UMb
dihydronomorphine
10684 14-Hydroxy-N-(2-methoxyethyl)-7,8- 2-MCV/UM
dihydronorisomorphine
10697 (-)5,9 -Dimethyl-2'-hydroxy-2- n-octyl-6,7- 6-UM
benzomorphan.HCl
10698 ( - ) 5 , 9 -Dimethyl-2'-hydroxy-2- n-octyl-6,7- 6-UM
benzomorphan.HCl
10700 1-[-(2-Hydroxyphenyl)cyclohexyl]-3,4- 10-UM
dehydroperidine.HCl
10701 6 -Iodo-3,14-dihydroxy-17-cyclopropylmethyl-4,5 2-UM
epoxymorphinan.oxalate
10702 6 -Iodo-3,14-dihydroxy-17-cyclopropylmethyl-4,5 2-UM
epoxymorphinan.oxalate
10703 N-[(3,4-Diclorophenyl)acetyl]-N,2-dimethyl-2- 10-UM
(N',N'-dimethylamino)ethylamine.oxalate
10705 N-(n-Propyl)-N'-3,4-dichlorophenylethyl) 10-UM
piperazine.2HBr
10735 (+)N-Benzyl-3-hydroxymorphinan.HCl 5-MCV
10738 4-(3-Hydroxyphenyl)-1-(4-nitrobenzyl)-4-(1- 7-MCV
oxopropyl)piperidine.HCl
10739 1-(4-Fluorobenzyl)-4-(3-hydroxybenzyl)-4-(1- 7-MCV
oxopropyl)piperidine.HCl
10741 ( S,3S,4S)-c i s-N-[1-(2( )-Hydroxy-2- 8-MCV
phenylethyl)3-methyl-4-piperidinyl]-N-
phenylpropanamide.HCl
10749 (+)-3-Hydroxy-N-(4-nitrobenzyl)morphinan oxalate 5-MCV
10762 (±)-c i s-N-[3-Methyl[2-oxo-2-(2-thienyl)ethyl]-4- 8-UM
piperidinyl]-N-phenylpropanamide.HCl
10765 (±) -cis -N-[1-(2-Hydroxy-1-phenylethyl)-3-methyl-4- 8-UM
piperidinyl]-N-phenylpropanamide.HCl
10773 Morphine-3-acetate-6-sulfate (zwitterion) 3-MCV/UM
10779 2,3-Dimethyl-5-(3-hydroxyphenyl)morphan.HBr 5-MCV/UM
10782 Rifampin (Rifampicin) 10-MCV/UM
10784 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4- 8-MCV
piperidinyl]-N-(3-fluorophenyl)propanamide.HCl
10785 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4- 8-MCV/UM
piperidinyl]-N-(4-fluorophenyl)propanamide.HCl
10786 (±)-cis-N-[1-[2-(4-Bromophenyl)(ethyl-2-hydroxy]-3- 9-MCV/UM
methyl-4-piperidinyl]-N-phenylpropanamide.HCl
10787 1-Chloronaltrexone.HCl 3-MCV/UM
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TABLE 1 (CONTINUED). NIH NUMBERS, CHEMICAL NAMES,
TABLE NUMBER, AND EVALUATING GROUP
10790
10791
(±)-1-(2-Hydroxy-2-phenylethyl)-t-3-methyl-4-[(1-
oxopropyl)phenylamino]-r-4-piperidinecarboxamide
Methyl Ester.HCl
(±)-1-(2-Hydroxy-2-phenylethyl)-c-3-methyl-4-[(1-
oxopropyl)phenylamino]-r-4-piperidinecarboxamide
Methyl Ester.HCl
(±)-1-(2-Hydroxy-2-phenylethyl)-t-3-methyl-4-[(1-
oxopropyl)phenylamino]-r-4-piperidinecarboxamide
Ethyl Ester.HCl
(±)-N-[1-(2-Hydroxy-2-phenylethyl)-4-
methoxymethyl-c-3-methyl-r-4-piperidinyl]-N-
phenylpropanamide oxalate
Amitriptylene.HCl
4-(3-Hydroxyphenyl-4-(1-oxopropyl)-1-(2-methyl-2-
butenyl) piperidine.HCl
(+)-N-(2-Methylpropenyl)-3-hydroxymorphinan.HBr
(-)-3-Hydroxy-N-(4-hydroxybenzyl)morphinan.HBr
(±)-N-Allylmecamylamine.HCl
1-Chlorodiprenorphine oxalate
N-Cyclopropylmethyl[7 ,8 2’,3’]cyclopentano-I’-
[R]hydroxy-6,14-endoethenotetrahydronororipavine
.HCl
N-Cyclopropylmethyl[7 8 2’,3’]cyclopentano-1’-
[S]hydroxy-6,14-endoethenotetrahydronororipavine
.HCl
N-Cyclopropylmethyl[7 8 2’,3’]cyclohexano-1’-
[S]hydroxy-6,14-endoethenotetrahydronororipavine
.HCl
10792
10793
10794
10795
10796
10802
10803
10805
10809
10810
10811
10812
10813
10814
10815
2-Nitrobuprenorphine.HCI
2-Nitrodiprenorphine.HCI
4-UM
4-UM
3-UM
11-UM
2-Nitronaltrexone.HCl
(+)-4-[( R) -(12S ,5R)-4-Allyl-2,5-dimethyl-1-
piperazinyl)-3-methoxybenzyl]-N,N-
diethylbenzamide
CPDD 2-(7-Chloro-1,8-naphthyridin-2-yl)-3-[(1,4-dioxa-S- 12-MCV/UM
0038 azaspiro[4.5]dec-8-yl)carbonylmethyl]isoindolin-1- /UMSb
one
CPDD Etryptamine acetate 12-MCV/
0041 UM/UMSb
a) For complete data from MCV, see reference 13, and see reference 14 for
complete data from UM.
b) See reference 16 for complete data from MCV, UM, and UMS.
9-MCV/UM
9-MCV/UM
9-MCV/UM
9-MCV/UM
11-MCV/UM
7-MCV
5-MCV
5-MCV/UM
11-MCV/UM
4-MCV/UM
4-MCV/UM
4-UM
4-UM
91
TABLE 2. 4,5-EPOXYMORPHINANSa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH # H P PPQ T F T F A RBH V D SDS
10683 0.3 0.03b 0.2 b I 8.2 nM 7E-6[NA]c NS(0.5-6)d
10684 I 2.6 I I 5.4 nM 4.9E-5[NA]e NS(1,4) t
10701 I g I g I g 0.08
g 5.2 nMg,h ANTg , i N S g , j
10702 I g I g I
g 0.04g 2.1 nMg,k ANT g , l N S g , m
a) See text for explanation of column headings and abbreviations.
b) AD50 (naloxone vs ED80) - PPQ: 0.6; - TF: 0.03.
c ) Not µ-like agonist; µ, -antagonist.
d) Not µ-like in monkey; MA: analgesic[A]; SA: substitutes for alfentanil (0.03
mg/kg/inj); DD: -agonist, not µ-agonist or antagonist; RF: suppression[A].
e) µ-Selective antagonist.
f) PPt-W: agonist-antagonist with slow onset and long duration; DD: no
agonist effects, substituted for naltrexone; MA: NE (antagonist); RF: NE;
SA: maintained self-injection in 2/3 monkeys, less efficacious than alfentanil.
g) Previously reported - 1992.
h) BIND : µ=1.06 nM, =26 nM, =0.34 nM
i ) Non-selective.
j ) PPt-W - PW.
k) BIND: µ=0.42 nM, 6=9.6 nM, =0.3 nM
1) µ-Selective.
m) Exacerbates withdrawal.
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TABLE 3 (CONTINUED). 4,5-EPOXYMORPHINANSa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH # HP PPQ TF T F A RBH VD SDS
10773 1.0 0.5 2.5 I 517 nM 139 NS
nM(81)[A]b (2.5,10)
10787 I I I
c
4.8E-4 0.38 nM ANT
d NS
(0.0016)e
10814 - - - - 196 nM 3.5E-9(23)[A]
f
-
a) See text for explanation of column headings and abbreviations.
b) Weak partial agonist.
c) pA2 vs M = 8.7, pA2 vs 10672 ( ) = complete antagonism.
d) Potent antagonist, slightly selective for µ-receptors.
e) PPt-W: PW [5 x naloxone].
f) Competitive antagonist at µ and insurmountable antagonist at
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TABLE 4. ENDOETHENO- AND ENDOETHANOORIPAVINESa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH # HP PPQ T F TFA RBH VD SDS
10805 I I I 0.09
b
0.61 nM ANT
c NS
(0.01-0.02)d
10809 I 0.01 0.1 9.3 0.49 nM 2.2E-9(74)[A]
e N S
(0.05-0.025)d,f
10810 - - - - 0.91 nM 8.8E-9(78)[A]
g -
10811 - 0.59 nM 0.86E-9(99)[A]
g- - - -
10812 - - - 3.81 µM 6.7E--
9(56)[NA]h
-
10813 140 nM 4E-7(44)[A]i- - - - -
a) See text for explanation of column headings and abbreviations.
b) pA2 vs M = non-competitive antagonist; pA2 vs 10672 ( ) =8.0 (high
affinity for ) .
c) Non-selective; insurmountable at
d) Exacerbates withdrawal; PPt-W: PW (like naloxone).
e) Relatively selective -agonist.
f) Longer-acting than naloxone. Partial µ-agonist; perhaps and -actions.
g) Relatively selective µ-agonist.
h) Very weak mixed antagonist, slightly more potent at and
i) Competitive antagonist at µ and  insurmountable antagonist at
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TABLE 5. MORPHINANS AND 5-PHENYLMORPHANa
NIH # HP PPQ T F TFA RBH VD SDS
04591 5 8
b
24 I I 1.4 µM - PS (4)
c
10735 I 6.1 I I >6 µM
d ANTd , e NS(1.8,7)f
10749 I I I I >6 µM
d Insolubled NS (4.16)
10779 4.8
d 0.3d 1.3d I
d 592 nMd 15.8 µMd,g CS (0.75,3)
10796 I 11.4 I I >6 µM
d ANTd , h PS (15)i
10802 I I I I 2.1 µM 108 nM(23) N T
[NA] j
MOUSE ED50/AD50 IN VITRO MONKEY
a) See text for explanation of column headings and abbreviations.
b) Previously reported - 1951.
c) Ataxia; PPt-W: - NE (1,4); PPD: Tolerance and withdrawal, exacerbated by
naltrexone. Some M-like signs missing; RI: SM - withdrawal, no weight
loss. Previously reported - SDS: NE, 1981.
d) Previously reported - 1993.
e) Low potency -antagonist activity (and some -antagonist activity).
f) Convulsions noted.
g) Low potency µ-partial agonist.
h) Weak -antagonist.
i) Not µ-opioid action; produces CNS excitation.
j) No opioid agonist action; µ-antagonist (not simple competitive).
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TABLE 6. 6,7-BENZOMORPHANSa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH # H P PPQ T F TFA RBH VD SDS
10560 I
b 1.4b I b 3.7b 144 nMb ANTAGb ,c NSd
10675 2.4
e 0.13f 1.7f I 89 nM 3.5E-7(100)g NS
(1.25,5)h
10697 5.4
i 0.5i 10.0i I i 226 nMi,j ANT i , k NS(1,4)l
10698 11.1
i 7.8 i I i I i 3.4 µMi,m ANT
i , n NS(4,16)i
a) See text for explanation of column headings and abbreviations.
b) Previously reported - 1988; TF: pA2 vs M: 5.85, µ-competitive.
c) Unusual, non-competitive, non-selective.
d) Exacerbates withdrawal.
f) Previously reported - 1992.
g) Agonist at µ and receptors.
h) Convulsions with cumulative dose of 11.5 mg/kg/hr; RI: SM - PS; RI: PPD
- µ-like withdrawal.
i) Previously reported - 1993.
j) BIND: µ=150, =197, =115 nM (non-selective).
k) Non-typical µ- and -agonist, weak µ-antagonist.
1) May exacerbate withdrawal, possible -agonist properties.
m) BIND: µ=763 nM, =21% at 6 µM, =2.8 µM (non-selective, low potency)
n) Weak µ- and -antagonist.
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TABLE 7. ARYLPIPERIDINESa
10795 8.3 2.2 9.7 I 507 nMb ANTb ,e PS(2.5,10)f
10738 I 7.3 I I 3.4 µMb ANTb ,c NS (3,12)
10739 I 18.3 I I 1.3 µMb ANTb , d NS (2.5,10)
MOUSE ED50/AD50 IN VITRO MONKEY
NIH # HP PPO TF T F RBH VD SDS
A
a) See text for explanation of column headings and abbreviations.
b) Previously reported - 1993.
c) Low potency - and -antagonist, not simple competitive-type.
d) Low potency, mostly -antagonist (some -antagonism), not competitive.
e) Weak non-opioid partial agonist; weak non-selective antagonist.
f) Non-dose related suppression. Some observed signs seen from abrupt
withdrawal are more typical from precipitated withdrawal.
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TABLE 8. FENTANYL-LIKE COMPOUNDSa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH# HP PPO TF TFA RBH V D SDS
10741 1E-4b 9E-5b 2E-4
b,c I b 5.9 nMb 56 fM
[A]b , d
CSb,e (1.5E-
4-3E-5)
10762 0.24b 0.02b 0.03b,f I b 569 nM >3 µg CS[60 x M]
b
10765 3.4b 0.1b 3.0b I b 6 µM ANTh CS
[1.5 x M]b
10784 0.005 0.001 0.004l I 6.5 nMb 7.6nM CS
[A] b , j [6000 x M]
10785 0.001 3.4E-4 0.002k I 4.5 nM 2.8 nM CS
(100)[A]l [1000 x M]
a) See text for explanation of column headings and abbreviations.
b) Previously reported - 1993.
c) Naloxone (AD50) vs ED80 of 10741=0.008. pA2 vs naloxone = 7.2,
suggesting competive interaction with µ-receptor.
d) Biphasic (also, 4 nM[A]). Complex actions - -agonist activity.
e) 20,000-50,000 x M.
f) Naloxone (AD50) vs ED80 of 10762=0.03.
g) Low potency µ-opioid agonist.
h) Very low potency µ-opioid antagonist.
i) Naloxone (AD50) vs ED80 of 10784=0.11.
j ) Potent µ-agonist.
k) Naloxone (AD50) vs ED80 of 10785=0.04.
1) -Selective agonist.
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TABLE 9 (CONTINUED). FENTANYL-LIKE COMPOUNDSa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH # H P PPQ TF TFA RBH VD SDS
10786 0.013 0.007 0.03
b I 22.9 1.4 µMc CS [60 x M]
nM
10790 6.1E-4 1E-4 4.4E-4d I 0.85 0.77 nM[A] CS
nM [6000 x M]
10791 0.001 8E-4 0.001e I 2.3 nM 1.3 nM[A]f CS
[6000 x M]
10792 0.003 1E-4 2.4E-4g I 1.2 nM 1.3 nM[A]f CS
[30,000 x M]
10793 3.1E-4 5E-4 0.0013h I 0.78 0.84 nM[A]
f CS
nM [10,000 x M]
a) See text for explanation of column headings and abbreviations.
b) Naloxone (AD50) vs ED80 of 10786=0.04.
c) Complex, multiphasic action, weak antagonist
d) Naloxone (AD50) vs ED80 of 10790=0.02; pA2 naloxone vs 10790 = 7.4.
e) Naloxone (AD50) vs ED80 of 10791=0.02; pA2 naloxone vs 10791 = 7.5.
f) Potent, somewhat µ-selective agonist.
g) Naloxone (AD50) vs ED80 of 10792=0.04.
h) Naloxone (AD50) vs ED80 of 10793=0.04.
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TABLE 10. MISCELLANEOUSa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH # HP PPQ T F TFA RBH VD SDS
10700 I
b 0.3b 4.8b ,c I 619 ANT
d , f
nM d , e
N T
10703 I
d 13.4d I d I d >6 µMd,g 49 µM(100)[A]d,h NS
d , i
10705 I
d 10.6d I d I d >6 µMd,j N E
d N S d , k
10782 I I I I >6 µM 3.7E-8(30)[A]
l N S m
a) See text for explanation of column headings and abbreviations.
b) Previously reported - 1991 (potent -ligand).
c) Straub tail, ataxia, convulsions.
d) Previously reported - 1992 (potent -ligand).
e) BIND: µ=62 nM, =2370 nM, =2695 nM.
f) Weak, non-selective narcotic antagonist.
g) BIND: µ=1791 nM, =>6 µM, =287 nM.
h) Possibly some , or mixed µ- activity.
i) Disorientation noted.
j) BIND: µ=5210 nM, =>6 µM, =3181 nM.
k) Exacerbates withdrawal signs.
1) Possible low potency agonist.
m) Cumulative dose of 11 mg/kg.
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TABLE 11 (CONTINUED). MISCELLANEOUSa
MOUSE ED50/AD50 IN VITRO MONKEY
NIH # HP PPQ TF TFA RBH VD SDS
10794 I 0.09 I I >6 µM 3E-9(39)[A]
b CS(2,8)[NA]c
10803 I 9.8 I I >6 µM 1.8E-9(23)[NA]
d N S e
10815 >6 µM- - - - 6.4E-9(100)[A]
f -
f) Relatively selective for -receptors.
a) See text for explanation of column headings and abbreviations.
b) Low efficacy µ-agonist, low potency antagonist.
c) Drug actions not opioid-like. In mice, naloxone did not prevent nor
antagonize drug actions. In non-dependent monkeys, the overt neurological
signs associated with withdrawal were not antagonized by naloxone.
d) Naloxone decreased maximum response without shift in concentration-effect
curve; weak partial agonist or non-opioid agonist.
e) Non-µ-opioid properties.
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TABLE 12. EVALUATION OF STIMULANT/DEPRESSANT DRUGS
CPDD# SLAa I S b PD-Sc PD-PPDd S A e D D f
0038 Stumulantg Impairedh N T NT Insoluble NO i
0041 Stumulant Impairedj N T NT YESk NOl
a)
b)
c)
d)
e)
f)
g)
h)
i)
j)
k)
l)
Spontaneous locomotor activity (mouse).
Inverted screen assay (mouse).
Physical dependence - substitution for pentobarbital (rat infusion).
Physical dependence - primary (rat infusion).
Self-administration (monkey).
Drug discrimination (intragastric administration, monkey).
Mild stimulation, not dose-related
Non-specific toxicity: impairment not dose-related. Drug actions not typical
of usual stimulants or depressants.
Does not share discriminative stimulus effects with d-amphetamine or
pentobarbital.
Stimulant efficacy and potency greater than cocaine and less than d-
amphetamine.
Reinforcing effects in two out of three cocaine-trained monkeys. Unusually
variable rates of responding.
Does not share discriminative stimulus effects with pentobarbital; may have
slight, but not full discriminative stimulus effects with d-amphetamine.
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PROGRESS REPORT FROM THE TESTING PROGRAM
FOR STIMULANT AND DEPRESSANT DRUGS (1994)
G. Winger; W. L. Woolverton; J. K. Rowlett; J. A. English; G. A. Patrick;
M. A. Nader; R. E. McDaniel; W. T. Hawkins; B. W. Massey; L. S. Harris;
and J. H. Woods
The research group involved in the evaluation of stimulant and depressant
compounds has been in existence for approximately ten years. The group
includes laboratories at Virginia Commonwealth University (Patrick, Harris,
McDaniel, Hawkins), University of Mississippi Medical Center (Woolverton,
Rowlett, English; earlier work at the University of Chicago was assisted by
Nader and Massey)), the University of Michigan (Winger, Woods) and NIH (Dr.
Aurthur E. Jacobson). The group is part of the Drug Evaluation Committee,
chaired by Dr. Ted Cicero, of the College on Problems of Drug Dependence
(CPDD) and is supported by both CPDD and NIDA. One of the purposes of the
group is to evalute new compounds, generally classified as either stimulants or
depressants, for their abuse liability and potential to produce dependence.
Compounds are received, coded and distributed by Dr. Jacobson for blind testing
in the various laboratories. They are evaluated for discriminative stimulus effect
(UMS), reinforcing effects (UM) and capacity to produce physical dependence
(VCU). This report includes the results of evaluation of the following
compounds: CPDD-0038 (2-(7-Chloro-1,8-naphthyridin-2-yl)-3-[(1,4-dioxa-8-
azaspiro[4,5]dec-8-yl)carbonylmethyl]isoindolin-1-one); CPDD-0041
(etryptamine acetate: -ethyl-1H-indole-3-ethanamine acetate).
METHODS
Reinforcing Effects in Rhesus Monkeys
The reinforcing effects of CPDD-0041 were evaluated in a substutution self-
administration procedure with cocaine serving as the baseline drug. Rhesus
monkeys were surgically prepared with indwelling silicone rubber catheters using
10 mg/kg i.m. ketamine and 2.0 mg/kg i.m. xylazine as anesthetics. Catheters
were implanted in jugular (internal or external), femoral or brachial veins as
necessary. The catheter passed subcutaneously from the site of the incision to
the mid-scapular region, where it exited the monkey and continued through a
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hollow restraining arm to the outside rear of the cage.
The restraint and catheter protection device has been described in detail by
Deneau et al. (1969). Monkeys were individually housed in stainless steel cages,
measuring 83.3 X 76.2 X 91.4 cm deep. Each monkey wore a tubular stainless
steel harness that protected the exit site of the catheter and allowed relatively
unrestricted movements within the cage. A Teflon cloth jacket (Alice King
Chatham Medical Arts, Los Angeles, CA) provided further protection for animals
who tended to locate and pull their catheters. The harness was connected to a
flexible spring arm that carried the catheter to the back of the cage where it
joined tubing passing through a roller infusion pump (Watson and Marlow Co.,
Model MHRK 55, Falmouth, UK).
A 16.4 cm square stimulus panel was located on the side of each cage,
approximately 10 cm from the front and 19 cm from the bottom of the cage.
Across the top of the stimulus panel, 2.5 cm apart, were three circles, 2.5 cm in
diameter, covered with translucent plastic and capable of being illuminated from
behind by 5 W colored bulbs. The two side lights could be illuminated red and
the center light green. Below each of the two red stimulus lights was a response
lever (Model 121-07; BRS-LVE, Beltsville, MD) capable of being operated by
10-15 gm of force. Experimental control was provided by an IBM PS/2
computer programmed with Med-PC (Med-Associates, Fairfield, VT) software
and located in an adjoining room.
The drug self-administration procedure has been described in detail, in Winger et
al. (1989). There were two daily sessions of drug availability each day: each
session was 130 min in duration. Sessions were signalled by the onset of a red
stimulus light over one of the levers. Each session was divided into four
components, and a different dose of cocaine was available during each
component. Approximately every third session, saline, rather than a cocaine
solution, was delivered for the entire session. Each component was 25 min or 20
injections in duration and was followed by a 10 min timeout period, during which
all lights were turned off in the cage and responding had no programmed
consequences. The schedule of drug delivery during each component was a
fixed-ratio 30 time-out 45 sec. Thirty responses on the lever beneath the light
turned off this light and turned on the infusion pump and the green light. Each
infusion was followed by a 45 sec period when all lights were extinguished and
responses had no programmed consequences. At the end of this time period, the
red stimulus light was again illuminated, signalling drug availability.
Changes in cocaine dose were accomplished by altering the duration of the
infusion pump. The durations were 0.50, 1.7, 5.0, and 16.7 sec, and the drug
concentration, based on the weight of monkey, provided for infusion doses of
0.001, 0.003, 0.01, and 0.03 mg/kg/inj. The same procedure was used to
evaluate CPDD-0041, but on different sessions the drug concentration was
altered so that a wide range of doses were evaluated. The infusion durations
during a single session were always the same: 0.5, 1.7, 5.0 and 16.7 sec.
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The order of drug dose was varied randomly among four orders on each session.
One of the dose orders was ascending, one was descending and two were mixed.
Earlier data with cocaine have shown that dose order did not modify greatly the
response rates maintained by an individual dose (Winger et al., 1989). This may
not be true of long-acting drugs,
Discriminative Stimulus Effects in Rhesus Monkeys
The subjects were adult rhesus monkeys weighing between 6.5 and 13 kg. All
monkeys had extensive experience with the present drug discrimination
procedure. They were housed individually in stainless steel cages in which water
was continuously available. They were fed 100 to 150 g of monkey chow after
each session and were given a chewable vitamin tablet 3 days/week. During
experimental sessions each monkey was seated in a Plas-Lab restraining chair and
placed in a wooden cubicle (175 cm high X 85 cm wide X 65 cm deep)
containing two response levers mounted 100 cm above the floor. A 40 W white
house light was mounted on the ceiling. The monkey’s feet were placed into
shoes, the bottoms of which were fitted with brass plates which could deliver
electric shocks. Programming and recording of experimental events were
accomplished by a computer (Aim 65 microprocessor or Macintosh II) located
in an adjacent room.
The monkeys had been trained previously to discriminate d-amphetamine
(AMPH) or pentobarbital (PB) from saline in a two-lever, discrete-trail shock
avoidance procedure similar to the one described by Holtzman (1982). One hour
after an intragastric infusion (via nasogastric tube) of the training drug (0.56 or
1.0 mg/kg AMPH or 10 mg/kg PB) or saline, the houselights and lever lights
were illuminated (trial) and responding on one lever (designated the correct
lever) avoided electric shock and extinguished the lights. Responding on the
incorrect lever started a 2-second changeover delay during which correct lever
responding had no consequence. If a correct lever response was not made within
5 seconds of onset of the lights, an electric shock (250 msec duration, 7mA
intensity) was delivered; if a correct response was made within 2 sec after the
first shock (escape), the trial was terminated, otherwise a second shock
automatically ended a trial. Two consecutive trials with escape failure
automatically ended the session. Trials were separated by a 30-sec TO. The
session lasted 30 trials or 20 min, whichever came first. The correct lever was
determined by the infusion that was administered before the session. For three
monkeys, the right lever was correct after drug infusion and the left lever was
correct after saline infusions. This condition was reversed for the other three
monkeys.
Monkeys were considered to be stable in the discrimination when more than 90%
of the trials were avoidance trials and the first response in the session was on the
correct lever on at least seven out of eight consecutive sessions. At this point,
testing was begun. Two 5-day sequences alternated drug, vehicle and test
sessions so that the first test session was preceded by two training sessions, one
with saline and one with drug pretreatment and the second test session of the
sequence was preceded by either vehicle or drug pretreatment. In the event that
the criterion for stimulus control was not met during the training sessions, the
training sequence was continued. During test sessions, both levers were
operational, i.e., shock could be avoided by responding on either lever.
Saline and at least three doses of each test drug were evaluated under the test
conditions for each monkey. The percentage of trials that were completed on the
drug lever is presented for each test session. In addition, the average time
between the onset of a trial and a lever press (average latency) was calculated for
each test session. Because these test compounds were evaluated blind without
any potency information, initial test doses were done in an ascending order from
0.1 mg/kg to doses that either significantly increased latency to respond or
resulted in at least 90% drug-appropriate responding. Out of concern for the
monkeys, doses greater than 30 mg/kg were not tested. If a dose substituted for
a training drug, that dose and doses higher and lower were tested again, in a
random order.
A stock solution of AMPH was dissolved in saline to a final concentration of 5
mg/ml. Sodium pentobarbital was diluted with 0.9% saline to a final
concentration of 40 mg/ml, from a stock solution of 400 mg/ml that contained
propylene glycol, 95% EtOH and water in a ratio of 4:1:5. CPDD-0038 was
dissolved in acetic acid immediately before administration. CPDD-0041 was
dissolved in saline. Doses of CPDD-0038 were tested twice in PB-trained
monkeys and once in AMPH-trained monkeys. Doses of CPDD-0041 were
tested twice in AMPH-trained monkeys and once in PB-trained monkeys.
Physical Dependence Studies in Rats and Potency Estimates in Mice
Male Sprague-Dawley rats (Harlan Labs, Dublin, VA) initially weighing 200-225
g were individually housed in stainless steel cages with food and water freely
available. They were used in the chronic infusion and substitution experiments.
CF-1 mice (Harlan Labs, Dublin, VA) weighing 25 to 35 g were housed in plastic
cages with food and water ad lib. The mice were used in initial studies of
potency estimation. All animals were acclimated to the animal facility for several
days prior to use in any study.
Rats were surgically prepared with an intraperitoneal cannula (PE90 tubing)
while under methoxytlurane anesthesia. Acclimation to the infusion system
occurred for at least two days during which the rats were infused with 0.9%
saline. This was followed by the continuous infusion of either saline (control),
pentobarbital sodium or cocaine hydrochloride for 12 consecutive days using an
escalating dosing schedule (Yutrzenka et al., 1985). At the end of the infusion
period most rats were receiving pentobarbital at a dose of 850-900 mg/kg/24 hr
or cocaine at a dose of 160-170 mg/kg/24 hr. Body weight was monitored daily
during the drug infusion period.
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Following the final day of pentobarbital or cocaine infusion, a 24-hour
substitution period commenced during which the rats were infused with either
saline, vehicle, or test drug. This was followed by a 24-hour drug withdrawal
period during which all rats received saline.
Every two hours for the first 12 hours and again at 24 hours of each period, rats
were assigned a withdrawal score based on the degree of expression of several
behavioral responses and signs. In addition, body weight was determined at 0,
8 and 24 hours of each period. Scores were assigned by two observers who were
blind to the drug treatment. Investigators were blind to the identity of the
compounds until all data were collected and analyzed (Yutrzenka et al., 1989).
Preliminary studies to ascertain potency of the test compounds were conducted
in mice. Drug-treated mice were assayed using the inverted screen test
(Coughenour et al, 1977) and alteration of spontaneous locomotor activity. At
least three doses of each drug, with at least six mice per dose, were used to
determine dose-response curves. Vehicle-treated mice served as controls and
were assayed concurrently with drug-treated mice.
Each mouse was placed on a wire screen (12.8 X 12.8 cm with a 6 mm mesh)
and the screen was then inverted. A positive drug effect was to cause the mouse
to fall from the screen within 60 seconds. A negative effect was scored if the
mouse climbed to the top of the screen within 60 sec. Hanging from the
underside of the screen was recorded as a one-half positive effect (Coughenour
et al., 1977). The inverted screen test was conducted at 30, 60, 120 and 240 min
following drug administration.
Spontaneous locomotor activity was determined using a 16-beam infrared
photocell (Omintech, Columbus, OH) which transected a plastic cage containing
one mouse. Movement of the mice disrupted the beam(s) and a “count” of
activity was recorded. Following drug administration, activity was recorded at
5-15 min, 35-50 min, 65-95 min, and 125-185 min. The ED50 dose for a
depressant drug was determined to be that dose which reduced spontaneous
locomotor activity to one-half that recorded for concurrently tested vehicle-
treated control mice. For stimulant drugs, activity at a given dose was expressed
as “percent of control activity”. Potency estimates of each test drug were
determined at time of peak activity and when, in addition, the vehicle effect was
no longer evident.
Pentobarbital sodium was dissolved in distilled water made isotonic with sodium
chloride. CPDD-0038 was suspended in a vehicle including Tween 80 (20%)
propylene glycol (20%) and 1 drop of acetic acid in distilled water to make 10
ml. CPDD-004 1 was dissolved in isotonic saline. The CPDD-0038 suspension
and the CPDD-0041 solution or vehicle were given by i.p. injection in a volume
of 10 mg/ml.
Withdrawal scores for each treatment group were compared to the control by use
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of the Mann-Whitney U-test. Alterations in body weight were tested for
significance by use of the t-test. ED50 values and 95% confidence intervals in
the inverted screen test aned locomotor activity measure were also determined
when appropriate by the method of Litchfield and Wilcoxon (1949).
* * *
CPDD-0038 2-(7-Chloro-1,8-haphthyridin-2-yl)-3-[(1,4-dioxa-8-
azaspiro[4.5]dec-8-yl)carbonylmethyl]isoindolin-1-one
Reinforcing Effects in Rhesus Monkeys
Due to limited solubility, CPDD-0038 could not be evaluated in tests of
intravenous reinforcing effects in monkeys.
Drug Discrimination in Studies in Rhesus Monkeys
CPDD-0038 occasioned primarily saline-appropriate responding in all monkeys
up to 30 mg/kg. Latency was not systematically affected. Some monkeys
vomited at 30 mg/kg.
Potency Estimation in Mice
The effects of CPDD-0038 on spontaneous locomotor activity were generally
unremarkable. A mild stimulant effect seemed most prevalent, but it was neither
profound nor clearly dose-related. At the highest dose (50 mg/kg) the mice
exhibited Straub tail and were jumping uncontrollably in their cages within
approximately 10 min after injection of drug.
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CPDD-0038 (continued)
Table 1: Effects of CPDD-0038 on Spontaneous Locomotor Activity
Time after Treatment (min)
Dose (mg/kg) 5-15 35-50 65-95 125-185
10 68a 120 159 120
20 106 52 77 56
40 119 158 1190* 116
a Values expressed as percent of control activity of concomitantly tested, vehicle-treated mice.
* Control mice exhibited unusually low activity, and one cage of test mice exhibited very high
activity compared to other treated pairs.
Inverted Screen Test
The lower doses of CPDD-0038 (10 and 20 mg) produced effects ranging
from 0% to 50% impairment in the performance of this task, but those effects
were not clearly time nor dose-related. The 40 mg/kg dose produced an
effect greater than 80% impairment across the time course up to 120 min
after injection.
Summary. CPDD-0038 does not fit the profile or either a typical stimulant
or depressant drug; it does not have PB- or AMPH-like discriminative effects.
CPDD-0041 Etryptamine acetate ( -ethyl-1H-indole-3-ethana-
mine acetate, or -ethyltryptamine acetate)
Reinforcing Effects in Rhesus Monkeys.
The reinforcing effects of CPDD-0041 ranging from 0.00001 to 1.0 mg/kg/inj
were evaluated in three monkeys. In monkey JA, none of these doses
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CPDD-0041 (continued)
maintained rates of responding indicative of a reinforcing effect. In monkeys
DA and HE, doses of 0.03 and 0.3 mg/kg/inj respectively maintained rates
indicative of a reinforcing effect. Rates maintained by these doses varied
considerably from one exposure to the next for no apparent reason. Monkey
HE, on one occasion, received a dose order that included 3.2 mg/kg/inj. He
self-administered approximately 25 mg/kg of CPDD-41 during this session,
and was markedly affected following the session. He had dilated pupils and
was tremoring and appeared to be pre-convulsive. One mg/kg diazepam was
administered, and the monkey appeared to be much calmer. Figure 1 shows
the results of the self-administration study.
Figure 1. Self-administration of CPDD-0041 in three rhesus monkeys. The open symbols are
rates of responding maintained by cocaine in these animals. The different symbols represent
data from individual monkeys, as indicated by the legend.
Drug Discrimination Studies in Rhesus Monkeys
CPDD-0041 engendered a maximum of 63.5% drug lever responding in one
AMPH-trained monkey at 17 mg/kg (8906; Table 2). There was little or no
drug lever responding up to 10 mg/kg CPDD-0041 in the other two monkeys.
Although 31% of the trials were completed by 7739 on the drug lever at 3.0
mg/kg, this was the result of averaging one test session with 93% of the trials
completed on the drug lever with two test sessions with no trials completed
on the drug lever. No trials were completed on the drug lever when the dose
was increased to 10 and 17 mg/kg, suggesting that the partial substitution in
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CPDD-0041 (continued)
7739 at 3.0 mg/kg probably involved “noise” rather than an actual AMPH-like
effect. Latency to respond increased with dose of CPDD-0041 in all
monkeys.
CPDD-0041 engendered essentially exclusive saline lever responding in all
three PB - trained monkeys. All monkeys ate preferred foor offered
immediately after the session at 10 mg/kg CPDD-0041. As with AMPH-
trained monkeys, latency to respond was not systematically affected by
CPDD-0041.
Table 2: Discriminative stimulus effects of intragastric administration of
CPDD-0041 in AMPH- or pentobarbital-trained monkeys
AMPH-
trained
subject
Saline 0.03 1 3 10 17
CPDD-0041 (mg/kg)
7739 0/ 0/ 31/ 0/ 0/
0.9 1.0 0.98 1.08 1.2
8906 0/ 26.5/ 18/ 63.5/
1.0 1.25 1.28
8515 nt 0/ 0/ 0/
0.06
nt
0.88
0/
0.5 0.52 0.62
PB-
trained
subject
7976 0/ 0/ 0/ n.t. 0/
0.99 1.0 0.9 1.0
8814 0/ 0/ 0/ 3/ 10/
0.85 0.77 0.78 0.87 0.63
8236 0/ 0/ 0/ 0/ 0/
0.93 0.77 1.61 0.87 1.1
Rhesus monkeys were trained to discriminate either 0.56 1.0 mg/kg (i.g.) AMPH or 10.0 mg/kg
(i.g.) PB from saline in a discrete-trials avoidance-escape paradigm Data presented represent
the percent drug-appropriate responding/average response latency (sec). CPDD-0041 was
administered via nasogastric tube 60 min prior to testing. In all cases 30 trials were completed.
nt=not tested
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CPDD-0041 (continued)
Potency Estimation in Mice
The compound caused a mild increase in activity at 2.0 to 5.0 mg/kg, and the
effect became significant at 10.0 mg/kg (Table 3). The stimulant effect was
dose-related, although the increase in activity with each increment in disage
was rather mild, and there was no appreciable difference between doses of 15
and 30 mg/kg. One notable aspect of the stimulant effect was that it seemed
rather slow in onset and prolonged in duration, with the last time interval
measured (125 to 185 min after treament) corresponding to the peak effect.
At the dose of 15.0 mg/kg there was a significant impairment of performance
in the inverted screen task, with an 88% effect at 30 min that rapidly declined
to 25% effect at 60 min post-treatment. At the 30.0 mg/kg dose all mice
were rendered unable to perform the task at 30 min, and a 75% effect
persisted for 240 min, probably indicative of some nonspecific toxicity at this
dosage.
Table 3: Effects of CPDD-0041 on Spontaneous Locomotor Activity
Time after Treatment (min)
Dose 5-15 35-50 65-95 125-185
(mg/kg)
2 196a 110 79 218
5 114 136 116 155
10 120 259 294 473
15 116 304 442 741
30 184 244 301 933
a Values expressed as percent of control activity have concomitantly tested,
vehicle-treated mice.
Infusion in Pentobarbital-Dependent Rats
When administered to rats undergoing withdrawal from pentobarbital, CPDD-
0041 caused a significant enhancement in both overt signs of withdrawal
(Figure 2) when compared with saline substitution. However, these effects
were no greater in pentobarbital-abstinent rats than in drug-naive rats that
were given CPDD-0041 following 12 days of infusion of saline, so the effect
does not appear to be additive with barbiturate withdrawal.
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CPDD-0041 (continued)
Substitution in Rats Chronically Infused with Cocaine
When CPDD-004 1 was infused in rats that had received cocaine for 12 days,
it produced suppression of food intake during the 24 hr in which it was
substituted. It also caused a significant loss in body weight, which persisted
for at least 24 hr after the drug itself was discontinued.
Figure 2. Mean withdrawal scores of control rats on PB - dependent rats during substitution
and subsequent withdrawal of CPDD-0041.
Summary. The general profile of activity of etryptamine is more stimulant
than depressant. The stimulant activity was not profound, however.
Etryptamine produced less locomotor stimulation than did AMPH in mice, it
produced a partial AMPH-like discriminative stimulus effect in only one
monkey, and was not self-administered at all by the third monkey.
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EVALUATION OF NEW COMPOUNDS FOR OPIOID
ACTIVITY 1994
J. H. Woods, F. Medizhradsky, C. B. Smith, C. P. France and
C. Winger
This report contains information on opioid abuse liability evaluations on
compounds that have been submitted to the Drug Evaluation Committee of the
College and released for publication by the submitters. The information
obtained can involve both in vitro evaluation in opioid binding assays and
smooth muscle (largely, mouse vas deferens preparations. In addition, the
compounds may be evaluated for discriminative and reinforcing effects.
Analgesic and respiratory function assays arc also possible. These behavioral
assessments are conducted in rhesus monkeys. Each of these assays is
described below. Usually when limited information is provided (e.g., in vitro
assessment only), it is because the sample provided by the submitter was
insufficient to carry out further evaluation.
The evaluation of new compounds by the programs at the University of
Michigan and the Medical College of Virginia is coordinated by Dr. Arthur E.
Jacobson, Laboratory of Medicinal Chemistry, NIDDK, National Institutes of
Health, Bethesda, MD. The compounds, which come originally from
pharmaceutical companies. universities, government laboratories, and
international organizations are submitted to Dr. Jacobson.
At the UM and MCV laboratories, drug samples arrive from Dr. Jacobson with
only the following information: (1) an identifying NIH number, (2) molecular
weight, (3) solubility information and (4) a recommended starting dose. After
the evaluation is complete and the report submitted to Dr. Jacobson, the
submitter is requested to release the chemical structure to include with the
evaluation data in the ANNUAL REPORT. The submitter has up to three
years before release of the structure is required. When the structure is released
all of the data on the compound are reported to the Drug Evaluation Committee.
DRUG DISCRIMINATION IN RHESUS MONKEYS
We currently use three groups of monkeys to test the discriminative stimulus
effects of submitted drugs: one of these groups discriminates the administration
of the agonist ethylketazocine (EKC); a second group discriminates the µ
agonist alfentanil; a third group is treated daily with morphine and
discriminates the opioid antagonist naltrexone.
The procedures used with the EKC-trained monkeys have been described by
Bertalmio et al., (1982). The monkeys are removed from their home cages
each day and seated in primate restraining chairs. These chairs arc placed in
isolation chambers equipped with two response levers, several stimulus lights
and a cup to receive Noyes, banana-flavored pellets. These monkeys are
required to make 100 consecutive responses on the correct one of the two
levers and receive ten 300-mg food pellets. The right lever is correct if they
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were given a subcutaneous injection of 0.0032 mg/kg EKC immediately prior
to the start of the cycle. The left lever is designated correct if they were given a
sham injection before the start of the cycle. Each cycle lasts 15-min and
consists of an initial 10-min black out period followed by a period of as long as
5 min, during which a blue light is illuminated in the chamber and the monkey
can respond for food. If the food pellets are delivered before the 5 min period
is completed, the lights are extinguished for the remainder of this time.
Typically, a daily session consists of several 15 min cycles. During a training
session, if EKC is given, it is given on the penultimate cycle of that session.
Responding on the drug-appropriate lever is reinforced during that cycle and
on the subsequent, final cycle of the day. These last two cycles may be
preceded by from zero to four sham cycles on a training day. A training
session of six sham cycles is also scheduled from time to time.
With this type of multiple, discrete-cycle training, the animals can be tested
with a cumulative dosing procedure. On a test session, the first cycle is
preceded by an injection of saline, and prior to subsequent cycles, increasing,
cumulative doses of the test drug are administered. One hundred consecutive
responses on either lever are reinforced throughout the test session. The test
drug is administered in increasing doses until the monkey either responds on
the drug-appropriate lever, the response rate falls to less than half of the saline-
control rate, or six cycles are given. In the latter situation, it is assumed that
the selected dose range is too low, and the test is continued at higher doses on
the next test session. Each test session is preceded and followed by a training
session. The criterion for satisfactory performance must be met on each
training session that is followed by a test session. This criterion is that at least
90% of the responses during each cycle of a training session must be on the
injection-appropriate lever, either sham or EKC.
The procedure for the alfentanil-trained monkeys is similar, but not identical.
These animals are also trained and tested in a discrete, multiple-cycle
procedure. The main difference between the alfentanil procedure and the EKC
procedure is that the alfentanil monkeys are required to make 20 rather than
100 responses, and they receive a single pellet for correct responses. They can
receive as many as 10 pellets during the 5-min, food-availability period of each
cycle, but each pellet is delivered after 20 responses. Because in this
procedure, monkeys can switch from one lever to another following the
delivery of food, an additional criterion is added for satisfactory performance.
In addition to making 90% or more of their responses on the correct lever, the
monkeys must make fewer than 20 responses on the incorrect lever prior to
delivery of the first food pellet of each cycle. Tests of the discriminative
stimulus effects of submitted drugs in the alfentanil-trained monkeys are also
done using a cumulative dosing procedure with dosing criteria identical to
those used in the EKC-trained monkeys.
The procedure for studying discriminative stimulus effects in morphine-treated
monkeys has been described previously (France and Woods, 1989). Daily
sessions are comprised of a 10-min time out during which lever presses have
no programmed consequence and a 5-min response period during which green
stimulus lights are illuminated and signal the activation of a schedule of
stimulus-shock termination. sessions consist of between two and six discrete,
15-min cycles with each cycle. Under these experimental conditions electric
shock is scheduled to be delivered to the subject’s feet every 15 seconds;
monkeys can terminate the lights and postpone scheduled shocks for 30
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seconds by pressing five times consecutively (i.e., fixed-ratio 5) the lever
appropriate for the solution administered during the first minute of the time out
(left lever, saline; right lever, naltrexone). Monkeys receive an injection of
saline (0.1 ml/kg) or drug (0.01 mg/kg naltrexone) during the first minute of
each time out. On drug training days a single injection of naltrexone is
administered during one time out and for that cycle and all subsequent cycles
on that day only responding on the right lever postpones shocks. A variable
number of saline cycles (0-5) precede the naltrexone cycle and on some days
saline is administered during the time out of all cycles. Under these conditions
monkeys switch their response choice from the saline lever to the naltrexone
lever with complete generalization occurring in all three subjects at a dose of
0.01 mg/kg. Responding on the naltrexone lever is accompanied by other
behavioral effects indicative of opioid withdrawal (e.g., irritability, miosis,
salivation). Moreover, when saline is substituted for the daily injection of 3.2
mg/kg of morphine monkeys respond predominantly on the naltrexone lever
and show directly observable signs of withdrawal; the discriminative stimulus
and other effects produced by morphine abstinence are reversed by some
opioid agonists (e.g., alfentanil; France and Woods, 1989; France et al.,
1990).
For test sessions increasing doses of drug arc administered during the first
minute of consecutive time outs and five consecutive responses on either lever
postpone shocks. In monkeys that receive 3.2 mg/kg of morphine 3 hours
earlier, increasing doses of a test compound are administered up to doses that
produce an average of at least 80% responding on the naltrexone lever or to
doses that disrupt responding and result in the delivery of electric shock.
Drugs that do not substitute for nultrexone (i.e., precipitate withdrawal) are
also studied for their ability to reverse responding on the naltrexone lever in
morphine-abstinent (i.e., withdrawn) subjects. Test compounds are studied
using a cumulative-dosing procedure in morphine-abstinent monkeys up to
doses that reverse completely responding on the naltrexone lever (<20%) or to
doses that disrupt responding. Some compounds that substitute for naltrexone
also are studied for their capacity to prevent the effects of cumulative doses of
opioid agonists. Monkeys that receive saline three hours earlier, rather than the
daily injection of morphine, receive saline (control) or a single injection of test
compound during the first cycle and increasing doses of agonist (alfentanil or
morphine) during subsequent cycles. Agonists are administered up to doses
that produce a switch from the naltrexone lever to the saline lever or to doses
that disrupt responding and result in the delivery of electric shock.
THERMAL ANALGESIA IN RHESUS MONKEYS
The tail withdrawal procedure used to study analgesic effects of test
compounds in rhesus monkeys has been described previously (Dykstra and
Woods, 1986). Monkeys are restrained loosely at the neck and arms while
seated in Plexiglas primate chairs. For tests of tail withdrawal latency, the
lower 10-12 cm of the shaved tail is immersed in a thermos containing water at
40°, 50°, or 55° C and the latency until the tail is withdrawn from the thermos
is recorded for each monkey at each temperature. When the tail is not
withdrawn within 20 seconds (cut-off latency) the experimenter removes the
thermos and a latency of 20 seconds is recorded. Experimental sessions begin
with several exposures to 40° C water. Four or five monkeys are tested
consecutively and the time between tail immersions for individual monkeys is 5
minutes. Generally, 40° C water does not produce tail withdrawal in rhesus
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monkeys (Dykstra and Woods, 1986); however, if a monkey fails to keep its
tail in 40° C water for 20 seconds on at least 3 of 4 immersions, that animal is
not tested further for that particular session. In a subsequent pre-test
component, tails are immersed in 40°, 50°, and 55° C water. The order in
which the three temperatures are presented is varied among subjects. If the
latencies for tail withdrawal in the pre-test component are at or near 20 seconds
for 40° C water and less than 5 seconds for 55° C water, monkeys receive the
test compound. The test is identical to the pre-test, except that monkeys
receive s.c. injections of drug 10 minutes prior to tail immersion. The time
between immersions for individual subjects is 5 minutes or less and the order
in which temperatures are presented varies among subjects and across cycles.
The inter-injection interval typically is 30 minutes and between four and six
doses are studied in a single experiment using the cumulative dosing
procedure. For some studies a single dose of an opioid antagonist is
administered prior to the test compound and for other studies a single dose of
test compound is administered prior to increasing doses of a µ (e.g., alfentanil)
or ( e.g., U-50,488) opioid agonist.
RESPIRATORY STUDIES IN RHESUS MONKEYS
The effects of test compounds on ventilatory function are studied in rhesus
monkeys breathing air or 5% CO2 in air (France and Woods, 1990; Howell et
al., 1988). Monkeys are restrained at the neck and waist while seated in a
Plexiglas primate chair. Normal air or 5% CO2 in air is delivered at a rate of
101/mm into a sealed helmet placed over the subject’s head. Changes in
pressure within the helmet are measured and recorded by a transducer and a
microprocessor, and are transformed according to known standards to
frequency of respiration (f) in breaths/minute and to tidal volume (VT) in
ml/inspiration. Data are recorded continuously during 23-minute exposures to
air alternating with 7-minute exposures to CO2. The last three minutes of
exposure to CO2 are used for data analyses and are compared to the last three
minutes of exposure to air only. Increasing doses of drug are administered
during the first minute of consecutive time outs so that the inter-injection
interval is 30 minutes. For some studies a single injection of an opioid
antagonist is administered prior to increasing doses of a test compound and for
other studies a single injection of test compound is administered prior to
cumulative doses of a standard compound (e.g., alfentanil).
SELF-ADMINISTRATION BY MONKEYS
Tests of self-administration determine the ability of the drug to maintain
responding in monkeys trained to self-inject codeine. Each of at least three
monkeys is studied with saline as a negative control and a number of doses of
the test compound until a maximum rate of responding was obtained or until,
in the absence of evidence of a reinforcing effect, observable changes in
behavior are produced by the compound.
The schedule of intravenous drug delivery is a fixed-ratio 30; when a light
above a lever is illuminated, the 30th response produces an intravenous drug
injection accompanied by another light that is illuminated during drug delivery.
After each injection, a 45 sec timeout period occurs. A component of the
session ends after 20 injections have been received or 25 min have passed,
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whichever occurs first. Different doses of the drug are available during each of
four components of a session. Other procedural details are given in Winger et
al., (1989).
DISPLACEMENT OF RADIOLABELED LIGAND BINDING
Details of the binding assay based on the displacement of 3H-etorphine in rat
brain membranes have been described previously (Medzihradsky et al., 1984).
Briefly, aliquots of a membrane preparation from rat cerebrum are incubated
with 3H-etorphine in the presence of 150 mM NaCl, and in the presence of
different concentrations of the drug under investigation. Specific, i.e., opioid-
receptor-related interaction of 3H-etorphine is determined as the difference in
binding obtained in the absence and presence of an appropriate excess of
unlabeled etorphine. The potency of the drugs in displacing the specific
binding of 3H-etorphine is determined from log-probit plots of the data. See
Table I for representative results with different opioids.
To enhance the characterization of novel opioids, we are also investigating their
selectivity in binding to µ-, -, and -opioid receptors in membranes from
monkey brain cortex. Thus, we are now providing Ki values of the tested
compounds in displacing the following radiolabeled opioid ligands:
etorphine (nonselective, reflects opioid character),
sufentanil or Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAMGO); (µ selective),
[D-Pen2-D-Pen5]enkephalin (DPDPE; selective),
U-69.593 ( selective).
Using the receptor-specific assays, we have described the selectivity of various
established opioids in brain membranes of different species (Clark et al.,
1988). The selection of monkey brain as the tissue for the selective binding
assays strengthens the correlation between this in vitro assessment and the
behavioral evaluation of the tested compounds. In the ANNUAL REPORT,
the results of the selective binding assays are listed under “Binding in monkey
brain cortex”. See Table II for representative results with different opioids in
rat and monkey brain.
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TABLE I
EC50's of representative opioids for displacement of 0.5 nM 
3H-etorphine from
rat brain membrane, and inhibition of the twitch of the mouse vas deferens
preparation.
Compound BINDING* MVD
EC50 (nM)
DPDPE
U50,488
Fentanyl
DAMGO
Etorphine
(-)Cyclazocine
Naltrexone
Bremazocine
UM 1071R**
Sufentanil
(-)SKF 10047
Ethylketazocine
Ketazocine
Morphine
DSLET
Dextrorphan
---
---
36.2
23.9
0.37
0.53
0.63
1.42
1.55
1.60
3.93
6.60
14.1
23.6
43.0
<6000
5.52
6.29
37.1
81.3
0.0068
11.9
---
0.29
---
4.43
---
11.6
1.18
395
1.71
1010
* In the presence of 150 mM NaCl.
** 1R-5R-9R-2”R-5,9-dimethyl-2’-hydroxy-2-tetrahydrofurfuryl-6,7-benzomorphan hydrochloride
122
TABLE II
Inhibition of radiolabeled sufentanil, DPDPE and U69,593 binding in rat and monkey brain. In
membranes from rat cerebrum and monkey brain cortex, the inhibition of specific equilibrium
binding of 0.5 nM [3H]sufentanil, 1.5 nM [3H]DPDPE and 1.5 nM [3H]U69,593 by five different
concentrations of the listed compounds was investigated in the presence of 150 mM NaCl (modified
from Clark et al., 1988).
EC50 (nM)
Compound [3H]Sufentanil [3H]DPDPE [3H]U69,593
Rat cerebrum
DAMGO 13.2 690
Sufentanil 1.25 45.0
Morphine 31.4 422
-FNA 6.99 43.9
-CNA 1.29 7.48
Naloxone 6.37 14.3
Etorphine 0.60 1.13
Buprenorphine 1.07 1.12
Bremazocine 1.79 1.12
Superfit 576 16.5
DSLET* 121 1.05
ICI- 174,864 58900 59.0
DPDPE 7720 6.44
U50,488 7230 13100
U69,593 38000 13400
Monkey cortex
Sufentanil
DPDPE
U69,593
1.18 81.1 >10000
18900 4.21 >10000
10700 17000 8.41
* (D-Ser2,Leu5)-enkephalin-Thr6
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ISOLATED, ELECTRICALLY-STIMULATED MOUSE VAS DEFERENS
PREPARATION
The development of new, highly selective antagonists such as the reversible
receptor antagonist norbinaltorphimine (Smith et al., 1989) and the competitive
receptor antagonist ICI-174864 have made possible the evaluation of selectivity
of opioid agonists and antagonists by use of the mouse vas deferens preparation.
Male, albino ICR mice, weighing between 25 and 30 g, are used. The mice are
decapitated, the vasa deferentia removed, and 1.5 cm segments are suspended in
organ baths which contain 30 ml of a modified Kreb’s physiological buffer. The
buffer contains the following (mM): NaCl, 118; KCl, 4.75; CaCl2, 2.54; MgSO4,
1.19; KH2PO4, 1.19; glucose, 11; NaHCO3, 25; pargyline HCl, 0.3; and disodium
edetate, 0.03. The buffer is saturated with 95% O2 - 5% CO2 and kept at 37° C.
The segments are attached to strain gauge transducers and suspended between
two platinum electrodes. After a 30-min equilibration period, the segments are
stimulated once every 10 sec with pairs of pulses of 2 msec duration, 1 msec apart
and at supramaximal voltage. See Table III for potencies of representative
agonists.
The following antagonists are studied: naltrexone HCl, ICI- 174864 [N,N-diallyl-
Tyr-Aib-Aib-Phe-Leu-OH] and norbinaltorphimine. The antagonists are added
to the organ baths 15 minutes before the determination of cumulative
concentration-effect relationships for the various agonists. See Table III for the
potencies of different competitive antagonists studied in relation to prototypic
agonists, EC50's are calculated by probit analysis, and pA2 values are determined
to assess relative potencies of antagonists.
All drugs which are submitted for evaluation are studied in the following manner:
1) the submitted drug is tested on the vas deferens preparation in the absence and
in the presence of a concentration of naltrexone sufficient to block µ, and
receptors, 2) If the submitted drug inhibits the twitch and its actions are blocked
by naltrexone, it is evaluated further in the absence and presence of ICI-174864
and norbinaltorphimine used in concentrations at which these antagonists are
selective for and receptors, respectively. 3) If the submitted drug is a partial
agonist or devoid of agonistic activity at opioid receptors, it is evaluated further
as an antagonist against the following agonists: sufentanil (µ selective), DSLET
( selective) and U50,488 ( selective). If the submitted drug has antagonistic
activity against any or all of the receptor-selective agonists or upon any of the
other preparations used in the Drug Evaluation Unit, the type of antagonism
(competitive, noncompetitive, irreversible) is determined. For further details of
the procedure and for a description of experiments in which µ-funaltrexamine
was used see Smith (1986). Drugs studied in the preparation prior to 1987 were
evaluated with the protocol reported in the 1985 Annual Report.
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TABLE III
Potencies of antagonists assessed in the mouse vas deferens
pA2 values* determined with three agonists
Sufentanil (µ) U50,488 ( ) (DSLET )
Antagonist
Naltrexone 8.76 7.74 7.41
Naloxone 7.99 6.90 7.35
Cyprodime* 7.41 6.15 5.98
Nalbuphine 7.23 6.3 1 5.76
Naltrindole 7.71 7.38 9.44
ICI- 174,864 <5.00 <5.00 7.90
*The pA2 value is the negative logarithm of the molar concentration of antagonist necessary to shift
the agonist concentration-effect curve to the right by a factor of 2-fold.
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SUMMARY OF TESTS PERFORMED
The compounds which were evaluated at the University of Michigan during the
past year, and the individual tests which were performed are shown in Table IV.
Also shown are dates of Reports to the Biological Coordinator, Dr. A.E.
Jacobson, in which results are reported.
TABLE IV
SUMMARY OF TESTS PERFORMED
NIH# SA MVD BIND DD
10683 + + + + + +
10684 + + + - + +
10697 - - MBC - - -
10698 - - MBC - - -
10700 - - MBC -
ANLG RSP REPORT*
02/03/92
02/10/92,
04/07/91
06/28/93
06/28/93
- - 06/28/93
10701 - - MBC - - - 06/28/93
10702 - - MBC - - - 06/28/93
10703 - - MBC - - - 06/28/93
- - - 06/28/93
- - - 03/25/92
- - - 03/25/92
- - - 05/07/93
- - - 04/23/93
- - - 10/30/92
10782 - + + - - - 03/05/93
10785 - + + - - - 05/07/93
10786 - + + - - 05/07/93-
05/03/93
10705 - MBC -
10738 - + +
10739 - + +
10762 - + +
10765 - + +
10773 - + +
10793 - + + - - -
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Table IV (continued)
NIH SA MVD BIND DD ANGL RSP REPORT*
10787 + + - - - 05/07/93
10790 - + + - - - 02/20/94
10791 - + + - - - 02/02/94
10792 - + + - - - 02/02/94
10793 - + + - - 02/14/94-
10802 - + + - - - 02/14/94
10803 - + + - - - 02/14/94
10805 - + + - - - 02/12/93
10809 - + + - - - 08/03/92
10810 - + + - - - 08/03/92
10811 - + + - - - 08/03/92
10812 - + + - - - 02/02/92
10813 - + + - - - 10/30/92
10814 - + + - - - 11/12/93
10815 + + - - - 03/09/93
* Date report was submitted to CPDD Biological Coordinator. MBC = Monkey Brain Cortex
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NIH 10683 14-Hydroxy-N-(2-methoxyethyl)-7,8-dihydro-
normorphine
DISPLACEMENT OF
[3H]ETORPHINE BINDING
EC50 of 8.24 nM in the presence of 150
mM NaCI.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum shift n
Response (%)
Control 7048.9 ± 1499.6 100 9
Naltrexone (100 nM) 6468.9 ± 1276.7 100 0.9 3
ICI 174864 (100 nM) 5898.3 ± 2685.4 100 0.8 3
Nor-BNI (10 nM) 15226.0 ± 9136.5 100 2.2 3
Agonist p A 2 Slope ± S.D. pA2 (Constrained) n
± S.E.
Sufentanil 7.35 1.01 ± 0.11 7.36 ± 0.34 6
DSLET 6.72 1.33 ± 0.12 6.96 ± 0.46 6
U50,488 6 . 8 3 1.34 ± .037 7.11 ± 0.47 6
DISCRIMINATIVE STIMULUS EFFECTS IN RHESUS MONKEYS
NIH 10683 was studied in rhesus monkeys for its discriminative stimulus effects,
analgesic effects, and effects on respiratory function. NIH 10683 substituted
completely for the opioid agonist ethylketocyclazocine in one of two monkeys
discriminating between saline and 0.032 mg/kg of ethylketocyclazocine. NM
10683 did not substitute for the opioid µ agonist alfentanil and also failed to
substitute for the opioid antagonist naltrexone in morphine-treated (3.2
mg/kg/day) monkeys discriminating between 0.01 mg/kg of naltrexone and
saline. When saline is substituted for the daily injection of morphine in monkeys
discriminating between naltrexone and saline, subjects respond on the naltrexone
lever; this naltrexone-lever responding is reversed by morphine-like opioids (e.g.,
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NIH 10683 (continued)
alfentanil) and appears to be related to opioid withdrawal. Up to a dose of 1.78
mg/kg, NIH 10683 failed to affect naltrexone-lever responding in morphine-
abstinent monkeys. Thus, with regard to discriminative stimulus effects, NIH
may have agonist effects and no µ agonist nor µ antagonist effects.
ANALGESIC EFFECTS IN RHESUS MONKEYS
NIH 10683 also was studied for its effects on the latency of monkeys to remove
their tails from warm water. Up to the largest dose that could be administered,
10.0 mg/kg, NIH 10683 produced 100% and 79% of the maximum possible
effect (i.e., 20-sec latency) with 50 and 55° C water, respectively. This analgesic
effect of NIH 10683 was markedly antagonized by a pretreatment of 1.0 mg/kg
of quadazocine. Whereas under control conditions a dose of 3.2 mg/kg of NIH
10683 produced a maximum effect with 50° C water, in the presence of 1.0
mg/kg of quadazocine this dose of NIH 10683 had no effect on tail withdrawal
latencies. A smaller dose of quadazocine, 0.1 mg/kg, produced a smaller
antagonism of NIH 10683 with 50° C water and no antagonism with 55° C
water.
RESPIRATORY FUNCTION STUDIES IN RHESUS MONKEYS
The effects of NIH 10683 on respiratory function were studied in a monkey
breathing air or 5% CO2 in air, the effects of NIH 10683 on respiratory function
in air when NIH 10683 was administered alone and when administered after
pretreatment with 1.0 mg/kg of the opioid antagonist quadazocine. Up to a dose
of 3.2 mg/kg, NIH 10683 produced dose-related decreases in ventilatory
frequency (f) and in ventilatory volume (VT) with maximum decreases to 50% of
control at the largest dose studied. Quadazocine attenuated decreases in f but
not decreases in VT. produced by NIH 10683. For example, under control
conditions NIH 10683 decreased fin air to 52% of control; in the presence of
quadazocine this dose of NIH 10683 decreased f to only 86% of control.
Qualitatively similar results were obtained when this subject breathed 5% CO2 in
air.
SELF-ADMINISTRATION STUDIES IN RHESUS MONKEYS
Doses of from 0.0001 to 0.1 mg/kg/inj NIH 10683 were evaluated. NIH 10683
at 0.03 mg/kg/inj maintained rates of responding that were slightly below those
maintained by the maximum rate-maintaining dose of alfentanil in the two
monkeys. No other dose of NIH 10683 maintained response rates above those
maintained by saline.
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NIH 10683 (continued)
SUMMARY
NIH 10683 had a very unusual spectrum of action across the preparations
described herein. Its binding results would predict that opioid potency would be
roughly comparable to morphine. This prediction was borne out by the in vivo
studies. The vas deferens preparation demonstrated that the compound had no
opioid agonist characteristics, but NIH 10683 did have antagonist actions against
each agonist used in the preparation. These data, taken at face value, might
argue for a naloxone-like action with less potency. This supposition was not
borne out behaviorally in the naltrexone discrimination studies in monkeys, The
other behavioral data suggest opioid agonist activity in some preparations. The
compound appeared to have agonist effects in the drug discrimination assay.
However, it suppressed respiratory function by an opioid mechanism. This is
inconsistent with agonist activity. NIH 10683 was self-injected in the dose
range expected from its behavioral protency in other assays.
NIH 10684
* * *
14-Hydroxy-N-(2-methoxyethyl)-7,8-dihydro-
norisomorphine
DISPLACEMENT OF
[3H] ETORPHINE BINDING
EC50 of 5.83 nM in the presence of 150
mM NaCI.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%)
Control 98.7 ± 1.3 3
Naltrexone (100 nM) 29125.0 ± 3785.0 96.8 ± 3.2 0.6 3
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NIH 10684 (continued)
Agonist pA 2 Slope ± S.D. pA2 (Constrained) ± n
S E
Sufentanil 9.31 0.94 ± 0.21 9.28 ± 1.27 6
DSLET 6.92 1.14±0.17 6.98±0.19 6
U50,488 7.49 1.22 ± 0.22 7.60 ± 0.41 6
DRUG DISCRIMINATION STUDIES IN RHESUS MONKEYS
In monkeys discriminating between saline and either 0.032 mg/kg of the opioid
agonist ethylketocyclazocine or 0.056 mg/kg of the opioid µ agonist alfentanil,
NIH 10684, up to a dose of 10.0 mg/kg, produced only saline-lever responding.
In morphine-treated (3.2 mg/kg/day) monkeys discriminating between 0.01
mg/kg of naltrexone and saline, NIH substituted completely for naltrexone at a
dose of 3.2 mg/kg. When saline is substituted for the daily injection of morphine
in monkeys discriminating between naltrexone and saline, subjects respond on the
naltrexone lever; this naltrexone-lever responding is reversed by morphine-like
opioids (e.g., alfentanil) and appears to be related to opioid withdrawal. Up to
a dose of 10.0 mg/kg, NIH 10684 had no effect on naltrexone-lever responding
in saline-treated (morphine-abstinent) monkeys. However, in morphine-abstinent
monkeys NIH 10684 antagonized the withdrawal-reversing effects of alfentanil
as evidenced by dose-related shifts to the right in the alfentanil dose-effect curve.
Antagonism of alfentanil by NIH 10684 was reversible and appeared to be
competitive (slope = -1.07) and the apparent affinity (i.e., pA2) of NIH 10684 for
µ opioid receptors was 6.49. Thus, with regard to discriminative stimulus
effects, NLH 10684 had no apparent opioid agonist effects, but did substitute for
the opioid antagonist naltrexone in morphine-treated monkeys. NIH 10684 was
100 times less potent than naltrexone (pA2 = 8.69) in drug discrimination studies.
NIH 10684 had no marked effect on rates of lever pressing.
ANALGESIA STUDIES IN RHESUS MONKEYS
NIH 10684 was also studied for its effects on the latency of monkeys to remove
their tails from warm water. Up to a dose of 17.8 mg/kg NIH 10684 had no
effect on tail withdrawal latency; however, a dose of 32.0 mg/kg produced 44%
and 8% of the maximum obtainable response (20 sec) with 50 and 55° C. water,
respectively. When administered as a pretreatment, NIH 10684 antagonized the
analgesic effects of alfentanil with a dose of 1.0 mg/kg of NIH 10684 producing
a 3-10 fold shift to the right in the alfentanil dose-effect curve.
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NIH 10684 (continued)
STUDIES ON RESPIRATORY FUNCTION IN RHESUS MONKEYS
The effects of NIH 10684 on respiratory function were studied in a monkey
breathing air or 5% CO, in air. Up to a dose of 32.0 mg/kg, NIH 10684 did not
have any consistent effect on ventilatory frequency (f) or ventilatory volume
(VT).
SELF-ADMINISTRATION IN RHESUS MONKEYS
The reinforcing effects of NIH 10684 were evaluated in three monkeys
experienced in responding and receiving intravenous infusions of alfentanil.
Doses of from 0.003 to 0.3 mg/kg/inj NIH 10684 were evaluated. NIH 10684
at 0.1 mg/kg/inj maintained rates of responding slightly below the maximum rate-
maintaining dose of alfentanil in monkey RC 213. RC 213 also responded
slightly above those rates maintained by 0.0003 alfentanil at 0.03 mg/kg/inj NIH
10684. No other dose maintained rates above the criterion rate for saline in
monkey RC 213. NIH 10684 at 0.1 mg/kg/inj was the only dose at which
monkey CH 852 maintained rates above the criterion rate for saline in this
experiment. NIH 10684 had virtually no capacity to maintain response rates
above those maintained by saline in monkey L 998. Rates for all monkeys
peaked at 0.1 mg/kg/inj NIH 10684.
In summary, NM 10684 was less potent and less efficacious than alfentanil in this
procedure. It reliabilty maintained self-injection responding in two of the three
monkeys.
SUMMARY
NIH 10684 was slightly less potent than naltrexone in the binding assay, and
more potent than naltrexone, but u-selective, in the vas deferens preparation, It
also had complex activity at concentrations above 100 nM which was not
blocked by naltrexone. In vivo, NIH 10684 substituted for naltrexone, but was
much less potent. This finding suggests that NIH 10684 may not have as
effective bioavailability as naltrexone. It was not effective in the thermal
analgesia assay. NIH 10684 was an opioid antagonist selective for u-receptor
mediated actions in a number of preparations. It did have weakly reinforcing
effects, but no other effects that suggested a morphine-like abuse liability.
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NIH 10697 (-)-5,9 -Dimethyl-2’-hydroxy-2-n-octyl-6,7-
benzomorphan hydro-chloride
Other in vivo data were presented in the 1992 Annual report
SELECTIVE RECEPTOR BINDING IN MONKEY BRAIN CORTEX
Assay IC50 r
2
[3H]DAGO (1.0 nM) 150 0.99
[3H]DPDPE (1.5 nM) 197 0.99
[3H]U69,593 (1.5 nM) 226 0.99
* * *
NIH 10698 (+)-5,9 -Dimethyl-2’-hydroxy-2-n-octyl-6,7-
benzomorphan hydro-chloride
Other in vitro data were presented in the 1992 Annual Report
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NIH 10698 (continued)
SELECTIVE RECEPTOR BINDING IN MONKEY BRAIN CORTEX
Assay
[3H]DAG0 (1.0 nM)
[3H]DPDPE (1.5 nM)
[3H]U69,593 (1.5 nM)
IC5 0 r
2
763 0.99
21% inhibition at 6000 nM
2839 0.98
* * *
NIH 10700 1-[1-(2-Hydroxyphenyl)cyclohexyl]-3,4-
dehydropiperidine hydro-chloride
Other in vitro data were presented in the 1992 Annual Report
SELECTlVE RECEPTOR BINDING IN MONKEY BRAIN CORTEX
I
Assay IC5 0 r
2
[3H]DAG0 (1.0 nM) 61.9 0.99
[3H]DPDPE (1.5 nM) 2370 0.99
[3H]U69,593 (1.5 nM) 2695 0.99
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NIH 10701 6 -Iodo-3,14-dihydroxy-17-cyclopropylmethyl-
4,5 -epoxymorphinan oxalate
Other in vivo data were presented in the 1992 Annual Report.
SELECTIVE RECEPTOR BINDING IN MONKEY BRAIN CORTEX
Assay
[3H]DAG0 (1.0 nM)
[3H]DPDPE (1.5 nM)
[3H]U69,593 (1.5 nM)
IC50 r
2
1.06 0.99
26.0 0.99
0.34 0.9
* * *
NIH 10702 6 -Iodo-3,14-dihydroxy-17-cyclopropylmethyl-
4,5 -epoxymorphinan oxalate
Other in vitro data were presented in the 1992 Annual Report
135
NIH 10702 (continued)
Assay IC5 0 r
2
[3H]DAG0 (1.0 nM) 0.42 0.98
[3H]DPDPE (1.5 nM) 9.57 0.99
[3H]U69,593 (1.5 nM) 0.30 0.98
* * *
NIH 10703 N-[(3,4-Dichlorophenyl)acetyl]-N,2-dimethyl-2-
(N’,N’-dimethylamino) ethylamine oxalate
Other in vitro data were presented in the 1992 Annual Report.
RECEPTOR SELECTIVE BINDING IN MONKEY BRAIN
Assay
[3H]DAG0 (1.0 nM)
[3H]DPDPE (1.5 nM)
[3H]U69,593 (1.5 nM)
IC50 r
2
1791 0.99
6% inhibition at 6000 nM
287 0.99
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NIH 10705 N-(n-Propyl)-N’-(3,4-dichlorophenylethyl)
piperazine dihydrobromide
Other in vitro data were presented in the 1992 Annual Report
RECEPTOR SELECTIVE BINDING IN MONKEY BRAIN CORTEX
Assay IC5 0 r
2
[3H]DAGO (1.0 nM) 5210 0.99
[3H]DPDPE (1.5 nM) 4% inhibition at 6000 nM
[3H]U69,593 (1.5 nM) 3181 0.99
* * *
NIH 10738 4-(3-Hydroxyphenyl)-1-(4-nitrobenzyl)-4-(1-
oxopropyl) piperidine hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 3.4 µM in the presence of 150 mM
NaCl.
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NIH 10738 (continued)
MOUSE VAS DEFERENS PREPARATION
Agonist p A 2 Slope ± S.D. pA2 n
(Constrained)
± S E
Sufentanil (µ) <5.5 3
DSLET ( ) 6.18 1.30 ± 0.04 6.38 ± 0.44 6
U50,488 ( ) 5.96 1.73 ± 0.42 6.29 ± 0.64 6
SUMMARY
NIH 10738 was of low potency in both preparations In the vas deferens
preparation it was devoid of opioid agonist activity. Concentrations of 10 and
30 µM markedly increased the magnitude of the twitch, an action that was not
blocked by 100 nM of naltrexone. NIH 10738 was an antagonist of low
potency on this preparation. It was equipotent as an antagonist at and
opioid receptors. At a concentration of 10 µM, the compound caused a 9.02-
fold shift in the concentration-effect curve. Because of its low potency and
direct actions on the smooth muscle preparation, pA2 values could not be
calculated for its antagonist activity at µ opioid receptors. The high slopes of
the Schild plots suggest that the antagonism produced by NIH 10738 is not a
simple competitive-type of antagonism.
* * *
NIH 10739 1-(4-Fluorobenzyl-4-(3-hydroxybenzyl)-4-
(1-oxopropyl) piperidine hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 1330 nM in the presence of 150 mM
NaC1.
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NIH 10739 (continued)
MOUSE VAS DEFERENS PREPARATION
Agonist p A 2 Slope ± S.D. pA 2 n
(Constrained)
± S.E.
Sufentanil (µ) <5.0 4
DSLET 6.37 1.66 ± 0.16 6.94 ± 0.59 6
U50,488 5.71 1.82 ± 0.52 5.88 ± 0.69 6
SUMMARY
NIH 10739 was not very potent in either preparation. It was devoid of opioid
agonist activity on the isolated, electrically stimulated mouse vas deferens
preparation. Concentrations of 10 and 30 µM markedly increased the
magnitude of the twitch, an action which was not blocked by 100 nM
naltrexone, NIH 10739 was an antagonist of low potency on this preparation.
It was ten times more potent as an antagonist at opioid receptors than at
opioid receptors. Although NIH 10739 did not shift the sufentanil
concentration-effect curve to the right, it significantly decreased the maximum
inhibitory action of sufentanil. NIH 10739, at a concentration of 10 µM,
reduced the maximum response to sufentanil to 43.1% of control values. The
high slopes of the Schild plots and the changes in the maximum responses to
sufentanil suggest that the antagonist produced by NIH 10739 is not
competitive.
*  *  *
NIH 10762 (±)-cis-N-[3-methyl-l-[2-oxo-2-(2-thienyl)ethyl]-4-
piperidinyl]-N-phenylpropanamide hydrochloride
DISPLACEMENT OF
SPECIFIC [3H]ETOR-
PHINE BINDING
EC50 of 569 nM in the presence
of 150 mM NaCl.
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NIH 10762 (continued)
MOUSE VAS DEFERENS PREPARATION
Concentrations up to 3 µM had no appreciable effect on this preparation. At a
concentration of 30 µM, NIH 10762 markedly increased the magnitude of the
twitch, an effect that was not modified by 100 nM naltrexone. When tested as
an antagonist, 30 µM NIH 10762 caused a
6.86-fold shift to the right in the sufentanil concentration-effect curve. Because
of the low potency of this drug as a µ opioid receptor antagonist, pA2 values
could not be determined. NIH 10762,30 µM, did not affect responses of the vas
deferens to DSLET or to U50,488. Thus, NIH 10762 appears to be a µ opioid
receptor antagonist of very low potency and to be devoid of opioid agonist
activity on the mouse vas deferens preparation.
SUMMARY
NIH 10762 had low potency in the binding assay and some possible opioid
antagonist activity in the mouse vas deferens preparation.
* * *
NIH 10765 (±)-cis-N-[1-(2-Hydroxy-1-phenylethyl)-3-methyl-
4-piperidinyl]-N-phenylpropanamide hydro-
chloride
DISPLACEMENT OF
[3H]ETORPHINE BINDING
EC50 of 3.4 µM in the presence
of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10765 was studied on the isolated, electrically stimulated mouse vas
deferens preparation in concentrations which ranged from 1 nM to 30 µM.
Concentrations up to 3 µM had no appreciable effect on this preparation. At a
concentrations of 30 µM NIH 10765 markedly increased the magnitude of the
twitch, an effect that was not modified by 100 nM naltrexone. When tested as an
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NIH 10765 (continued)
antagonist 30 µM NIH 10765 caused a 9.53-fold shift to the right in the
sufentanil concentration-effect curve. Because of the low potency of this drug
as a µ-opioid receptor antagonist, pA2 vaues could not be determined. NIH
10765, 30 µM, did not affect responses of the vas deferens to DSLET, a
opioid receptor agonist, or to U50,488, a receptor selective antagonist. Thus,
in the vas deferens preparation, NIH 10765 appears to be a µ-opioid receptor
antagonist of very low potency and to be devoid of agonist-activity.
SUMMARY
NIH 10765 had insignificant opioid activity in both in vivo assays
*  *  *
NIH 10773 Morphine 3-acetate 6-sulfate zwitterion
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 517 nM in the presence of 150 mM
NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%0 (x-fold)
Control 139.9 ± 25.4 81.3 ± 5.1 9
Naltrexone 836.5 ± 119.7 94.8 ± 2.8 6 .0 3
(100 nM)
ICI-174,864 127.6 ± 25.1 87.3 ± 2.7 0.9 3
(100 nM)
Nor-BNI 194.9 ± 12.9 65.0 ± 2.4 1.4 3
(10 nM)
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NIH 10773 (continued)
SUMMARY
NIH 10773 was weakly active in both preparations. In the mouse vas deferens
preparation, it acted as a partial inhibitor of the twitch, with actions mediated
predominantly by µ opioid receptors. No evidence of opioid antagonist activity
was found.
* * *
NIH 10782 3-[4-Methylpiperazinylliminomethyl]
rifamycin (Rifampin, or Rifampicin)
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of >6000 nM (2% inhibition at 6 µM) in the presence of NaCl
MOUSE VAS DEFERENS PREPARATION
Condition*
Control
Naltrexone
(100 nM)
EC50 (nM) Maximum Shift n
Response (%) (x-fold)
36.9 ± 13.2 29.6 ± 5.8 3
309.5 ± 90.8 20.1 ± 2.9 5.7 3
* NOTE: Evaluated as a 3 mM solution in 32% ethanol.
SUMMARY
NIH 10782 had no significant activity in the binding assay. In the mouse vas
deferens preparation it acted as an agonist of low potency that might act on µ
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NIH 10782 (continued)
opioid receptors. When tested in a concentration of 10 µM as an antagonist, it
failed to block the actions of sufentanil, DSLET or U50,488.
* * *
NIH 10785 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-
4-piperidinyll-N-(4-fluorophenyl)propanamide
hydrochloride
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of 4.54 nM in the presence of 150 mM NaCI.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Control 2.83 ± 0.61 100 9
Naltrexone 60.0 ± 18.8 100 21.2 3
(100 nM)
ICI 174,864 50.0 ± 9.30 100 17.6 3
(100 nM)
Nor-BNI 6.87 ± 1.24 100 2.4 3
(10 nM)
SUMMARY
NIH 10785 had significant opioid activity in the binding assay and, in the mouse
vas deferens preparation, it acted as a potent agonist with both naltrexone and
ICI 174,864 causing shifts to the right in the NIH 10785 concentration-effect
curve. Nor-binaltorphimine neither shifted the NIH 10785 concentration-effect
curve appreciably nor significantly altered the maximum response. Thus, NIH
10785 would seem to be an agonist with actions at opioid receptors.
143
NIH 10786 (±)-cis-N-[1-[2-(4-Bromophenyl)ethyl-2-hydroxyl-
3-methyl-bpiperidinyl]-N-phenylpropanamide
hydrochloride
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of 22.9 nM in the presence of 150 mM NaCl
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (µM) Maximum Shift n
Response (%) (x-fold)
Control 1.44 ± 0.35 98.8 ± 0.6 9
Naltrexone 3.47 ± 0.88 100 2.4 3
(100 nM)
ICI 174,864 10.3 ± 9.3 99.1 ± 0.9 7.2 3
(100 nM)
Nor-BNI 0.07 ± 0.03 31.8 ± 2.4 0.0 3
(10 nM)
Agonist p A 2 Slope ± S.D. pA2 (Constrained) n
± SE
Sufentanil (µ) 5.98 1.13 ± 0.10 6.04 ± 0.38 3
SUMMARY
NIH 10786 had significant opioid activity in the binding assay. In the mouse vas
deferens preparation, it had complex agonist actions. Because the concentration-
effect curve appears to be multi-phasic, interpretation of results is difficult. Both
naltrexone and ICI 174,864 caused shifts to the right in the NIH 10786
concentration effect curve. Nor-binaltorphimine markedly decreased the
maximum response obtained with NIH 10786. Concentrations of NIH 10786
above 1 µM markedly increased the magnitude of the twitch in the presence of
nor-binaltorphimine. NIH 10786 also acted as a weak antagonist. At a
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NIH 10786 (continued)
concentration of 3 µM, NIH 10786 caused a 4.07-fold shift in the DSLET
concentration-effect curve and a 5.3-fold shift in the U50,488 concentration
effect curve.
* * *
NIH 10787 1-Chloronaltrexone hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 0.38 nM in presence of 150
mM NaCI.
MOUSE VAS DEFERENS PREPARATION
Agonist pA 2 Slope ± S.D. pA2 (Constrained) n
±S.E.
Sufentanil (µ) 9.49 0.96 9.46 ± 0.32 3
DSLET ( ) 8.73 1.05 8.77 ± 0.36 3
U50,488 ( ) 8 94 1.08 8.98 ± 0.38 3
SUMMARY
NIH 10787 had high potency in the binding assay. In the vas deferens
preparation it had potent opioid antagonist activity with slight selectivity for µ
opioid receptors.
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NIH 10790 (±)-1-(2-Hydroxy-2-phenylethyl)-t-3-methyl-4-[1-
oxopropyl)phenyl amino]-r-4-piperidinecarboxylic
acid methyl ester hydrochloride
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of 0.85 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition
Control
Naltrexone
(100 nM)
ICI 174,864
(100 nM)
Nor-BNI
(10 nM)
SUMMARY
EC50 (nM) Maximum Shift n
Response (%) (x-fold)
0.77 ± 0.09 100 9
12.4 ± 2.2 100 16.0 3
1.64 ± 0.76 100 2.1 3
1.55 ± 0.58 100 2.0 3
NIH 10790 had high affinity in the binding assay and, in the mouse vas deferens
preparation, it acted as a potent agonist with some selectivity for µ opioid
receptors.
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NIH 10791 (±)-1-(2-Hydroxy-2-phenylethyl)-c-3-methyl-4-[(1-
oxopropyl)phenyl amino]-r-4-piperidinecarboxylic
acid methyl ester hydrochloride
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of 2.29 nM in presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (s-fold)
Control 1.3 ± 0.25 100 9
Naltrexone 23.3 ± 3.4 100 17.8 3
(100 nM)
ICI 174,864 1.96 ± 0.80 100 1.5 3
(100 nM)
Nor-BNI 1.28 ± 0.22 100 1.0 3
(10 nM)
NIH 10791 had high affinity in the binding assay and, in the mouse vas deferens
preparation, it acted as a potent agonist with some selectivity for µ opioid
receptors.
SUMMARY
NIH 10791 had high affinity in the binding assay and, in the mouse vas deferens
preparation, it acted as a potent agonist with some selectivity for µ opioid
receptors.
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NIH 10792 (±)-1-(2-Hydroxy-2-phenylethyl)-t-3-methyl-4-[(1-
oxopropyl)phenyl amino]-r-4-piperidinecarboxylic
acid ethyl ester hydrochloride
DISPLACEMENT
SPECIFIC [3H]ETOR-
PHINE BINDING
EC50 of 1.19 nM in the
presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Control 1.29 ± 0.26 100 9
Naltrexone 12.7 ± 2.4 100 9.9 3
(100 nM)
ICI 174,864 2.08 ± 0.68 100 1.6 3
(100 nM)
Nor-BNI 0.93 ± 0. 17 100 0.7 3
(10 nM)
SUMMARY
NIH 10792 had high affinity in the binding assay and, in the mouse vas deferens
preparation, it acted as a potent agonist with some selectivity for µ opioid
receptors.
* * *
NIH 10793 (±)-N-[1-(2-Hydroxy-2-phenylethyl)-4-
methoxymethyl-c-3-methyl-4-4-piperidinyl]-N-
phenylpropanamide oxalate
DISPLACEMENT
SPECIFIC [3H]ETOR-
PHINE BINDING
EC50 of 0.78 nM in the
presence of 150 mM NaCl.
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NIH 10793 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Cont ro l 0.84 ± 0.15 100 9
Naltrexone 19.7 ± 6.0 100 23.5 3
(100 nM)
ICI 174,864 1.81 ± 0.63 100 2.2 3
(100 nM)
Nor-BNI 3.82 ± 1.04 100 4.5 3
(10 nM)
SUMMARY
NIH 10793 had high affinity in the binding assay and, in the mouse vas deferens
preparation, it acted as a potent agonist with some selectivity for µ opioid
receptors.
NIH 10802 (±)-3-Hydroxy-N-(4-hydroxybenzyl)morphinan
hydrobromide
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of 2140 nM in presence of 150 mM NaCl.
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NIH 10802 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Control 108.4 ± 43.6 22.9 ± 1.7 3
Naltrexone 113.9 ± 51.7 22.1 ± 0.6 1.1 3
(100 nM)
SUMMARY
NIH 10802 had very low affinity in the binding assay. In the mouse vas deferens
preparation it was devoid of opioid agonist actions. When tested as an
antagonist, NIH 10802 produced unusual results. It blocked responses of the vas
deferens to sufentanil (µ opioid receptor agonist). The pA2 value for this action
was 5.5 ± 1.4 and the slope of the Schild plot was 2.78 ± 1.4. This high slope
indicates that the antagonism is not simply competitive. NIH 10802, 10 nM, did
not cause significant shifts in the concentration-effect curves for DSLET, a
opioid receptor agonist, or to U50,488, a -opioid receptor agonist.
* * *
NIH 10803 (±)-N-Allylmecamylamine hydrochloride
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of >6,000 nM (45% inhibition at 6 µM) in the presence of 150 mM NaCl.
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NIH 10803 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Control 1.83 ± 0.52 22.9 ± 1.7 3
Naltrexone 0.69 ± 0.09 12.0 ± 1.2 0.4 3
(100 nM) I
SUMMARY
NIH 10803 had no significant activity in the binding assay. In the mouse vas
deferens preparation it acted as a quite weak partial agonist or a non-opioid
agonist. Naltrexone, 100 nM, decreased the maximum response of this drug, but
did not shift its concentration-effect curve. When tested as an antagonist, 30 µM
NIH 10803 did not affect responses of the vas deferens to sufentnail (µ opioid
agonist), DSLET ( opioid agonist) or U50,488 ( opioid antagonist).
* * *
NIH 10805 1-Chlorodiprenorphine oxalate
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 0.61 nM in the presence of 150 mM
NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Control 1.04 ± 0.10 27 2 ± 0.6 3
Naltrexone 134 ± 0.44 27.9 ± 1.5 1.3 3
(100 nM)
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NIH 10805 (continued)
Agonist pA 2 Slope ± pA2 (Constrained) n
S.D. ± S.E.
Sufentanil (µ) 9.91 1.34 10.21 ± 0.46 3
DSLET ( ) 9.27 0.85 9.01 ± 1.13 3
U50,488 ( ) SEE BELOW
SUMMARY
NIH 10805 had high potency in the binding assay. In the vas deferens
preparation, MH 10805, in concentrations of 0.1 nM to 100 nM decreased the
magnitude of the twitch of the electrically stimulated mouse vas deferens
preparation. This response was not blocked by naltrexone. Concentrations
above 100 nM markedly increased the magnitude of the twitch.
NIH 10805 was a very potent antagonist at µ, , and receptors. The
antagonism of U50,488 was insurmountable and began at a concentration of 1
nM. Although the antagonism of DSLET and sufentanil appeared to be
competitive, because of the population of spare and µ receptors in this
preparation, an insurmountable antagonism might have been revealed if very high
concentrations of NIH 10805 were studied.
* * *
NIH 10809 N-Cyclopropylmethyl[7 ,8 ,2’,3’]cyclopentano-1’-
[ R ]hydroxy-6,14-endoethenotetrahydro-
nororipavine hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 0.49 nM in the presence of 150 mM
NaCl.
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NIH 10809 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Control 2.21 ± 0.17 74.2 ± 1.8 9
Naltrexone 27.6 ± 4.8 80.4 ± 2.4 12.5 3
(100 nM)
ICI 174,864 3.31 ± 1.22 75.9 ± 3.4 1.5 3
(100 nM)
Nor-BNI 40.1 ± 7.42 69.9 ± 0.7 18.1 3
(10 nM)
SUMMARY
NIH 10809 had high affinity in the binding assay and, in the mouse vas deferens
preparation, acted as an agonist relatively selective for opioid receptors.
* * *
NIH 10810 N-Cyclopropylmethyl[7 , 8 ,2’,3’]cyclopentano-1’-
[ S ]hydroxy-6,14- endoe thenote trahydro-
nororipavine hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 0.91 nM in the presence of 150 mM
NaCl.
153
NIH 10810 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Control 8.77 ± 0.50 77.7 ± 1.7 9
Naltrexone 60.4 ± 4.7 73.9 ± 2.7 6.9 3
(100 nM)
ICI 174,864 8.00 ± 0.93 73.9 ± 2.7 0.9 3
(100 nM)
Nor-BNI 13.4 ± 0.7 75.6 ± 4.9 1.5 3
(10 nM)
SUMMARY
NIH 10810 had high affinity in the binding assay and, in the mouse vas deferens
preparation, acted as an agonist relatively selective for µ opioid receptors.
* * *
NIH 10811 N-Cyclopropylmethyl[7 ,8 ,2’,3’]cyclohexano-1’-
[S]hydroxy-6,14-endo ethenotetrahydronororipavine
hydrochloride
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of 0.59 nM in the presence of 150 mM NaCl.
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NIH 10811 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Control 0.86 ± 0.06 99.1 ± 0.9 9
Naltrexone 6.41 ± 1.16 96.3 ± 1.7 2 .7 3
(100 nM)
ICI 174864 1.89 ± 96.3 100 2 . 2 3
(100 nM)
Nor-BNI 1.15 98.7 ± 0.7 1.3 3
(10 nM)
SUMMARY
NIH 10811 had high affinity in the binding assay and, in the mouse vas deferens
preparation, acted as an agonist, perhaps, relatively selective for opioid
receptors.
* * *
NIH 10812 2-Nitrobuprenorphine hydrochloride
D I S P L A C E M E N T  O F
SPECIFIC [3H]ETOR-
PHINE BINDING
EC50 of 3805 nM in the
presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition
Control
Naltrexone
(100 nM)
EC50 (nM) Maximum Shift n
Response (%) (x-fold)
6.65 ± 1.69 55.9 ± 3.7 3
1.19 ± 5.58 40.0 ± 1.7 1.2 3
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NIH 10812 (continued)
Agonist pA 2 Slope ± S.E. pA2 (Constrained) n
± S.E.
DSLET ( ) 5.31 1.34 ± 0.04 5.35 ± 1.04 3
U50,488 ( ) 5.90 1.02 ± 0.16 5.92 ± 0.78 3
SUMMARY
* * *
NIH 10812 had low affinity in the binding assay. In concentrations of 0.1 nM to
100 µM, it decreased the magnitude of the twitch of the electrically-stimulated
mouse vas deferens preparation. The NIH 10812 concentration-effect curve was
not shifted by naltrexone, although the maximum response was slightly
decreased. NIH 10812 was a very weak antagonist at µ, , and receptors. In
the presence of NIH 10812, 10 µM, there was a 2.8-fold shift to the right in the
sufentanil concentration-effect curve. This drug was slightly more potent as an
antagonist at and opioid receptors.
NIH 10813 2-Nitrodiprenorphine hydrochloride
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of 140 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition
Control
Naltrexone
EC50 (nM)
412.7 ± 29.0
1865.1 ± 84.8
Maximum
Response (%)
44.3 ± 4.2
32.5 ± 4.4
Shift n
(x-fold)
3
4.5 3
(100 nM)
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NIH 10813 (continued)
Agonist pA2 Slope ± S.E. pA2 (Constrained) n
± S.E.
Sufentanil (µ) 7.47 1.01 ± 0.06 7.49 ± 0.34 6
DSLGT ( ) 6.24 1.20 ± 0.19 6.39 ± 0.4 I 6
U50,488 ( ) See  below
SUMMARY
NIH 10813 had moderate affinity in the binding assay. In concentrations of 100
nM to 30 µM, it decreased the magnitude of the twitch of the electrically-
stimulated mouse vas deferens preparation. Naltrexone, 100 nM, shifted the
NIH 10813 concentration effect curve to the right and decreased the maximum
response. NIH 108 13 was an antagonist at µ, , and receptors. The
antagonism of U50,488 was unsurmountable and began at a concentration of 1
µM. The antagonism of DSLET and sufentanil appear to be competitive, and
NIH 108 13 was more potent as an antagonist at receptors than at opioid
receptors.
* * *
NIH 10814 2-Nitronaltrexone hydrochloride
DISPLACEMENT OF SPECIFIC
[3H]ETORPHINE BINDING
EC50 of 196 nM in the presence of 150 mM
NaCl.
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Control 3.48 ± 1.14 22.9 ± 4.4 3
Naltrexone 6.73 ± 1.49 24.7 ± 2.4 19 3
(100 nM)
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NIH 10814 (continued)
Agonist pA 2 Slope ± S.D. pA2 (Constrained) n
± S.E.
Sufentanil (µ) 7.43 0.88 ± 0.27 7.31 ± 0.34 6
DSLET ( ) 6.03 1.27 ± 0.14 6.18 ± 0.43 6
U50,488 ( ) See below
SUMMARY
NIH 10814 had moderate affinity in the binding assay. In concentrations of 1 nM
to 100 µM, it decreased the magnitude of the twitch of the electrically-stimulated
mouse vas deferens preparation. Naltrexone, 100 nM, shifted the NIH 10814
concentration effect curve to the right but did not decrease the maximum
response. NIH 108 14 was an antagonist at µ, , and receptors. The
antagonism of U50,488 was unsurmountable and began at a concentration of 1
µM. The antagonism of DSLET and sufentanil appear to be competitive, and
NIH 108 14 was more potent as an antagonist at µ receptors than at opioid
receptors.
* * *
NIH 10815 (+)-4-[( R )- (12 S , 5R )-4-Allyl-2,5-dimethyl-1-
piperazinyl)-3-methoxybenzyl]-N,N-
diethylbenzamide
DISPLACEMENT OF SPECIFIC [3H]ETORPHINE BINDING
EC50 of >6,000 nM (43% inhibition at 6 µM) in the presence of 150 mM NaCl.
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NIH 10815 (continued)
MOUSE VAS DEFERENS PREPARATION
Condition EC50 (nM) Maximum Shift n
Response (%) (x-fold)
Control 6.38 ± 0.58 100 9
Nalfrexone 25.0 ± 8.8 100 3.9 3
(100 nM)
ICI 174,864 18.9 ± 2.6 100 3.0 3
(100 nM)
Nor-BNI 11.4 ± 0.46 100 1.8 3
(10 nM)
SUMMARY
NIH 10815 had no significant activity in the binding assay and, in the mouse vas
deferens preparation, acted as an agonist relatively selective for opioid
receptors. It should be noted that the results of the two preparations are
discordant.
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DEPENDENCE STUDIES OF NEW COMPOUNDS IN
THE RHESUS MONKEY, RAT AND MOUSE (1994)
M.D. Aceto, E.R. Bowman, L.S. Harris and E.L. May
All compounds, except dextrorphan tartrate were supplied by Dr. Arthur
Jacobson, Laboratory of Medicinal Chemistry, NIDDK, NIH. The identities of
all the compounds, except that indicated above, were unknown to us when they
were originally submitted. These studies were conducted under the auspices of
the Drug Evaluation Committee of the College on Problems of Drug
Dependence.
Dependence-Liability Studies in Rhesus Monkeys
Substitution-for-Morphine (SDS) Test. Male and female rhesus monkeys (M.
mulatta) weighing 2.5-7.5 kg were used, and they received 3 mg/kg, s.c., of
morphiney·SO4 every 6 h. All the animals had received morphine for at least 3
months and were maximally dependent on morphine (Seevers and Deneau
1963). A minimal 2-week recuperation period was allowed between tests. At
least 3 monkeys/dose were used. The assay (Aceto and co-workers, 1977 and
1978) was initiated by a subcutaneous injection of the test drug or control
substances (morphine and vehicle) into animals in a group that had not received
morphine for 14-15 h and showed definite signs of withdrawal. Each animal
was randomly chosen to receive one of the following treatments: a) a dose of the
compound under investigation; b) morphine control, 3.0 mg/kg; and c) vehicle
control, 1 ml/kg. The animals were scored for suppression of withdrawal signs
during a 2.5-h observation period. The observer was “blind” regarding the
choice of treatments. At the end of the study, the data were grouped according
to dose and drug. The mean cumulative score ± SEM was calculated and the
data illustrated in figure form. If indicated, the data were analysed using the
Kruskal-Wallis Anova and posthoc Mann-Whitney U-Tests.
Precipitated-Withdrawal (PPT-W) Test. This evaluation was done under the
same conditions as described above, except that the animals were administered a
test compound 2-3 h after the last dose of morphine. These animals were not in
withdrawal. Naloxone·HCl (0.05 mg/kg, s.c.) served as the positive control.
Primary-Physical-Dependence (PPD) Study. Drug-naive monkeys were
medicated with drug, using escalating dose regimens, periodically challenged
with naloxone or placed in abrupt withdrawal. They were observed for overt
behavioral signs during drug administration and when they were challenged
with antagonist or abruptly withdrawn from the drug.
Rat-Infusion Studies
The continuous-infusion method was reported by Teiger (1974) and certain
modifications are indicated as follows. Rats were anesthetized after which each
was fitted with a specially prepared cannula which was passed subcutaneously
from the nape of the neck to the lateral side of the lower abdomen and then
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inserted into the peritoneal cavity. The cannula was anchored at both ends with
silk sutures and attached to a flow-through swivel mechanism which allowed
the animal to move about in the cage and eat and drink normally. The swivel
was connected to a syringe which was attached to a syringe pump. The animals
received 7-10 ml of solution every 24 h. Occasionally, when deemed
necessary, as with cocaine, infusions were given via the right jugular vein.
Substitution-for-Morphine (SM) Test. The rats received morphine·SO4 (50
mg/kg/24 h on the first day, 100 mg/kg/24 h on the second day, and 200
mg/kg/24 h from days 3 and 4). Then, a test drug was substituted for 2 days.
The morphine controls received an infusion of water. The animals were
observed for changes in body weight and for behavioral-withdrawal signs for
0.5 h at 6,24,48,72 and/or 96 h after stopping the infusion of morphine.
Primary-Physical-Dependence (PPD) Study. The rats received test compound,
as specified above, for 6 days and then, were placed in abrupt withdrawal and
observed for overt behavioral signs.
Mouse-Antinociception Tests
Male mice, weighing 20-30 g, were used. All drugs were dissolved in distilled
water or in the vehicle indicated and injected subcutaneously (s.c.). At least
three doses were tested, and 6-10 animals per dose were used. When
applicable, ED50’s were calculated by using computerized probit analysis.
Tail-Flick (TF) and (TF vs M) Assays. The procedure and modifications were
described (D’Amour and Smith, 1941 and Dewey et al., 1970 and 1971) in the
literature. Briefly, the mouse’s tail was placed in a groove which contained a
slit under which was located a photoelectric cell. When the heat source of
noxious stimulus was turned on, the heat focused on the tail, and the animal
responded by flicking its tail out of the groove. Thus, light passed through the
slit and activated the photocell which, in turn, stopped the recording timer. The
heat source was adjusted to produce tail flick of 2-4 s under control conditions.
Mice were injected with drug or vehicle and tested 20 m later. In the assay for
antagonism of the antinociceptive effect, the potential antagonists were
administered 10 m before the agonist, and evaluation occurred 20 m later.
Phenylquinone Abdominal-Stretching (PPQ) Assay. The procedure was
reported previously (Pearl and Harris, 1966). The mice were injected with test
drugs and 10 m later received 2.0 mg/kg ip of a freshly prepared
paraphenylquinone (PPQ) solution. The mice were then placed in cages in
groups of two each. Ten minutes after the PPQ injection, the total number of
stretches per group were counted over a l-m period. A stretch was
characterized by an elongation of the mouse’s body, development of tension in
the abdominal muscles, and extension of the forelimbs. The antinociceptive
response was expressed as the percent inhibition of the PPQ-induced stretching
response.
Hot-Plate (HP) Assay. The method was also reported previously (Eddy and
Leimbach, 1953 and Atwell and Jacobson, 1978). The hot plate was held at
55°C. Mice were placed on the hot plate and activity was scored if the animal
jumped or licked its paws after a delay of 5 s or more, but no more than 30 s
beyond the control time. Table 2 contains a summary of all the new data
generated this year on compounds that had not previously been tested.
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Table 1
Comparative Data (ED50, mg/kg s.c.) [95% C.L.] of Selected Standards in 4
Mouse Agonist-Antagonist Tests
Antagonist
Tail-FlickTail-FlickDrug Phenylquinone Hot-Plate
Pentazocine 15% at 10.0 1 8
(12-26)
Cyclazocine 17% at 1.0a 0.03
(0.020-0.78)
Nalorphine·HCl None at 10.0 2.6
(0.7-10.0)
Naloxone·HCl None at 10.0 0.04
(0.01-0.09)
Naltrexone·HCl None at 10.0 0.007
(.002-0.02)
Morphine·SO4
b 0.7b
(0.4-1.5)
Inactive
Codeine·PO4
Meperidine·HCl
- - -
- - -
Inactive
Inactive
1.7
(l.0-2.5)
0.01
(0.005-0.03)
0 . 6
(0.03-1.44)
No Activity
- - -
- - -
- - -
- - -
No Activity - - -
0.4 b
(0.2-0.8)
- - -
(0.39-16.8)
- - -
3.1b
(1.5-6.4)
6.4
(0.39-16.8)
4 .6
(1.8-11.7)
aMice were ataxic at 3.0 and 10.0 mg/kg but there was no further increase in
reaction time
bICR - Harlan-Sprague-Dawley Inc.
Calculation of Apparent pA2 Using the tail-flick assay, the apparent pA2 and
95% confidence limits were calculated using Schild and constrained plots as
described in Tallarida and Murray (Manual of Pharmacologic Calculations with
Computer Programs, 2nd ed., Springer Verlag, NY., 1987).
Briefly, mice were pretreated with vehicle or various doses of antagonist
followed 10 m later by an injection of agonist. The mice were tested 30 m after
receiving the antagonist. Dose-response lines for antinociception were plotted
using at least 3 doses of each opioid agonist in the presence of vehicle or one of
the selected doses of antagonist. ED50s were estimated according to the method
of Litchfield and Wilcoxon (J. Pharmacol, Exp. Ther., 96, 399, 1949). Each
dose ratio (x) was calculated by dividing the ED50 of the opioid in the presence
of a given dose of antagonist by that of the agonist alone. Log (x-1) was
plotted against the negative logarithm of the molar dose of the antagonist. At
least 3 logs (x-1) were plotted. The pA2 values for the antagonist were
calculated from the point of intersection of the regression line with the abscissa.
See Table 2 for summary of results.
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Table 2. Apparent pA2 values
a using the mouse tail-flick assay
Treatment Schild PloT Constrained Plot
Antagonist/Agonist  pA2  (95% C.L) Slope pA2 (95% C.L) 
1) Naloxone/Morphine
2 ) Nalmefene/Morphine
3) Naltrexone/Morphine
4) (-)-Quadazocine/Morphine
5) Naloxone/Sufentanil
6) Naloxone/Sufentanil
7) Naloxone/Mirfentanil
8) Naloxone (-)-Nicotine
9 ) Naloxone/U-50,488
kappa agonist
10) Naloxone/NIH 10672
selective kappa agonist
11) (-)-Quadazocine/NIH 10672
12) nor BNI/NIH 10672
13) Mecamylamine/(-)-Nicotine
7.2 (7.0 - 7.4)-1.2
8.0 (7.6 - 8.3)-1.1
7.7 (4.9 - 10.5)-0.8
6.8 (6.7 - 7.0)-0.9
7.0 (6.9 - 7.1)-1.0
7.0 (6.5 - 7.5)-1.0
7.6 (7.3 - 8.0)-0.7
5.3 (5.3-5.3)-0.5
6.6 (6.3 - 6.9)-1.1
6.1 (5.6 - 6.6)-1.2
6.2 (6.1 - 6.2)-1.7
6.5 (5.9 - 7.0)-1.3
6.6 (6.2 - 6.9)-0.9
7.3 (7.1-7.6)
8.0 (7.7 - 7.6)
7.6 (7.1 - 8.3)
6.8 (6.1 -0 7.6)
7.0 (6.9 - 7.0)
7.0 (6.8 - 7.1)
7.2 (6.9 - 7.5)
7.0 (6.9 - 7.0)
7.2 (6.9 - 7.5)
6.6 (6.3 - 7.0)
6.2 (5.9 - 7.3)
6.7 (6.6 - 6.8)
6.6 (5.9 - 7.3)
6.5 (6.4 - 6.6)
aNegative logarithm of the molar concentrations of antagonist required to
produce a two-fold shift of the agonist dose-response curve to the right.
Competitive antagonism can be assumed when slope = -1. pA2 provides a
measure of the relative potency and affinity of the antagonist. When the slope
differs significantly from unity, this may indicate non-equilibrium conditions,
interactions with multireceptors, receptor sensitization, precoupling
mechanisms, or multiple drug properties. With a constrained plot, the slope of
the regression line is restricted to slope = -1.
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SUMMARY OF NEW DATA
3-Hydroxymorphan + +
6,7-Benzomorphan + a
6,7-Benzomorphan + +
Epoxymorphinan + b c + + + +
Epoxymorphinan + + + + + +
3-Hydroxymorphinan + + + + +
10738 4-Phenylpiperidine + + + + +
10739 4-Phenylpiperidine + + + + +
10741 4-Amidopiperidine + + a
10749 3-Hydroxymorphinan + + + + +
+ +
10782 Rifampicin Piperazine + + + + + d
10784 4-Amidopiperidine + b + + + +
+10785 4-Amidopiperidine + b + + +
10786 4-Amidopiperidine + b + + + +
1-Cloronaltrexone Epoxymorphinan +
e + + + + +
4-Amidopiperidine + b + + + +
+ b + + +
+ + +
10793
+
4-Amidopiperidine +
Compound
NIH or Generic Class T F TFvsM PPQ H P PA2 SM SDS PPt-W PPD
Chemical Name MOUSE RAT MONKEY
P P D
04591 Dextrorphan Tartrate
1 0 5 6 0
10675
10683
10684
10735
10787
10790
10791 4-Amidopiperidine +
+
+ b + + +
10773 Epoxymorphinan + + + + I +
10779 Phenylmophan + + +
10792 4-Amidopiperidine
SUMMARY OF NEW DATA
Compound
NIH or Generic Class TF TFvsM PPQ HP PA2 SM PPD SDS PPt-W PPD
Chemical Name MOUSE RAT MONKEY
10794 Amitriptyline Dibenzycycloheptane +
h + + + + a
10795 4-Phenylpiperidine + + + + +
10796 3-Hydroxymorphinan + + + + +
10802 3-Hydroxymorphinan + + + +
10803 Mecamylamine + + + + +
10805 Epoxymorphinan + j + + + + d +
10809 Endoethenonororipavine + + + + +
aSpecial - pA2 vs morphine in TF. 
bSpecial - Naloxone vs ED80 in TF. cSpecial - Naloxone vs ED80 in PPQ.
dSpecial - Preliminary test in one
monkey. eSpecial vs moprhine in TF. fSpecial - vs NIH 10672 (kappa agonist) in TF. gSpec ial vs Naloxone in TF. hSpecial - Naloxone-overt-
behavior-challenge test. iSpecial - Naloxone challenge of overt neurological signs. jSpecial - Time-course study vs morphine in TF.
NIH 04591
Tartrate
(+)-3-Hydroxy-N-methmylmorphinan tartrate or Dextrorphan
MOUSE DATA - ED50 OR AD50
mg/kg (95% C.L.) or % change
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TF vs. M - 13% at 10.0, 30% at
30.0a and 61% at 100.0
3) PPQ - 23.8 (12.3 - 46.0)a,b
4) HP - Approx 30.0a
aPublished previously (NIDA
Monog. 67, 1986)
bAt 0.1 and 1.0 mg/kg naloxone
partly antagonized this effect
MONKEY - Monkey data reported previously in NIDA Monog. 67, 1986.
A. SDS
Dextrorphan reduced the total number of withdrawal signs but at 4.0 mg/kg, it
produced severe ataxia, slowing, body sag and partial eyelid ptosis. Dose range
studied was 0.25 - 4.0 mg/kg s.c.
B. PPt-W
At doses of 1.0 and 4.0 mg/kg dextrorphan did not precipitate withdrawal.
Dose-related side-effects as indicated above.
C . PPD
Given 4-6 times a day for 30 days at doses ranging from 3.0 to 13.0 mg/kg,
dextrorphan produced withdrawal phenomena. Tolerance to the acute effects
developed rapidly up to a dose of 10.0 mg/kg. When the monkeys were placed
in abrupt withdrawal, a syndrome characterized by the signs lying on side or
abdomen, scratching, wet-dog shakes, fighting, pacing, frequent touching of
genital area, and rubbing face against pen wall was observed. When the
monkeys were challenged with naltrexone (1.0 mg/kg s.c.) withdrawal was
exacerbated. However, none of the monkeys ever showed rigid abdominal
muscles or vocalized when their abdomens were palpated. These signs are
considered important and distinguished morphine withdrawal from dextrorphan
withdrawal in the monkey.
RAT DATA (New data)
SM
Unanesthetized, male, Sprague-Dawley rats previously fitted with intraperitoneal
cannulas (Teiger, JPET, 1974) were made maximally dependent by
continuously administered morphine using the following dose regimen: 50
mg/kg, day 1; 100 mg/kg, day 2 and 200 mg/kg, days 3 and 4. At the end of
day 4, morphine was abruptly withdrawn and dextrorphan (200 or 400 mg/kg
per day) or vehicle (8 ml per day) was substituted for morphine. A dose-related
reduction in behavioral withdrawal signs was observed in rats receiving
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NM 04591 (+)-3-Hydroxy-N-methmylmorphinan tartrate or Dextrophan
Tartrate (continued)
dextrorphan (see Fig. 1). The morphine-dependent rats given vehicle displayed
the usual full complement of behavioral withdrawal signs. These behavioral
signs were designated hypersensitivity, squeaking, aggression, wet-dog shakes,
rubbing and chewing. None of the vehicle controls showed any withdrawal
signs. However, the precipitous loss of body weight which occurred in the rats
receiving morphine and vehicle or morphine and dextrorphan indicated that
dextrorphan had no influence on this particular physiological withdrawal
parameter (see Fig. 2). The results suggest that dextrorphan may selectively
alter the behavioral expression of opioid dependence.
DEXTRORPHAN SM IN RAT INFUSION
26
169
NIH 04591 (+)-3-Hydroxy-N-methmylmorphinan tartrate or Dextrophan
Tartrate (continued)
DEXTRORPHAN SM IN RAT INFUSION
Comments:
Taken together, the results suggest that dextrorphan may interact indirectly with
the opiate system, perhaps via the NMDA (N-Methyl-D-Aspartate) system.
NIH 10560 (-)-5,9 -Dimethyl-2-ethy1-2’hydroxy-6,7-benzomorphan
hydrochloride
MOUSE DATA - ED50 OR AD50
mg/kg (95% C.L.) or % change
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TF vs. M - 3.7 (1.8 - 7.8)a
3) PPQ - 1.4 (0.5 - 4.1)a
4) HP - 13% at 1.0, 25% at 10.0 and
30.0a
aReported previously - NIDA Res
Monog 90, 1988.
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NIH 10560 (-)-5,9 -Dimethyl-2-ethyl-2’hydroxy-6,7-benzomorphan
hydrochloride (continued)
MOUSE DATA - New Data
pA 2 Assay 10560 vs morphine in TF. 
NIH 10560 produced parallel shifts in the dose-response curve of morphine.
The apparant pA2 and slope shown in the accompanying fig suggest that NIH
10560 has low affinity for mu receptors and that the interaction is competitive.
NIH 10560 VERSUS MORPHINE IN TAIL-FLICK
Apparent pA2 Schild
MONKEY DATA - Reported previously - op cit
SDS
Did not substitute for morphine; instead, it exacerbated withdrawal
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MOUSE DATA - ED50 OR AD50, mg/kg
(95% C.L.) or % change
1)
2)
TF - 1.7 (1.1 - 2.7)a,b
TF vs. M - Inactive at 1.0, 10.0 and
30.0 a ,b
3) PPQ - 0.13 (0.002 - 0.99)a,b
4) HP - 2.4 (1.1 - 5.1)a,c
NIH 10675 (-)-5,9 -Dimethyl-2- n -heptyl-2’-hydroxyl-6,7-benzomorphan
hydrochloride
aVehicle propylene glycol and water
bReported previously in NIDA Res.
Monog. 119, 1992
cReported in NIDA Res Monog. (in press,
1994)
MONKEY DATA
(SDS)
Reported previously op cit.
Neither substituted for morphine nor exacerbated withdrawal.
RAT DATA - CONTINOUS INFUSIONa - New Data
A .  S M
The results are summarized in the appropriate fig and table. NIH 10675 partly
suppressed morphine-induced withdrawal in terms of body weight loss or with
regard to suppression of withdrawal signs.
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NIH 10675 (-)-5,9 -Dimethyl-2- n -heptyl-2’-hydroxyl-6,7-benzomorphan
hydrochloride (continued)
NIH 10675 SM IN RATS
B. PPDb
NIH 10675 produced a definite mu-like withdrawal syndrome when abruptly
withdrawn after a 4-day infusion on a dose regimen similar to that of morphine.
a) A new dose regimen was used in this study. Instead of the usual 6-day
regimen, we found that a 4-day regimen (see Table) was just as effecttve in
producing physical dependence.
b) Three of the 6 rats appeared tranquilized.
Comments:
NM 10675 did not substitute for morphine in the monkey model. However, in
both rodent models, it showed actions associated with mu-like agonists.
Metabolic considerations may underlie the difference between the monkey and
rodent models.
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Table: Primary Physical Dependence (PPD) and Substitution for Morphine Studies (SM) with NIH 10675 in
Continuously-Infused Rats
Treatment Hr in Withdrawal
24 (day 5) 48 (day 6) 72 (day 7) 96 (day 8)
Mean Number of Withdrawal Signsa,b,c
1. Vehicle Controlsd 0.8 1.8 0 0.3
2. Morphine Controlse 8.4 12.0
b 9.2b 8.0
3. NIH 10675 - PPDf 7.8
b 4.3c 4.2 b , c 0.7
4. NIH 10675 - SMg 3.4
b 3.0c 13.6b 7.8
aHypersensitivity, squeaking, aggression, wet-dog shakes, rubbing and chewing;
bOne-tailed test Mann-Whitney-U test, p < 0.05, probability value vs. vehicle controls;
cOne-tailed test Mann-Whitney-U test, p < 0.05, probability value vs morphine controls;
d8 ml/24 hr. N = 4;
eDose regimen of morphine, SO4, 50 mg/kg on day 1,100 mg/kg on day 2,200 mg/kg on days 3 and 4. N = 5;
fDose regimen of NIH 10675,50 mg/kg on day 1,100 mgkg on day 2,200 mg/kg on days 3 and 4. N=6;
gMorphine SO4 infusion, days 1-4 as above then, NIH 10675 100 mg/kg on days 5 and 6, and vehicle as above on days 7
and 8. N=5.
NIH 10683 14-Hydroxy-N-(2-methoxyethyl)-7,8-dihydronormorphine
MOUSE DATA - ED50 OR
AD50, mg/kg
1)
2)
(95% C.L.) or % change
1) TF - 0.2 (0.1 - 0.4)a
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0a
3) PPQ - 0.03 (0.01 - 0.09)a
4) HP - 0.3 (0.1 - 0.9)a
aVehicle -phosphoric acid and
water
Special Tests
Naloxone vs ED80 of NIH 10683 in TF - AD50 = 0.03 (0.01 - 0.1)
Naloxone vs ED80 of NIH 10683 in PPQ - AD50 = 0.6 (0.1 - 1.7)
MONKEY DATA
(SDS)
NIH 10683 niether substituted for morphine nor exacerbated withdrawal at
doses of 0.5, 2.0 and 6.0 mg/kg (see graph). A non-dose related reduction in
the signs designated retching and wet-dog shakes was noted. Vehicle was
H3PO4 and H2O.
Comments:
NIH 10683 may have multiple (mu, kappa and/or delta) opioid properties in the
mouse. In the monkey, the effects are not mu-like.
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NIH 10684 14-Hydroxy-N-(2-methoxyethyl)-7,8-dihydronorisomorphine
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TFvs.M - 4% at 1.0, 26% at
10.0 and 30.0a
3) PPQ - 2.6 (0.5 - 13.7)a
4) HP - 13% at 1.0, 10.0 and 30.0a
aVehicle -phosphoric acid and water
MONKEY DATA
A. (SDS)
As shown in the accompanying illustration, this compound did not substitute for
morphine. Instead, it appeared to exacerbate withdrawal in a dose-related
manner. One monkey was still showing withdrawal signs at 6:00 p.m. in spite
of the fact that the dose of morphine was doubled. Some of the animals were
very aggressive towards the handler. Vehicle was phosphoric acid and water.
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NIH 10684 14-Hydroxy-N-(2-methoxyethyl)-7,8-dihydronorisomorphine
(continued)
B. (PPt-W)
NIH 10684 precipitated withdrawal and the actin was dose-related. While
naloxone had a quick onset and short duration of action, this compound had a
slower onset and long duration of action (see graph).
Comments:
NM 10684 has mixed agonist/antagonist properties in the mouse. In the
monkey, the drug has mu antagonist properties. Onset of action is slow and
offset is of long duration. This compound appears to be either devoid of mu
antinociceptive activity or lacks potency.
177
NIH 10735 (+)-N-Benzyl-3-hydroxymorphinan hydrochloride
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 6.1(2.0 - 19.2)a
4) HP - Inactive at 1.0 and 10.0,
25% at 30.0a,b
aVehicle - DMSO, propylene
glycol and water
bSome eyelid ptosis, convulsions
in one mouse at 30.0
MONKEY DATA
(SDS)
In the preliminary study, shortly after receiving a cumulative dose of 15.0 mg/kg
(1.0, 2.0, 4.0 and 8.0 mg/kg at 15-m intervals), the monkey dropped from the
perch and convulsed. Pentobarbital quickly terminated the convulsions.
In the regular SDS study, at doses of 1.75 and 7.0 mg/kg, NIH 10735 did not
substitute for morphine or exacerbate withdrawal (see fig.). Vehicle was 25%
hydroxypropyl- -cyclodextrin.
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NIH 10738 4-(3-Hydroxyphenyl)-1-(4-nitrobenzyl)-1-4-(1-oxopropyl)
piperidine hydrochloride
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
TF vs. M - Inactive at 1.0, 10.0
and 30.0a
PPQ - 7.3 (2.2 - 24.7)a
HP - Inactive at 1.0, 15% at
10.0 and 30.0a
1) TF - Inactive at 1.0, 10.0 and
30.0a
2)
Vehicle - DMSO in water
MONKEY DATA
(SDS)
As shown in the accompanying fig. (NIH 10738, SDS), this compound neither
substituted for morphine nor exacerbated withdrawal at doses of 3.0 or 12.0
mg/kg. Vehicle was 25% hydroxypropyl- -cyclodextrin in water.
Comments:
Although some antinociceptive activity was noted, the results do not suggest
opioid properties.
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NIH 10739 1-(4-Fluorobenzyl)-4-(3-hydroxyphenyl)-4-(1-oxopropyl)-
piperidine hydrochloride
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 18.3 (9.7 - 34.7)a
4) HP -Inactive at 1.0 and 10.0,
25% at 30.0a
aVehicle - DMSO in water.
MONKEY DATA
(SDS)
At doses of 2.5 and 10.0 mg/kg, NIH 10739 did not show appreciable activity
in morphine-dependent monkeys, i.e., it neither substituted for morphine nor
exacerbated withdrawal. Vehicle was 25% hydropropyl- -cyclodextrin aqueous
solution.
Comments:
The drug has weak antinociceptive activity. The biological profile suggests that
it lacks significant opioid activity.
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NIH 10741 ( S,3R,4S)-(+)-cis-N-[1-(2( )-Hydroxy-2-phenylethyl)-3-
methyl-4-piperidinyl]-N-phenylpropanamide hydrochloride
MOUSE DATA-ED50 OR AD50
(95% C.L.) or % change (mg/kg)
1) TF - 2 x 10-4 (1 x 10-4 - 3 x
10-4)a
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0a
3) PPQ - 9 x 10-5 (3 x 10-5 - 2 x
10-4)a
4) HP - 1 x 10-4 (5 x 10-5 - 2 x
10-4)a
aReported Previously. NIDA Res.
Monog. (in press).
MOUSE DATA
Special Test: (op cit) Naloxone vs ED80 of NIH 10741 in TF: AD50 = 8.3 x
10-3 (4 x 10-3 - 1.7 x 10-2)
pA2 Assay NIH 10741: A pA2 of 7.2 and slope of -0.98 was calculated.
The results suggest a competitive interaction with the mu receptor (see
accompanying fig.).
NALOXONE VERSUS NIH 10741 IN TAILFLICK
Apparent pA2 Schild
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NIH 10741 ( S,3R,4S)-(+)- c i s-N-[1-(2( )-Hydroxy-2-phenylethyl)-3-
methyl-4-piperidinyl]-N-phenylpropanamide hydrochloride (continued)
MONKEY DATA
SDS
Reported previously - op cit. Substituted completely for morphine 20,000 -
50,000 x more potent than morphine.
N I H  1 0 7 4 1  ( S,3R,4S)-(+)-cis-N-[1-(2( )-Hydroxy-2-phenylethyl)-3-
methyl-4-piperidinyl]-N-phenylpropanamide hydrochloride (continued)
Comments:
Because this compound was extremely potent and because the naloxone AD50
suggested unusual sensitivity to naloxone, the pA2 test was conducted. The
results indicate that NIH 10741 interacts competively with naloxone at the mu
receptor.
NIH 10749 (+)-3-Hydroxy-N-(4-nitrobenzyl)morphinan oxalate
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 23% at 1.0, 14% at 10.0
and 54% at 30.0a
4) HP - Inactive at 1.0, 10.0 and
30.0a
aVehicle - Tween 80,
Propyleneglycol and water
MONKEY DATA
SDS
As shown in the graph (NIH 10749 SDS), at doses of 4.0 or 16.0 mg/kg, this
compound did not substitute for morphine. Neither did it exacerbate
withdrawal. Vehicle was 25% hydroxypropyl- -cyclodextrin.
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NIH 10749 (+)-3-Hydroxy-N-(4-nitrobenzyl)morphinan oxalate (continued)
Comments:
This compound did not display remarkable activity in the mouse antinociceptive
tests and in morphine-dependent monkeys, It is probably devoid of mu and
kappa opioid properties.
NIH 10773 Morphine 3-acetate 6-sulfate zwitterion
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - 2.5 (1.2 - 5.0)a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 0.5 (0.2 - 1.5)a
4) HP - 1.0 (0.4 - 2.5)a
aVehicle - 25% Tween 80, water with
gentle warming
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NIH 10773 Morphine 3-acetate 6-sulfate zwitterion (continued)
MONKEY DATA
SDS
At doses of 2.5 and 10.0 mg/kg, NIH 10773 did not substitute for morphine nor
did it exacerbate withdrawal. Vehicle was DMSO 10-15% in water. Solutions
were cloudy.
Comments:
The results suggest species difference and/or solubility problems. In any case,
in the mouse antinociceptive models, NIH 10773 appears to be morphine-like.
NM 10779 2,3-Dimethyl-5-(3-hydroxyphenyl)morphan hydrochloride
MOUSE DATA - ED50 OR
AD50, mg/kg
(95% C.L.) or % change
1)
10.0 and 30.0
3) PPQ - 0.3 (0.1 - 0.6)
4) HP - 4.8 (1.9 - 12.4)
2)
TF - 1.3 (0.5 - 3.2)
TF vs. M - Inactive at 1.0,
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NIH 10779 2,3-Dimethyl-5-(3-hydroxyphenyl)morphan hydrochloride
(continued)
MONKEY DATA
SDS
NIH 10779 substituted completely for morphine (see fig. NIH 10779 SDS).
Potency, onset of action and duration of action appear comparable to morphine.
Comments:
This drug displays a profile of activity similar to that of morphine.
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NM 10782 3-[4-Methylpiperazinyliminomethyl]rifamycin (Rifampin or
Rifampicin)
MOUSE DATA - ED50 OF
AD50, mg/kg
(95% C.L.) or % change
1)
2)
3)
4)
TF - Inactive at 1.0, 10.0
and 30.0a
TF vs. M - Inactive at
1.0, 10.0 and 30.0a
PPQ - Inactive at 1.0,
10.0 and 30.0a
HP - Inactive at 1.0, 10.0
a n d  3 0 . 0 a
aVehicle 0.5% Tween80 in
aqueous solution.
MONKEY DATA
Preliminary (SDS)
NIH 10782 was injected at 15-m intervals with doses of 1.0, 2.0, 4.0 and 4.0
mg/kg, respectively for a total cumulative dose of 11.0 mg/kg. Withdrawal
signs were neither attenuated nor suppressed. Because the drug formed a
reddish solution which stained tissue, there was concern regarding the
production of skin lesions in monkeys, no further studies were initiated.
Vehicle was hydroxypropyl -cyclodextrin in water.
Comments:
The results from this preliminary study suggested that the compound had no
apparent mu or kappa opioid activity.
NIH 10784 (±)-cis-N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-
piperidinyl]-N-(3-fluorophenyl)propanamide hydrochloride
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - 0.004 (0.001 - 0.009)
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 0.001 (0.005 - 0.003)
4) HP - 0.005 (0.002 - 0.01)
aStraub tail at 1.0. Loss of righting
reflex at 30.0 and 10.0
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NIH 10784 (±)-c i s-N-[l-(2-Hydroxy-2-phenylethyl)-3-methyl-4-
piperidinyl]-N-(3-fluorophenyl)propanamide hydrochloride (continued)
Special test: Naloxone vs ED80 of NM 10784 in TF - AD50 = 0.11 (0.04 -
0.33)
MONKEY DATA
(SDS)
NIH 10784 is a highly potent (6000 x morphine) mu opioid agonist and,
accordingly, substituted completely for morphine in morphine-dependent
monkeys. Onset of action was rapid and duration of action was at least as long
as that of morphine. See accompanying fig.
Comments:
This compound is a potent mu agonist.
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NIH 10785 (±)-cis -N-[1-(2-Hydroxy-2-phenylethyl)-3-methyl-4-
piperidinyl]-N-(4-fluorophenyl)propanamide hydrochloride
MOUSE DATA - ED50 OF
AD50, mg/kg
(95% C.L.) or % change
1) TF - 0.002 (0.001 - 0.005)
2) TF vs. M - Inactive at 1.0,
30.0 and 10.0a
3) PPQ - 0.00034 (0.00012 -
0.00093)
4 ) HP - 0.001 (0.0004 -
0.0029)
aat 1.0 mg/kg dose of righting
reflex
Special Test: Naloxone AD50 vs ED80 of NM 10785 in TF = 0.04 (0.02-0.09)
MONKEY DATA
(SDS)
As can be seen in the figure, NM 10785 produced a dose-related and complete
suppression of withdrawal signs. Onset of action was rapid, offset was
morphine-like. Potency estimate is 1000 x morphine. Some scratching was
noted at the high dose.
Comments:
The profile of activity indicates that NM 10785 is a potent mu agonist.
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NIH 10786 (±)-cis-N-[1-[1-(4-Bromophenyl)ethyl-2-hydroxyl-3-methyl-4-
piperidyl]-N-phenylpropanamide•HCl
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - 0.03 (0.22 - 0.51)
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0
3) PPQ - 0.007 (0.003 - 0.018)
4) HP - 0.013 (0.006 - 0.032)
Special: Naloxone AD50 vs ED80 of 10786 in TF - 0.13 (0.05 - 0.32)
MONKEY DATA
A .  ( S D S )
NIH 10786 dose-dependently substituted completely for morphine (see graph).
This compound is estimated to be 60 x more potent than the reference standard
morphine sulfate. The drug acts quickly and its duration of action is at least as
long as that of morphine.
Comments:
The profile of activity suggests that NIH 10786 has potent mu agonist
properties.
NIH 10787 1-Chloronaltrexone•HCl
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - Inactive at 1.0, 10.0 and 30.0
2) TF vs. M - 4.8 x 10-4 (1.9 x 10-4
x 1.2 x 10-3)
3) PPQ - Inactive at 1.0, 10.0 and
30.0
4) HP - Inactive at 1.0, 10.0 and 30.0
MOUSE DATA
1. pA2 determination vs morphine in TF test
As shown in the accompanying fig., NIH 10787 competitively antagonized
morphine-induced antinociception. The pA2 was calculated at 8.7 which
indicates that the affinity for the mu receptor is much greater than that of
naloxone or nalmefene.
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NIH 10787 1-Chloronaltrexone•HCl (continued)
NIH 10787 VERSUS MORPHINE IN TAIL-FLICK
Apparent pA2 Schild
2. pA2 determination vs NIH 10672 (Kappa agonist) in TF test
NIH 10787 competitively antagonized antinociception induced by the potent
kappa agonist NIH 10672. The affinity of 10787 for the kappa receptor is also
impressive.
NIH 10787 VERSUS NIH 10672 IN TAIL-FLICK
Apparent pA2 Schild
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NIH 10787 1-Chloronaltrexone•HCl (continued)
MONKEY DATA
A. (SDS)
As illustrated in the fig., NIH 10787 SDS, NIH 10787 did not substitute for
morphine at doses of 0.0004 or 0.0016 mg/kg.
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NIH 10787 1-Chloronaltrexone•HCl (continued)
B. (PPt-W)
NIH 10787 dose-dependently precipitated withdrawal in morphine-dependent
monkeys. Onset of action was prompt and duration of action was at least as
long as that of naloxone. Potency estimate in the monkey is approximately 5 x
that of naloxone.
Comments;
In the mouse, NIH 10787 is an extraordinarily potent competitive antagonist
especially at mu and to a lessor extent on kappa receptors. Although the drug is
active in the monkey model, potency is only approximately 5 x that of naloxone.
Perhaps the species differences can be reconciled by metabolic studies.
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NIH 10790 (±)-1-(2-Hydroxy-2-phenylethyl)-t-3-methyl-4-[(1-
oxopropyl)phenylamino]-r-4-piperidinecarboxamide methyl ester•HC1
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - 4.4 x 10-4 (2.2 x 10-4 -
8.7 x 10-4)a
2) TF vs. M - Inactive at 0.1, 0.3
and 1.0b
3) PPQ - 1.0 x 1.0-4
4 ) HP - 6.1 x 10-4 (2.8 x 10-4 -
1.3 x 10-3)a
aStraub tail at 0.001 mg/kg
bTwo of 6 mice died at 1.0
Special Test: A: Naloxone AD50 vs ED50 of NIH 10790 in TF = 0.02
(0.006 - 0.09)
B: pA2 (Naloxone vs NIH 10790) 7.4 (Schild); 7.1
(constrained). See accompanying illustrated data.
NALOXONE VERSUS NIH 10790 IN TAIL-FLICK
Apparant pA2 (Schild)
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NIH 10790 (±)-1-(2-Hydroxy-2-phenylethyl)-t-3-methyl-4-[(1-
oxopropyl)phenylamino]-r-4-piperidinecarboxamide methyl ester•HC1
(continued)
MONKEY DATA
(SDS)
This compound dose-dependently substituted completely for morphine (see
fig.). Onset and offset of action are similar to those of morphine. Potency
estimate: 6000 x morphine.
Comments:
All the data indicate that NIH 10790 is a potent mu agonist that interacts
competitively with naloxone.
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NIH 10791 (±)-1-(2-Hydroxy-2-phenylethyl)-c-3-methyl-4-[(1-
oxopropyl)phenylamino]-r-4-piperidinecarboxylic acid methyl ester
hydrochloride
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L) or % change
1) TF - 0.001 (0.0004 - 0.003)a
2) TF vs M - Inactive at 1.0, 10.0 and
30.0b
3) PPQ - 8.0 x 10-4 (3.0 x 1.0-4 x 2.1
x 10-4)
4) HP - 0.001 (0.0005 - 0.002)a
aStraub tail at 0.003 mg/kg
bOne mouse died at 30.0
Special Test: A: Naloxone AD50 vs ED80 of NIH 10791 in TF = 0.02 (0.01 -
0.0 4)
B: pA2 (naloxone vs 10791) = 7.95 (Schild), 7.5 (constrained)
see accompanying fig.
NALOXONE VERSUS NIH 10791 IN TAIL-FLICK
Apparent pA2 (Schild)
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NIH 10791 (±)-1-(2-Hydroxy-2-phenylethyl)-c-3-methyl-4-[(1-
oxopropyl)phenylamino]-r-4-piperidinecarboxylic acid methyl ester
hydrochloride (continued)
MONKEY DATA
(SDS)
As shown in the fig., NIH 10791 dose-dependently substituted completely for
morphine. Onset of action was rapid and duration of action was at least as long
as that of morphine. Potency estimate: 6000 x morphine.
Comments: All the data suggested that NIH 10791 was a potent mu agonist. In
addition, naloxone interacted competitively with this compound.
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NIH 10792 (±)-1-(2-Hydroxy-2-phenylethyl)-t-3-methyl-t-[(1-
oxopropyl)phenylamino-r-4-piperidinecarboxylic acid ethyl ester hydrochloride
MOUSE DATA - ED50 OR AD50,
mg/kg 95% C.L.) or % change
1) TF - 2.4 x 10-4 (1.4 x 10-4 - 4.0 x
10-4)
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 1.0 x 10-4 (5.0 x 10-5 -
21.0 x 10-4)
4 ) HP -0.003 (0.001 - 0.009)a
aOne mouse died at 30.0 mg/kg
Special Test: Naloxone AD50 vs ED80 of NIH 10792 in TF = 0.04 (0.01 -
0.12)
MONKEY DATA
(SDS)
As shown in the accompanying fig., NIH 10792 substituted completely for
morphine at 0.0001 and 0.0004 mg/kg. Onset of action was similar to that of
morphine, however, duration of action was shorter. Potency estimate is 30,000
x morphine. One monkey receiving the high dose was scratching. This sign is
commonly seen either when morphine is given to non-dependent monkeys or
when excessive doses are given to dependent monkeys.
Comments:
The profile of activity indicates that NIH 10792 is an extremely potent mu
agonist.
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NIH 10793 (±)-N-[1-(2-Hydroxy-2-phenylethyl)-4-metethyl-c-3-
methyl-r-4-piperidinyl]-N-phenylpropanamide oxalate
MOUSE DATA - ED50 OR AD50,
mg/kg (95% C.L.) or % change
1) TF - 0.0013 (0.0004 - 0.004)a
2 ) TF vs. M - Inactive at 1.0, 10.0
and 30.0b
3) PPQ - 5  x 10-4 (2.0 x 10-4 - 1.9 x
10 - 3 ) a
4) HP - 3.1 x 10-4 (1.0 x 10-4 - 9.0 x
10 -4)a
aStraub test and locomotor stimulation
at 0.001, bOne mouse died at 10.0
Special Test: Naloxone AD50 vs ED80 NIH 10793 in TF = 0.04 (0.02 - 0.08)
MONKEY DATA
(SDS)
NIH 10793 is approximately 10,000 times more potent than morphine. Onset of
action is prompt and duration of action is less than that of morphine. At the high
dose (0.0006 mg/kg) overt signs designated body sag, ataxia, and slowing were
noted. The cummulative withdrawal scores were plotted for each observation
period and are illustrated in the fig.
Comments:
NIH 10793 displays potent biological properties commonly associated with mu
agonists.
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NIH 10794 Amitriptyline hydrochloride
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - 11% at 1.0, 16% at 10.0 and
15% at 30.0
2) TP vs. M - Inactive at 1.0 and 30.0
and 20% at 10.0
3) PPQ -0.09 (0.03 - 0.31)
4) HP - 0% at 1.0, 5% at 10.0 and
38% at 30.0a
aThe mice had splayed limbs at 10.0
and 30.0 mg/kg
Special Test: Naloxone Overt Behavior Challenge Tests
A. Reversal Test
Mice were injected s.c. with 30 mg/kg NIH 10794. Twenty m later they
received 1.0 mg/kg/s.c. of naloxone and observed 10 m later. Naloxone did not
abolish the sign designated splayed legs and eyelid ptosis.
B. Prevention
Mice received 1.0 mg/kg/s.c. of naloxone followed 10 m later by 30.0
mg/kg/s.c. of NIH 10794 and observed 20 m later. Naloxone did not prevent
the emergence of the signs indicated above
Results: In both tests, naloxone failed to prevent or reverse the sign designated
splayed legs or eyelid ptosis.
Monkey
A. SDS
Although the data in the accompanying group suggested that NIH 10794 was
dose-dependently suppressing withdrawal, suppression was associated with
head and body jerks, slowing, ataxia, or incoordination, jaw sag and eyelid
ptosis. The neurological actions probably interfered with the expression of the
withdrawal signs.
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NIH 10794 Amitriptyline hydrochloride (continued)
B. Non-Morphine-Dependent
In order to determine whether the overt neurological signs indicated above were
associated with opioid properties, one monkey was given NIH 10794, at 15-m
intervals, 1.0 mg/kg, 2.0 mg/kg and 4.0 mg/kg, respectively for a total dose of
7.0 mg/kg. The signs designated slowing, body sag, ataxia (incoordination)
and splayed legs were noted. The animal was given 1.0 mg/kg/s.c. of naloxone
and observed for 90 m. Naloxone failed to antagonize any and all of the signs
observed.
Comments:
10794 produced effects in mice and monkeys which suggested antinociception
and suppression of withdrawal. However, these effects were associated with
neurological signs which were not antagonized by naloxone. We conclude that
NIH 10794’s actions are not associated with opiatergic mechanisms.
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NIH 10795 4-(3-Hydroxyphenyl-4-(1-oxopropyl)-1-(2-methyl-2-
butenyl)piperidine hydrochloride
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - 9.7 (4.7 - 20.3)
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0
3 ) PPQ - 2.2 (1.1 - 4.2)
4) HP - 8.3 (3.7 - 19.0)
MONKEY DATA
(SDS)
NIH partially suppressed withdrawal in a non-dose-related manner (see fig.).
The suppression involved the signs designated lying on side or abdomen,
fighting, and restlessness. However, at the high dose, during the first half-hour
observation period, vomiting, coughing and frothy salivation was observed in
one monkey and vomiting in another. These latter signs are sometimes seen
during precipitated withdrawal and not during abrupt withdrawal. Perhaps slow
onset of action confounded the interpretation.
Comments:
The rodent data are typical of substances with opioid properties. However, the
results in primates are not definitive and additional studies are indicated.
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NIH 10796 (+)-N-(2-Methylpropenyl)-3-hydroxymorphinan hydrochloride
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - 23% at 30.0, Inactive at 1.0
and 10.0a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - 11.4 (5.3 - 24.4)a
4) HP - 25% at 30.0, Inactive at 1.0
and 10.0a
aVehicle-10% hydroxypropyl-
cyclodextrin aqueous solution
MONKEY DATA
SDS
As shown in the fig., NIH 10796 partly attenuated withdrawal at 15 mg/kg.
Most of this action was due to a reduction in the signs designated retching and
wet-dog. One monkey receiving the high dose convulsed. The convulsions
were controlled with pentobarbital (30 mg i.p.). Vehicle was 25%
hydroxypropyl- -cyclodextrin aqueous solution.
Comments:
NIH 10796 does not display salient mu opioid activity. However, the drug
produced CNS excitation.
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NIH 10802 (-)-3-Hydroxy-N-(4-hydroxybenzyl)morphinan hydrobromide
MOUSE DATA - ED50 OF AD50,
mg/kg
(95% C.L.) or % change
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0a
3) PPQ - Inactive at 1.0, 14% at 10.0
and 24% at 30.0a
4) HP - Inactive at 1.0, 10.0 and
30.0a
aVehicle 5% hydroxypropyl-
cyclodextrin in water.
Comments:
Antinociceptively, NIH 10802 is not remarkable.
NIH 10803 (±)-N-Allylmecamylamine•HCl
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - Inactive at 1.0, 10.0 and 30.0
2) TF vs. M - Inactive at 1.0, 10.0
and 30.0
3) PPQ - 9.8 (4.0 - 23.8)
4) HP -Inactive at 1.0 and 10.0, 25%
at 30.0
MONKEY DATA
(SDS)
Although NIH 10803 appeared to partially suppress withdrawal (see fig.), this
effect was accompanied by slowing and ataxia. One monkey receiving the high
dose (15 mg/kg) also appeared very subdued and confused. It is concluded that
the drug neither substituted for morphine nor exacerbated withdrawal.
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NIH 10803 (±)-N-Allylmecamylamine·HCl (continued)
Comments:
NIH 10803 showed weak antinociceptive activity in the PPQ assay and had little
effect on abstinence in morphine-dependent monkeys.
NIH 10805 1-Chlorodiprenorphine oxalate
(95% C.L.) or % change
MOUSE DATA - ED50 OR AD50,
mg/kg
1) TF - Inactive at 1.0, 10.0 and 30.0
2) TF vs. M - 0.09 (0.03 - 0.3)
3) PPQ - Inactive at 1.0, 10.0 and 14%
at 30.0
4) HP - Inactive at 1.0, 10.0 and 25%
at 30.0
5) Apparent pA2  vs Morphine (mu agonist) in Tail-Flick Test
As shown in the fig., NIH 10805 behaved as a non-competitive
antagonist.
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NIH 10805 1-Chlorodiprenorphine oxalate (cont.)
NIH 10805 VERSUS MORPHINE IN TAIL-FLICK
6) Apparent pA2 vs NIH 10672 (kappa agonist) in Tail-Flick Test.
An apparent pA2  of 8.0 was calculated for NIH 10672 (see
accompanying fig.). The results indicate that NIH 10672 has a high
affinity for the kappa receptor.
NIH 10805 VERSUS NIH 10672 IN TAIL-FLICK
Apparent pA2 Schild
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NIH 10805 1-Chlorodiprenorphine oxalate (continued)
7. Special Time-Course Study vs ED80 of morphine in Tail-Flick.
The results illustrated in the fig. suggest that NIH 10805 acts promptly
and has a duration of action in excess of 4 hrs.
TIME COURSE OF NIH 10805 ANTAGONISM OF MORPHINE-
INDUCED ANTINOCICEPTION IN TAILFLICK TEST
MONKEY
1. Preliminary SDS
At doses of 0.01, 0.02 and 0.02 mg/kg at 15 m intervals respectively, NIH
10805 exacerbated withdrawal. Two 3.0 mg/kg doses of morphine did not
completely attenuate withdrawal.
2. PPt-W
NIH 10805 dose-dependently precipitated withdrawal in morphine-dependent
monkeys. Onset and duration of action are similar to those of naloxone at
equipotent doses. In addition, potency is estimated to be equivalent to that of
naloxone. At the highest dose tested, some of the monkeys defecated, showed
body jerks, ejaculated frequently and uttered clucking noises.
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NIH 10805 1-Chlorodiprenorphine oxalate (continued)
Comments:
NIH 10805 is a potent opioid antagonist with an unusual combination of
mechanisms in the mouse; it behaved as a noncompetitive antagonist on mu
receptors and as a competitive antagonist on kappa receptors. In the monkey
studies, it can be said that NIH 10805 has mu antagonist properties.
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NIH 10809 N-Cyclopropylmethyl[7 ,8 ,2’3’]cyclopentano-1’[R]hydroxy-
6,14-3-endoethenotetrahydronororipavine•HCl
MOUSE DATA - ED50 OR AD50,
mg/kg
(95% C.L.) or % change
1) TF - 1) 0.1 (0.03 - 0.34)
2) 0.3 (0.83-2.7)
2) TF vs. M - 9.3 (3.6 - 23.9)
0.3 (0.83-2.7)
3) PPQ - 0.01 (0.004 - 0.03)
4) HP - 1) 0.13% at 0.1, 25% at 0.3,
50% at 1.0, 3.0, 10.0 and
30.0a
2) 50% at 0.03, 0.1 and 1.0,
25% at 3.0, 38% at 10.0 and
63% at 30.0
aModerate ataxia, copious urination.
At the highest dose the mice were
not ambulating.
MONKEY DATA
A. (SDS)
As shown in the graph, NIH 10809 appeared to exacerbate withdrawal.
However, at doses of 0.05 and 0.025 mg/kg, the results were not dose-related.
In addition, a number of overt behavioral signs were noted including slowing,
ataxia, jaw sag, piloerection, clucking sounds, severe tremors and body jerks.
Perhaps lower doses should be tested to detect agonist activity.
208
NIH 10809 N-Cyclopropylmethyl[7 2’3’]cyclopentano-1’[R]hydroxy-
6,14-3-endoethenotetrahydronororipavine·HC1 (continued)
B. (PPt-W)
As shown in the illustration, NIH 10809 precipitated withdrawal at doses of
0.05 and 0.25 mg/kg. Whereas onset of action was as rapid as the control
naloxone, duration of action was at least 150 m; much longer than that of
naloxone. Potency is estimated as equivalent to naloxone. Many of the
monkeys receiving NIH 10809 made a clucking noise and vocalized. Profuse
salivation, disorientation, slowing of long duration, and increased aggressive
behavior towards handler were also noted in some monkeys.
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NIH 10809 N-Cyclopropylmethyl[7 2’3’]cyclopentano-1’[R]hydroxy-
6,14-3-endoethenotetrahydronororipavine·HCl (continued)
Comments:
The results in mice suggest that NIH 10809 is a partial opioid (mu) agonist. In
the monkey, it manifests itself as a potent mu antagonist with a long duration of
action. Some overt behavior also hint at kappa and sigma actions.
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